Official Title of Study:  
Randomized, Non -comparative Neoadjuvant Phase II Study in Patients with ER+/HER2 - Breast Cancer ‚â• 2 
cm with Safety Run -in, Assessing Nivolumab + Palbociclib + Anastrozole  
(CheckMate 7A8: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7A8)  
 
 
PROTOCOL(S) CA209 -7A8 
 
Study ID: [REMOVED] 
  
Document Date (Date in which document was last revised): March 13 , 2020 
Page: 1
Protocol Number: CA2097A8
IND Number: 136,843
EX-US Non-IND
EUDRACT Number: 2019-001334-34
Date: 02-May-2019
Revised Date: 13-Mar-2020
CLINICAL PROTOCOL CA2097A8
Randomized, Non-comparative Neoadjuvant Phase II Study in Patie nts with ER+/HER2- Breast 
Cancer ‚â•2 cm with Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole
(CheckMate 7A8: CHECKpoint pathway and nivoluMAb clinical Trial  Evaluation 7A8)
Short Title:
Nivolumab with Palbociclib, plus Anastrozole in Patients with ER+/ HER2- Breast Cancer ‚â•2 cm
Revised Protocol 03
24-hr Emergency Telephone Number
USA: 
International: 
Bristol-Myers Squibb Research and Development
3401 Princeton Pike
Lawrenceville, NJ 08648
Avenue de Finlande 4
B-1420 Braine-l‚ÄôAlleud, Belgium
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or to your Independent Ethics Committee (s). Any other use, 
copying, disclosure or disseminati on of this information is str ictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg,  amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 2this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to B MS in this protocol may apply 
to partners to which BMS has transferred obligations, eg, a Con tract Research Organization 
(CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a copy 
of this revised protocol to all study pers onnel under your supervision, and archive the previous 
versions.
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised 
Protocol 0313-Mar-2020Closed the abemaciclib safety run-i n Cohort 1 and removed the 
abemaciclib-containing combinations from the randomization phas e.
Removed eligibility criteria based on RECIST 1.1 as it has been  covered by 
inclusion criteria 2.a.i. Added further instructions on unidimensional measurement for response assessment using ultrasound and mammogram as 
modifications.
Incorporated Administrative Letter 01 and Germany specific amend ment.
Revised 
Protocol 0224-Jul-2019Added men, additional dose-limiting toxicity (DLT) criteria, and  early 
study termination criteria. Updated definition of DLT, inclusion/exclusion 
criteria, and dose modifications.
Revised 
Protocol 0112-Jun-2019Decreased and clarified the frequency of assessments and sample  
collections, clarified participant eligibility and stratification, and reduced 
the dose-limiting toxicity period. These changes were made to re duce 
participant burden and increase overall feasibility of the stud y.
Original 
Protocol02-May-2019 Not applicable
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
OVERALL RATIONALE FOR REVISED PROTOCOL 03:
On 6-Mar-2020, Bristol Myers Squibb (BMS) decided to permanentl y discontinue enrollment and 
dosing in the nivolumab + ab emaciclib + anastrozol e cohorts of the CA2097A8 study.  
 
 
 
 
 
The study 
is currently in the Safety Run-In Phase. A t implementation of R evised Protocol 03, the study will 
only evaluate whether the combination of nivolumab, with palboc iclib, plus anastrozole is a safe 
and effective neoadjuvant treatment for men and postmenopausal women with primary BC ‚â•2 cm 
that is ER+ and HER2- subtype who are suitable to receive NET an d willing to undergo SOC 
breast surgery after completion of the study treatment. Partici pants must have histologically 
confirmed invasive breast carcinoma meeting the characteristics  described in the Inclusion 
Criteria. Participants in screening and not yet treated were off ered the option to join the safety
lead-in of the nivolumab + pal bociclib + anastrozole arm. Parti cipants on treatment with 
nivolumab + abemaciclib + anastrozole were to be re-consented an d continue on anastrozole alone, 
or taken off study. Safety monitoring for ILD/pneumonitis (base line chest X-ray, periodic pulse 
oximetry) as risk mitigation measures have also been included. 
Additional changes were made to include the updates from Admin istrative Letter 01 and 
clarifications.
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
All Removed references where 
applicable to abemaciclib-containing 
treatment in the randomization phaseAs of 6-March-2020, cohort 1 is 
closed for enrollment and study will 
not move forward with abemaciclib-containing treatment in the randomization phase as an urgent safety measure
Section 2  Schedule Of Activities, 
Table 2-1 : Screening Procedural 
Outline (Safety Run-in Phase and 
Randomized Phase; CA2097A8)
Section 5.1.1  Screening Period
Section 6.1 Inclusion Criteria
 
 Updated Pretreatment Tumor Sample 
Submission sample collection 
timing.Clarity
Revised Protocol No.: 03
Date: 13-Mar-2020 4
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
Section 2 Schedule Of Activities, 
Table 2-1 : Screening Procedural 
Outline (Safety Run-in Phase and 
Randomized Phase; CA2097A8)
Section 5.1 Overall DesignAdded Chest X-ray procedure Safety monitoring for 
ILD/pneumonitis
Section 2 Schedule Of Activities, 
Table 2-1: Screening Procedural 
Outline (Safety Run-in Phase and 
Randomized Phase; CA2097A8)Added Estradiol to the required 
laboratory testing for women ‚â§55Updated per the Administrative 
Letter 01 to align with the inclusion criteria
Table 2-2 On-treatment Pre-surgery 
(Neoadjuvant) Procedural Outline 
(Safety Run-in Phase and 
Randomized Phase; CA2097A8)‚Ä¢Updated footnote b in indicate that participants will undergo 
surgical treatment within 4 
weeks of last dose instead of 1 week.
‚Ä¢Footnote e added to table.‚Ä¢Clarifying inconsistency within the protocol. 
‚Ä¢Cohort 1 is now closed for enrollment and samples will no longer be collected or analyzed for existing Cohort 1 participants to alleviate patient 
burdens.
Table 2-2 On-treatment Pre-surgery 
(Neoadjuvant) Procedural Outline 
(Safety Run-in Phase and 
Randomized Phase; CA2097A8)
Section 5.1 Overall DesignPulse Oximetry has been added to Day 1 of the On-treatment Pre-
surgery (Neoadjuvant) Procedural OutlineSafety monitoring for 
ILD/pneumonitis
Table 2-2 On-treatment Pre-surgery 
(Neoadjuvant) Procedural Outline 
(Safety Run-in Phase and 
Randomized Phase; CA2097A8)
Section 5.1.2.1 Safety Run-in Phase
Section 7.1 Treatments Administered
Section 7.1.1 Nivolumab Dosing 
(Safety Run-in Cohorts and 
Randomized Phase Arms A, B, D, 
and E)
Section 7.1.2 CDK4/6 Inhibitors and 
Anastrozole DosingLanguage has been removed 
regarding first dose of nivolumab 
being administered following 
treatment assignment for participants 
in the Safety Run in PhaseClarity
Section 3.3 Benefit/Risk Assessment Added following s entence: As of 
Protocol Revision 03, the benefit-risk  
profile of the abemaciclib-containing 
combination is no longer considered favorable; thus BMS will not move forward with randomization to nivolumab in combination with abemaciclib and anastrozole (see Section 5.1).As of 6-March-2020, cohort 1 is closed for enrollment and study will 
not move forward with 
abemaciclib-containing treatment in the randomization phase as an urgent safety measure
Revised Protocol No.: 03
Date: 13-Mar-2020 5
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
Section 3.3.3 CDK4/6 Inhibitor and 
Nivolumab Combination Safety 
ProfileAdded the following paragraph:
In a Phase 2 study of 
pembrolizumab, palbociclib and letrozole (AI) in patients with metastatic ER+, HER2- BC ([STUDY_ID_REMOVED]), of 20 patients treated with the triple combination, Grade 3 pneumonitis was reported in 1 patient  during the DLT assessment 
period. The median follow up for this study was 13.7 months (95% CI 6.4-16.9) and progression-free survival (PFS) has not been reached.  Also in a phase 1 study exploring safety and efficacy of avelumab, palbociclib and axitinib (tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer ([STUDY_ID_REMOVED]), of 13 patients treated at 3 dose levels, 1 patient 
with baseline chronic obstructive 
pulmonary disease at dose level 3 developed a respiratory failure event possibly related to study treatment and died. No Grade 3 or above ILD/pneumonitis events were reported.  A randomized Phase 2 trial assessing a triple combination regimen of palbociclib + avelumab (anti-PD-L1 inhibitor) + fulvestrant (estrogen receptor antagonist) for patients with pre-treated metastatic 
ER+/HER2- BC has been ongoing 
since Aug-2017; no clinical data have been reported to date. ([STUDY_ID_REMOVED]). Thus, the potential benefit of the palbociclib combination therapy appears to outweigh the known risks and warrants clinical investigation.Additional supporting information.
Section 4  Objectives and Endpoints For pCR secondary  
endpoints the definitions of pCR were expandedConsistency across program protocols.
Section 5.1 Overall Design Added the following paragraphs and removed reference to equal 
distribution of participants in both 
safety run-in cohorts: 
On 6-Mar-2020, Bristol Myers 
Squibb (BMS) decided to permanently discontinue enrollment Cohort 1 is now closed for enrollment.
Revised Protocol No.: 03
Date: 13-Mar-2020 6
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
and dosing in the nivolumab + 
abemaciclib + anastrozole cohorts of the CA2097A8 study during the Safety Run-in Phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At implementation of Revised Protocol 03, the study will only evaluate whether the combination of nivolumab, with palbociclib, plus 
anastrozole is a safe and effective 
neoadjuvant treatment for men and postmenopausal women with 
primary BC ‚â•2 cm that is ER+ and 
HER2- subtype who are suitable to 
receive NET and willing to undergo SOC breast surgery after completion of the study treatment. Participants must have histologically confirmed invasive breast carcinoma meeting the characteristics described in Section 6.1  (Inclusion Criteria). 
Participants in screening and not yet 
treated were offered the option to 
join the safety lead-in of the nivolumab + palbociclib + anastrozole arm. Participants on treatment with nivolumab + abemaciclib + anastrozole were to be re-consented and continue on anastrozole alone, OR taken off study. In addition, baseline chest X-ray and periodic pulse oximetry are implemented to monitor ILD/pneumonitis in patients who 
Revised Protocol No.: 03
Date: 13-Mar-2020 7
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
will be treated with nivolumab + 
palbociclib + anastrozole.
Figure 5.1-1: Study Design 
SchematicUpdated study design schematic to 
remove abemaciclib-containing
treatment in the randomization phaseand updated study numbers. Added two footnotes to clarify the closing of Cohort 1 to enrollment and the removal of abemaciclib-containingtreatment in the randomization 
phase.Study will not move forward with abemaciclib-containing treatment in 
the randomization phase
Section 5.1.2.1  Safety Run-in Phase Added the following paragraph:  As 
of Revised Protocol 03, Cohort 1 will 
be discontinued. Participants in screening and not yet treated were offered the option to join the nivolumab + palbociclib + anastrozole arm. Participants on treatment were to be re-consented and continue on anastrozole alone, OR taken off study.
Removed references to abemaciclib, 
and to equal distribution of participants in both safety run-in cohorts.
Deleted the following text: At the 
end of the Safety Run-in Phase, the Sponsor will evaluate the safety profile of the 2 cohorts. In the case that the treatment regimen for 1 of the 2 cohorts is not deemed to be tolerable for use in the Randomization Phase, then the treatment regimen for the other 
cohort will advance to the 
Randomization Phase, with the statistical assumptions remaining unchanged for this part, as captured in Section 10 (Statistical 
Considerations).Cohort 1 is now closed for 
enrollment.
Section 5.1.2.1 Safety Run-in Phase Updated to include additiona l DLTs  
 Integrated all the AEs 
that require discontinuation of 
nivolumab per approved label into the list of DLTs.
Section 5.1.2.2 Randomized Phase Updated randomization and text to reflect removal of Arms A-CStudy will not move forward with Arms A, B, and C.
Revised Protocol No.: 03
Date: 13-Mar-2020 8
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
Section 5.2  Number of Patients
Section 10.1 Sample Size 
DeterminationUpdated participant numbers to 
reflect the closing of enrollment for Cohort 1 and removal of 
abemaciclib-containing treatment in
the randomization phaseCohort 1 is now closed for enrollment and study will not move forward with abemaciclib-
containing treatment in the 
randomization phase.
Section 6.1  Inclusion Criteria Removed the criterion requiring 
measurable disease per RECIST 
v1.1.RECIST 1.1 is not used in this
study and the criterion for
measurable disease criterion is already included in inclusion criterion.
Section 6.2 . Exclusion Criteria Removed the following exclusion 
criterion from Medical Conditions:
C) Active hepatitis B or hepatitis C 
with abnormal liver function tests.Redundant to another criterion.
Section 6.2. Exclusion Criteria Added the following qualifier to a 
prior/concomitant therapy exclusion 
criteria:
e) Prior ET or CDK4/6 inhibitors 
for BC within 5 yearsClarity
Section 6.2. Exclusion Criteria Updated criterion 1, e.
Criterion 3, i no longer applicable
Added criterion 3, l
Added crterion 3, mupdated language, criterion 3, l and 
m replace criterion 3, i
Table 7.1-1  Selection and Timing of 
Dose - Safety Run-in Phase and 
Table 7.1-2  Selection and Timing of 
Dose - Randomized PhaseDdded the following footnote:
Note: At the time of Revised 
Protocol 03, 2 participants had been treated in Cohort 1 (nivolumab + abemaciclib + anastrozole), which was subsequently closed for enrollment.Cohort 1 is now closed for enrollment and study will not move 
forward with abemaciclib-
containing treatment in the randomization phase.
Section 7.1.2 CDK4/6 Inhibitors and 
Anastrozole DosingAdded the following text: The selected CDK4/6 inhibitor cannot be 
changed or switched to another one 
once the study treatment has been initiated. At implementation of Revised Protocol 03, the study will only evaluate the combination of nivolumab with palbociclib plus anastrozole. Patients in screening and not yet treated were offered the option to join the nivolumab + palbociclib + anastrozole arm. Patients on treatment were to be re-
consented and continue on 
anastrozole alone, OR taken off study.Cohort 1 is now closed for enrollment and study will not move 
forward with abemaciclib-
containing treatment in the randomization phase.
Revised Protocol No.: 03
Date: 13-Mar-2020 9
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title Description of Change Brief Rationale
Removed text about equal 
distribution between cohorts.
Section 7.4  Dosage Modification
Section 7.4.1 . Dose Modifications 
for Abemaciclib
Section 7.4.2 Dose Modifications for 
PalbociclibRemoved summary tables of dose 
reduction, interruption or 
discontinuation of individual study drugs in the management of study drug-related adverse reactions and added language to consult the individual drug labels
Specifically removed Table 7.4.1-1, 
Table 7.4.1-2, Table 7.4.1-3, Table 7.4.1-4, Table 7.4.1-5, Table 7.4.2-2, and Table 7.4.2-3Referenced the approved package 
inserts instead .
Section 7.7.3.1 Imaging Restriction 
and PrecautionsRemoved reference to the image 
acquisition manualPer imaging lead.
Section 8.1.2  Abemaciclib Dose 
DiscontinuationChanged text to read: At the implementation of Revised Protocol 03, abemaciclib dosing will be 
discontinued in all patients.No longer studying abemaciclib-
containg combination.
Section 9.1.3 . Clinical Response 
AssessmentsRemoved reference to RECIST
v1.1.Added language regarding 
reporting the longest diameter of the initial lesion as the baseline measurement and used to characterize the objective tumor response.Clarified expectations and 
procedures for tumor measurement 
assessments.
Section 9.1.3.1 Objective Response 
RateAdded new section To define radiographic response assessments
Section 9  Study Assessments And 
Procedures, 
Table 9.4.4-1 : Clinical Safety 
Laboratory Assessments, Other 
AnalysesAdded the following text regarding Estradiol levels
‚ÄúEstradiol level - only required to 
confirm menopause in women ‚â§age 
55‚ÄùUpdated per the Administrative 
Letter 01 to align with the inclusion criteria 
Section 10.3.4 Interim Analysis Removed interim analysis No longer applicable.
APPENDIX 9 Concomitant 
MedicationsRemoved Category and Drug Name 
for Strong CYP2D6 Inhibitors or 
Inducers (for participants receiving tamoxifen)Not applicable for the current 
treatment regimen. 
All Minor formatting and typographical corrections.Incorporate corrections for clarity and consistency within the document. These changes were minor, and therefore have not been 
summarized.
Revised Protocol No.: 03
Date: 13-Mar-2020 10
Approved 5.0 v
Approved
1.0
v
7$%/(2)&217(176
7,7/(3$*(
'2&80(17+,6725< 
29(5$//5$7,21$/()255(9,6('35272&2/ 
6800$5<2).(<&+$1*(6)255(9,6('35272&2/ 
7$%/(2)&217(176
6<1236,6 
6&+('8/(2)$&7,9,7,(6
,1752'8&7,21 
6WXG\5DWLRQDOH
3.1.1 Research Hypothesis ................................................................................ 
%DFNJURXQG 
3.2.1 ER+/HER2- Breast Cancer ..................................................................... 
3.2.2 Neoadjuvant Endocrine Treatment .......................................................... 
3.2.3 Nivolumab Mechanism of Action ............................................................. 
3.2.4 CDK 4/6 Inhibitors and Mechanism of Action ........................................ 
3.2.5 Clinical Experience with Nivolumab ....................................................... 
3.2.6 Clinical Experience with CDK 4/6 Inhibitors and Endocrine Therapy ... 
%HQHILW5LVN$VVHVVPHQW 
3.3.1 Nivolumab Safety Profile ......................................................................... 
3.3.2 CDK 4/6 Inhibitor and Endocrine Therapy Combination Safety Profile  
3.3.3 CDK4/6 Inhibitor and Nivolumab Combination Safety Profile ............... 
2%-(&7,9(6$1'(1'32,176 
678'<'(6,*1
2YHUDOO'HVLJQ 
5.1.1 Screening Period ...................................................................................... 
5.1.2 On-treatment Pre-surgery (neoadjuvant) Period .................................... 
5.1.2.1 Safety Run-in Phase ........................................................................ 
5.1.2.2 Randomized Phase .......................................................................... 
5.1.3 Safety Follow-up Period .......................................................................... 
5.1.4 External Committees ................................................................................ 
5.1.4.1 Study Steering Committee ............................................................... 
1XPEHURI3DUWLFLSDQWV
(QGRI6WXG\'HILQLWLRQ 
(DUO\6WXG\7HUPLQDWLRQ&ULWHULD
6FLHQWLILF5DWLRQDOHIRU6WXG\'HVLJQ 
5.5.1 Rationale for the Choice of Patient Population ....................................... 
5.5.2 Rationale for Choice of Endpoint (Residual Cancer Burden 0-I Rate) ... 
5.5.3 Rationale for CDK 4/6 Plus PD-1 Inhibition .......................................... 
5.5.4 Rationale for Phased Therapy (Arm B) ................................................... 
-XVWLILFDWLRQIRU'RVH 


















&OLQLFDO 3URWRFRO
%06&$$
QLYROXPDE
5HYLVHG 3URWRFRO 1R 'DWH 0DU 
Approved 5.0 v
Approved
1.0
v
5.6.1 Justification for Dose of Nivolumab ........................................................ 
5.6.2 Justification for Dose of CDK4/6 Inhibitors ............................................ 
5.6.3 Justification for Dose of Anastrozole ....................................................... 
678'<3238/$7,21
,QFOXVLRQ&ULWHULD
([FOXVLRQ&ULWHULD 
/LIHVW\OH5HVWULFWLRQV
6.3.1 Meals and Dietary Restrictions for CDK 4/6 Inhibitor ........................... 
6FUHHQ)DLOXUHV 
6.4.1 Retesting During Screening or Lead-In Phase ........................................ 
75($70(17 
7UHDWPHQWV$GPLQLVWHUHG 
7.1.1 Nivolumab Dosing (Safety Run-in Cohorts and Randomized Phase Arms 
A and B) ...................................................................................................... 
7.1.2 CDK4/6 Inhibitors and Anastrozole Dosing ............................................ 
0HWKRGRI7UHDWPHQW$VVLJQPHQW 
%OLQGLQJ
'RVDJH0RGLILFDWLRQ 
7.4.1 Dose Modifications for Abemaciclib ....................................................... 
7.4.2 Dose Modifications for Palbociclib ......................................................... 
7.4.3 Dose Modification for Anastrozole .......................................................... 
7.4.4 Dose Modifications for Nivolumab .......................................................... 
7.4.4.1 Dose Omission Criteria for Nivolumab .......................................... 
7.4.4.2 Criteria to Resume Treatment with Nivolumab .............................. 
7.4.4.3 Treatment of Nivolumab Infusion Reaction .................................... 
3UHSDUDWLRQ+DQGOLQJ6WRUDJH$FFRXQWDELOLW\ 
7.5.1 Retained Samples for Bioavailability/Bioequivalence/Biocomparability  
7UHDWPHQW&RPSOLDQFH 
&RQFRPLWDQW7KHUDS\ 
7.7.1 Prohibited and/or Restricted Treatments for Nivolumab ........................ 
7.7.2 Prohibited and/or Restricted Treatments for Abemaciclib and Palbociclib
..................................................................................................................... 
7.7.3 Other Restrictions and Precautions ......................................................... 
7.7.3.1 Imaging Restriction and Precautions ............................................. 
7.7.4 Permitted Therapy ................................................................................... 
7UHDWPHQW$IWHUWKH(QGRIWKH6WXG\ 
',6&217,18$7,21&5,7(5,$
'LVFRQWLQXDWLRQIURP6WXG\7UHDWPHQW
8.1.1 Nivolumab Dose Discontinuation ............................................................ 
8.1.2 Abemaciclib Dose Discontinuation .......................................................... 
8.1.3 Palbociclib Dose Discontinuation ........................................................... 
8.1.4 Anastrozole Dose Discontinuation .......................................................... 
8.1.5 Post-study Treatment Study Follow-up .................................................... 
'LVFRQWLQXDWLRQIURPWKH6WXG\ 
/RVWWR)ROORZXS 
678'<$66(660(176$1'352&('85(6 

























&OLQLFDO 3URWRFRO
%06&$$
QLYROXPDE
5HYLVHG 3URWRFRO 1R 'DWH 0DU 
Approved 5.0 v
Approved
1.0
v
(IILFDF\$VVHVVPHQWV
9.1.1 Blinded Independent Pathology Review .................................................. 
9.1.2 Pathologic Assessment of Effect .............................................................. 
9.1.2.1 RCB Determination ......................................................................... 
9.1.2.2 Pathological Complete Response Determination ........................... 
9.1.3 Clinical Response Assessments ................................................................ 
9.1.3.1 Objective Response Rate Assessed by Imaging .............................. 
9.1.4 Breast Conserving Surgery Rate .............................................................. 
$GYHUVH(YHQWV
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 
9.2.7 Potential Drug-Induced Liver Injury ....................................................... 
9.2.8 Other Safety Considerations .................................................................... 
9.2.9 Management Algorithms for Nivolumab .................................................. 
2YHUGRVH 
6DIHW\
9.4.1 Physical Examinations ............................................................................. 
9.4.2 Vital Signs ................................................................................................ 
9.4.3 Electrocardiograms/ECHO (preferred) or MUGA ................................. 
9.4.4 Clinical Safety Laboratory Assessments .................................................. 













&OLQLFDO 3URWRFRO
%06&$$
QLYROXPDE
5HYLVHG 3URWRFRO 1R 'DWH 0DU 
Approved 5.0 v
Approved
1.0
v
+HDOWK(FRQRPLFV250HGLFDO5HVRXUFH8WLOL]DWLRQDQG+HDOWK (FRQRPLFV
67$7,67,&$/&216,'(5$7,216 
6DPSOH6L]H'HWHUPLQDWLRQ 
3RSXODWLRQVIRU$QDO\VHV 
6WDWLVWLFDO$QDO\VHV
10.3.1 Efficacy Analyses ................................................................................... 
10.3.2 Safety Analyses....................................................................................... 
10.3.4 Interim Analysis ..................................................................................... 
5()(5(1&(6 
$33(1',&(6 
$33(1',;$%%5(9,$7,216$1'75$'(0$5.6 
$33(1',;678'<*29(51$1&(&216,'(5$7,216 
$33(1',;$'9(56((9(176$1'6(5,286$'9(56((9(176
'(),1,7,216$1'352&('85(6)255(&25',1*(9$/8$7,1*
)2//2:83$1'5(3257,1* 
$33(1',;:20(12)&+,/'%($5,1*327(17,$/'(),1,7,216$1'
0(7+2'62)&2175$&(37,21 
$33(1',;(&2*3(5)250$1&(67$786
$33(1',;1,92/80$%0$1$*(0(17$/*25,7+06 
$33(1',;'(7$,/('3$7+2/2*<0(7+2'6)2586,1*5(6,'8$/
&$1&(5%85'(1 
$33(1',;5(63216((9$/8$7,21&5,7(5,$,162/,'780256
*8,'(/,1(69(56,21 
$33(1',;&28175<63(&,),&$0(1'0(176 
$33(1',;&21&20,7$170(',&$7,216 
$33(1',;1<+$)81&7,21$/&/$66,),&$7,21 
$33(1',;5(9,6('35272&2/6800$5<2)&+$1*(+,6725<
 















&OLQLFDO 3URWRFRO
%06&$$
QLYROXPDE
5HYLVHG 3URWRFRO 1R 'DWH 0DU 
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
1 SYNOPSIS
Protocol Title: Randomized, Non-comparative Neoadjuvant Phase II Study in Patie nts with 
ER+/HER2- Breast Cancer ‚â•2 cm with Safety Run-in, Assessing Nivolumab + Palbociclib + 
Anastrozole
Short Title: Nivolumab with Palbociclib plus Anastrozole in Patients with ER+/HE R2- Breast 
Cancer‚â•2 cm
Study Phase: 2
Rationale:
Blockade of the programmed cell death-1 (PD-1) pathway has demo nstrated clinical activity across 
multiple tumor types, includi ng breast cancer (BC). An accumula ting body of evidence supports 
PD-1/cyclin-dependent kinases (CDK)4/6 blockade potential synergy , as it has become more 
apparent that CDK4/6 inhibitors affect the tumor immune microen vironment (ie, increases 
expression of programmed death-liga nd 1 [PD-L1], enhances antig en presentation and secretion 
of cytokines from both tumor and CD8+ T cells, and suppresses p roliferation of 
immunosuppressive regulatory T cells [Tregs]). Preliminary clinical data supporting synergistic 
activity of the combination o f pembrolizumab and abemaciclib ha s been demonstrated in a Phase 
1b study of heavily pretreated p articipants with metastatic hormone receptor-positive (HR+), 
human epidermal growth factor receptor 2-negative (HER2-) BC. C linical data on combinations 
of other CDK4/6 inhibitors coupled with PD-(L)1 inhibition are be ing generated in multiple 
clinical trials spanning from the neo adjuvant to metastatic set ting (ClinicalTrials.gov: 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]).
The aim of CA2097A8 is to assess the potential synergistic acti vity of nivolumab with palboci clib 
and anastrozole in participants with newly diagnosed, previously untreated primary estrogen 
receptor-positive (ER+), HER2- BC ‚â•2 cm, defined by significantly improved residual cancer
burden (RCB; 0-I) rate.  
 
Additional objectives of the 
study include characterization of safety and tolerability of thi s combination  
 
. 
Study Population:
Participants will include men and postme nopausal women with ER+ and HER2- pr imary 
BC‚â•2c m .
Revised Protocol No.: 03
Date: 13-Mar-2020 15
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Objectives and Endpoints:
Objectives Endpoints
Primary
‚Ä¢Safety Run-in Phase: Number of 
participants with occurrence of DLT.‚Ä¢DLT is defined as TEAE (graded according to the NCI CTCAE v5.0) that occurs during the first 4 weeks after 
treatment start and that meets specific criteria.
‚Ä¢Randomized Phase: To assess RCB 0-I rate
by central assessment of palbociclib plus anastrozole with or without nivolumab in all participants with untreated pr imary BC 
‚â•2 cm (ER+, HER2-).‚Ä¢RCB 0-I r ate assessed by central assessment at the time of 
definitive surgery.
‚Ä¢RCB is a conti nuous index combining pathological 
measurements of primary tumor (s ize and cellularity) and 
nodal metastases (number and size) defined by a point system at surgery (refer to Appendix 7).
Secondary
‚Ä¢To assess the safety and tolerability of palbociclib plus anastrozole with or without nivolumab.‚Ä¢Incidence of AEs, SAEs, AEs leading to discontinuation, immune-related AEs, deaths, and laboratory abnormalities in all participants.
‚Ä¢To assess pCR rate by local assessment of palbociclib plus anast rozole with or without 
nivolumab in participants with untreated 
primary BC ‚â•2 cm (ER+, HER2-).‚Ä¢pCR rate in all participants assessed by the local pathologist 
at the time of definitive surgery. pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen 
and all sampled regional lymph nodes following completion 
of neoadjuvant systemic therapy (ie, ypT0/Tis ypN0 in the current AJCC staging system).
‚àípCR, defined as no invasive residual disease in breast 
or lymph nodes (ie, ypT0/is, ypN0) in the current AJCC 
staging system.
‚Ä¢To assess ORR (clinical and radiological 
[ultrasound (preferred) or mammography]) by Investigator assessment and BCS rate of palbociclib plus anastrozole with or without nivolumab in participants with untreated 
primary BC ‚â•2 cm (ER+, HER2-).‚Ä¢ORR is defined as the number of participants with a BOR 
of CR or PR divided by the number of randomized participants for each treatment group at the end of the study treatment period.
‚Ä¢BCS rate is defined as the number of participants who undergo BCS after completing the study treatments divided by the number of randomized participants for each treatment group.
Revised Protocol No.: 03
Date: 13-Mar-2020 16
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Objectives Endpoints
Abbreviations:  AE = adverse event; AJCC = American Jo int Committee on Cancer;
BC = breast cancer; BCS = breast-conserving surgery; BOR = best overall response; CR = complete response; 
CTCAE = Common Terminology Criteria for Adverse Events; DLT = dose -limiting toxicity;  
 
HER2- = human epidermal growth factor receptor 2-negative;  NCI = National Cancer 
Institute; ORR = objective response rate; pCR = pathological comp lete response;  
 PR = partial response; 
R CB = Residual 
Cancer Burden; SAE = serious adverse event; TEAE = treatment-em ergent adverse event; TIL = tumor-infiltrating 
lymphocyte; .
Overall Design:
This randomized, open-label Phase 2 study was to evaluate whethe r the combination of nivolumab, 
with palbociclib, plus anastrozole is a safe and effective neoad juvant treatment for men and
postmenopausal women with primary BC ‚â•2 cm that is ER+ and HER2- subtype who are suitable 
Revised Protocol No.: 03
Date: 13-Mar-2020 17
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
to receive neoadjuvant endocrine therapy (NET) and willing to u ndergo standard-of-care (SOC) 
breast surgery after completion of the study treatment. 
On 6-Mar-2020, Bristol Myers Squibb (BMS) decided to permanentl y discontinue enrollment and 
dosing in the nivolumab + abemaciclib + anastrozole cohorts of the CA209-7A8 study during the 
Safety Run-in phase.  
 
 
 
 
 
At implementation of Revised Protocol  03, the study will only e valuate whether the combination 
of nivolumab, with palbociclib plus anastrozole is a safe and e ffective neoadjuvant treatment for 
men and postmenopausal women with primary BC ‚â•2 cm that is ER+ and HER2- subtype who 
are suitable to receive NET and willing to undergo SOC breast s urgery after completion of the 
study treatment. Participants must have histologically confirme d invasive breast carcinoma 
meeting the characteristics described in the Inclusion Criteria . Participants in screening and not 
yet treated were be offered the option to join the safety lead- in of the nivolumab + palbociclib + 
anastrozole arm. Participants on treatment with nivolumab + abe maciclib + anastrozole were to be 
re-consented and continue on anastrozole alone, OR taken off st udy. In addition, baseline chest X-
ray and periodic pulse oximetry are implemented to monitor ILD/ pneumonitis in patients who will 
be treated with nivolumab + palbociclib + anastrozole.
The study is divided into 3 periods: Screening Period, On-treat ment Pre-surgery (neoadjuvant) 
Period (Safety Run-in Phase and Randomized Phase), and Safety Fo llow-up Period.
The study started with a Safety Run-in Phase for the combination  of nivolumab, w ith abemaciclib 
or palbociclib, plus anastrozole and will begin the Randomized Ph ase after the regimen is 
determined to be safe. Participants in the Safety Run-in Phase will move to the Safety Follow-up 
Period upon completion of the neoadjuvant treatment or upon dis continuation. Potential needs for 
additional enrollment or for dose de-escalation w ill be discussed with Investigators and BMS 
during the Saf ety Run-in Phase. Once a safe dose for the regimen  has been determined by BMS in 
collaboration with Investigators, the Randomized Phase of the s tudy will begin.
In the Randomized Phase, participants will be randomly assigned  by an IRT system to 3 different 
treatment arms and stratified by the following factors:  
 2) evaluation of l ymph nodes (cytologically positiv e vs radiologically or 
cytologically negative); and 3) tumor size (> 3 cm or ‚â§3 cm).
For both the Safety Run-in Phase and Randomized Phase, particip ants will be tr eated for a 
maximum of 5 cycles (1 cycle = 4 weeks). Participants with prog ressive disease prior to 
completion of the 5-cycle study treatment must discontinue all s tudy drugs and proceed to the 
Safety Follow-up Period. Participants who permanently discontin ue the study drugs for any reason 
are considered to have completed the On-treatment Pre-surgery ( neoadjuvant) Period, and hence 
Revised Protocol No.: 03
Date: 13-Mar-2020 18
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
reach end of tr eatment (EOT). After Cy cle 5 or EOT, p articipants must co ntinue to receive 
anastrozole (as concomitant medication and not as study treatme nt) until subsequent SOC breast 
surgery. Followi ng the completion of neoadjuvant tr eatment, all participants who remain operative 
candidates will undergo definitive surgery for BC within 4 week s of the last neoadjuvant treatment 
administration. If anastrozole can no longer be administered aft er EOT, participants will go to 
breast surgery right away. Pr e-surgical lym ph node biopsy is not  allowed. Information on the type 
of the surgery will be collected and recorded in the electronic  case report form (eCRF). Surgical
specimens will be collected for the analyses outlined in the pr otocol. Depending on treatment 
assignment, up to 2 safety follow- up visits will be conducted in person. The first safety follow- up 
visit (FU1) will be comp leted for all participants within 30 days ( ¬±7 days) from the last study 
treatment (oral or intravenous [IV ], whichever occurs later). The second safety follow-up visit 
(FU2) will occ ur approximately within 100 days ( ¬±7 days) from the last dose of nivolumab and 
will be required for participants in the Safety Run-in Phase an d participants randomized to Arms A
or Bin the Randomized Phase. Further planned tr eatment of participants in the adjuvant setting 
(ie, radiotherapy, endocrine treatment, chemotherapy or any othe r treatment mod ality) will be at 
the discretion of the treating physician, following local clini cal guidelines, and collected in the 
appropriate eCRF. 
The study design schematic is presented in the Figure below.
Revised Protocol No.: 03
Date: 13-Mar-2020 19
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Study Design Schematic
Abbreviations: Abema = abemaciclib; ANZ = anastrozole; BID = tw ice d aily; cm = cen timeter; ECOG = Eastern Cooperative Oncology Group; 
ER+ = estrogen-receptor-positiv e; FU1 = follow-up vi sit 1; FU2 = follow-up visit 2; HER2- = human epidermal growth factor recepto r 2-negative; mg = milligram; 
IV = intravenous; N = number; Nivo = nivolumab; Palbo = palbociclib ;  PO = per os (by mouth); PS = performance status; 
Q4W = every 4 weeks; QD = once daily; Rand = randomized; wk = week.
aFU1 begins at the end of study treatment.
bCytologically positive vs radiologically or cytologically negati ve.Screening Period Pre-surgery Treatment Period (N = 115~136) Safety Follow-up Period
Key Inclusion 
Criteria
‚Ä¢ Newly diagnosed, 
histologically 
proven ER+, 
HER2- primary 
breast cancer‚â• 2 cm
‚Ä¢M e n  a n d  
postmenopausal 
women
‚Ä¢ ECOG PS 0-1Safety Run-in Phase
(3 + 3 Approach)
(n = 3~24)cRandomized Phase
(n = 110)dFU1a
(All Participants in he 
Safety Run-in Phase and 
the Randomized Phase)FU2
(All Participants in the 
Safety Run-in Phase and 
Arms A and B Only in 
the Randomized Phase)
Investigator‚Äôs Choice
Cohort 1 (n = 3~24)
Nivo 480 mg Q4W IV
+ Abema 150 mg BID PO 
+ ANZ 1 mg QD PO
x 5 cycles
Cohort 2 (n = 3~24)
Nivo 480 mg Q4W IV
+ Pa bo 125 mg QD PO 
3 wks on 1 wk off
+ ANZ 1 mg QD PO
x 5 cyclesArm A (n = 40)
Nivo 480 mg Q4W IV + Palbo 125 mg QD PO 3 wks on 
1 wk off + ANZ 1 mg QD PO x 5 cycles
Arm B (n = 40)
Palbo 125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg 
QD PO x 1 cycle THEN Nivo 480 mg Q4W IV + Palbo
125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg QD PO 
x 4 cycles
Arm C (n = 30)
Palbo 125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg 
QD PO x 5 cycles
Rand
4:4:330-Day Safety 
Follow-up100-Day Safety 
Follow-up
(from last Nivo dose)
30-Day Safety 
Follow-up100-Day Safety 
Follow-up
(from last Nivo dose)
30-Day Safety 
Follow-up
Stratify Randomized 
Phase Participants by:
‚Ä¢ Node (+ or -)b
‚Ä¢ Tumor size
(> 3 cm or ‚â§ 3 cm)
Revised Protocol No.: 03
Date: 13-Mar-2020 20
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
cAt the time of Revised Protocol 03, 2 sub jects had been treated in Cohort 1 (nivolumab + abemaciclib + a nastrozole), which was subsequently closed for 
enrollment.
dAt time of Revised Protocol 03, the decision was made to no long er evaluate abemaciclib in combination with nivolumab plus anas trozole; thus, the abemaciclib-
containing combination arms have been removed from the Randomization Phase of the study.
Revised Protocol No.: 03
Date: 13-Mar-2020 21
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Number of Participants:
A total of approximately 115~136 participants w ill be tr eated in the study. It is anticipated that 
approximately 3~24 participants (up to approximately 30 screened ) will be t reated in each cohort 
in the Safety Run-in Phase. At the time of Revised Protocol 03,  2 subjects had been treated in 
Cohort 1 (nivolumab + abemaciclib + anastrozole), which was subs equently closed for enrollment. 
Approximately 138 participants w ill be screened for 110 participants to be treated in the 
Randomized Phase, assuming a screen failure rate of approximately 20%. 
Originally, approximately 3~24 parti cipants will be  treated in t he Safety Run-in Phase in each 
cohort (Cohort 1: nivolumab + abemaciclib + anastrozole for 5 cycl es; n = 3‚àº6 per dose level of 
abemaciclib; Cohort 2: nivolumab + palbociclib + anastrozole for 5 cycles; n = 3 ‚àº6 per dose level 
of palbociclib). At the time of R evised Protocol 03, 2 subjects had been treated in Cohort 1 
(nivolumab + abemaciclib + anastrozole), which was subsequently closed for enrollment.
Approximately 110 participants are planned to be randomized in t his study at a 4:4:3 ratio into 
Arm A (nivolumab + palbociclib + anastrozole for 5 cycles; n = 4 0), Arm B (palbociclib + 
anastrozole for 1 cycle, followed by nivolumab + palbociclib + anastrozole fo r 4 cycles;  n = 40), 
and Arm C (palbociclib + anatroz ole for 5 cycles ; n = 30), respectively. Participants will be 
stratified by  node status, and tumor size.
Treatment Arms and Duration:
The treatment arms and duration for the Safety Run-in Phase and Randomized Phase are provided 
in the tables below.
Selection and Timing of Dose - Safety Run-in Phase
CohortStudy 
TreatmentDosage Levela Frequency of
AdministrationStart and Duration 
of TreatmentRoute of 
Administration
1Nivolumab 480 mg Q4W Cycle 1-5 IV
Abemaciclib 150 mg BID Cycle 1-5PO (with or 
without food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
2Nivolumab 480 mg Q4W Cycle 1-5 IV
Palbociclib 125 mgQD √ó3 weeks on
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Abbreviations: BID = t wice daily; EOT = end of treatment; IV = intravenous; mg = milligram; PO  = per os (by mouth); 
Q4W = every 4 weeks; QD = once daily.
Note: At the time of Revised Protocol  03, 2 sub jects had been treated  in Cohort 1 (nivolumab + abemaciclib + 
anastrozole), which was subsequently closed for enrollment.
aFor abemaciclib and palbociclib, this is the starting dose leve l. Dose levels may be reduced per Dosage Modification 
guidelines in the main protocol.
bAfter 5 cycles or EOT, all participants should continue to recei ve anastrozole until breast surgery. Anastrozole is 
not considered study therapy beyond completion of Cycle 5 or EO T.
Revised Protocol No.: 03
Date: 13-Mar-2020 22
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Selection and Timing of Dose - Randomized Phase
ArmStudy 
TreatmentDosage Levela Frequency of
AdministrationStart and Duration 
of TreatmentRoute of 
Administration
ANivolumab 480 mg Q4W Cycle 1-5 IV
Palbociclib 125 mgQD √ó3 weeks on
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
BPalbociclib 125 mgQD √ó3 weeks on
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Nivolumab 480 mg Q4W Cycle 2-5 IV
CPalbociclib 125 mgQD √ó3 weeks on
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Abbreviations: BID = twice daily; EOT  = end of treatment; IV = intravenous; mg = milligram; PO = per  os (by mouth); 
Q4W = every 4 weeks; QD = once daily.
Note: As of Revised Protocol 03, the abemaciclib-containing comb ination arms have been removed from the 
Randomization Phase of the study.
aFor palbociclib, the starting dose level will be the safe dose determined upon completion of the Safety Run-in 
Phase.
bAfter 5 cycles or EOT, all participants should continue to recei ve anastrozole until breast surgery. Anastrozole is 
not considered study therapy beyond completion of Cycle 5 or EOT.
Revised Protocol No.: 03
Date: 13-Mar-2020 23
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Study Treatment:
Study Drug for CA2097A8
Medication Potency IP/Non-IP 
Nivolumab Injection 10 mg/mL; 100 mg fill volume
and
10 mg/mL; 40-mg fill volumeIP
Abemaciclib Tablets 150 mg, 100 mg, and 50 mg IP
Palbociclib Capsules 125 mg, 100 mg, and 75 mg IP
Anastrozole Tablets 1 mg IP
Abbreviations: IP = investigational product; mg = milligram; mL  = milliliter.
Data Monitoring Committee: No
Revised Protocol No.: 03
Date: 13-Mar-2020 24
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (Safety Run-in Phase and Randomized Phase; CA2097A8)
Procedurea Screening
VisitNotes
All windows are based on calendar days.
Eligibility Assessments
Informed Consent XMust be obtained prior to any study-related procedures.
Register in IRT system to obtain participant number.
Inclusion/Exclusion Criteria XMust be assessed at screening and must be confirmed prior to: 
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized participants: randomization
Medical History X All medical history relevant to the disease und er study, including tobacco history.
Documentation of Postmenopausal Status XPlease see inclusion criterion 3) b) in Section 6.1 (Inclusion Criteria) for a definition of 
postmenopausal women.
Pretreatment Tumor Sample Submission XA recent archival tumor biopsy (collected within 90 days prior to enrollment) is required in the format 
of FFPE block (strongly preferred) or 22 unstained tumor slides (sectioned within 60 days prior to 
enrollment from a tissue sample collected within 90 days prior to enrollment). If a recent tumor 
specimen is not available, a fresh tumor biopsy collection is required. At least 15 unstained slides 
must be submitted for a participant to be eligible. If < 15 unst ained slides are available, the participant 
is not eligible.
‚Ä¢Safety Run-in participants: Participant can start study treatme nt before confirmation of receipt of 
the tumor sample by the central laboratory. However, receipt of  the tumor sample by the central 
laboratory must occur within 28 days of the first dose.
Safety Assessments
Targeted PE, Measurements, Vital Signs, 
and ECOG PSXHeight, weight, BP, HR, RR, temperature, and ECOG PS ( Appendix 5). Must be collected within 
14 days prior to: 
‚Ä¢Safety Run-in participants: first dose
Revised Protocol No.: 03
Date: 13-Mar-2020 25
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (Safety Run-in Phase and Randomized Phase; CA2097A8)
Procedurea Screening
VisitNotes
All windows are based on calendar days.
‚Ä¢Randomized participants: randomization
‚Ä¢Targeted PE must include ocular examination.
ECG XMust be performed within 28 days prior to: 
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized participant: randomization
ECHO (preferred) or MUGA XMust be performed within 28 days prior to:  
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized participants: randomization
Assessment of Signs and Symptoms XMust be performed within 14 days prior to:  
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized participants: randomization
Concomitant Medication Use XMust be performed within 14 days prior to: 
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized participants: randomization
Vaccine use within 30 days prior to first dose.
Chest X-ray XMust be performed within 14 days prior to: 
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized Phase participants: randomization
SAE Assessment X SAE collection from time of consent.
Laboratory Tests
CBC with Differential, Chemistry, 
Endocrine, and SerologyXMust be performed within 14 days prior to:  
‚Ä¢Safety Run-in participants: first dose
‚Ä¢Randomized Phase participants: randomization
FSH and Estradiol are require d for women ‚â§ 55.
See Section 9.4.4 for a list of laboratory tests to conduct.
Revised Protocol No.: 03
Date: 13-Mar-2020 26
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (Safety Run-in Phase and Randomized Phase; CA2097A8)
Procedurea Screening
VisitNotes
All windows are based on calendar days.
Efficacy Assessments
Documentation of Planned Surgery X Record type of planned BC surg ery (ie, BCS, mastectomy).
Clinical Breast Examination X Clinical breast examination by palpation of breast and axilla.
Breast and Axilla Ultrasound (Preferred) 
or MammogramXPerform breast and axilla ultrasound (preferred) or a mammogram w ithin 28 days prior to:  
‚Ä¢Safety-run in participants: first dose
‚Ä¢Randomized participant: randomization
‚Ä¢Every attempt should be made to image each participant using an identical imaging modality and 
acquisition protocol for all imaging time points.
Other Imaging (eg, Bone Scan) XAs clinically indicated per local standards, including patholog ic examination of suspected lesions.
See Section 9.1 (Efficacy Assessments) for further details.
Axillary Lymph Nodes Fine Needle 
Biopsy or Core BiopsyXThis procedure at screening will be omitted if there is no suspicion for positive axillary lymph node(s) radiographically, or if a pathological report of suspic ious lymph nodes of the results of a fine 
needle biopsy or core biopsy are available prior to the Screeni ng Period. 
Abbreviations: BC = breast cancer; BCS = breast-conserving surg ery; BP = blood pressure; CBC = complete blood c ount; ECG = electrocardiogram; 
ECHO = echocardiogram; ECOG = Eastern Cooperative Oncol ogy G roup; eCRF = electronic case report form; ER = estrogen recepto r; FFPE = formalin-fixed, 
paraffin-embedded; FSH = follicle-stimulating hormone; HR = heart r ate; IHC = immunohistochemistry; IRT = Interactive Response Techn ology; 
MUGA = mu ltiple gated acquisition;  PE = phy sical examination; PS = performance status; RR = respiratory rat e; 
SAE = serious adverse event.
aSome of the assessments referred to in this section may not be c aptured as data in the eCRF. They are intended to be used as sa fety monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
Revised Protocol No.: 03
Date: 13-Mar-2020 27
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-2: On-treatment Pre-surgery (Neoadjuvant) Procedural Out line (Safety Run-in Phase and Randomized 
Phase; CA2097A8)
ProcedureaNeoadjuvant Treatmentb,c
Cycle 1-5 (1 cycle = 4 weeks)Pre-surgery
(within 7 days 
prior to surgery)Notesd
Day 1 Day 8 Day 15 Day 22
Safety Assessments
Targeted PE, 
Measurements, Vital Signs, 
and ECOG PSXC2D15
(see Notes)XWeight, BP, HR, temperature, and ECOG PS 
(Appendix 5 ) on Day 1 of each cycle.
Targeted PE must also include ocular 
examination at C1D1, C2D15, and as clinically 
indicated.
Pulse OximetryX
(predose)For each testing, two measurements are needed, i.e. at rest and immediately post ambulation
ECGC1D1
(predose)C1D15
(predose)Triplicate ECG (collected within ~ 5 minute window) at C1D1, C1D15 , and as clinically 
indicated.
AEs Assessment (including SAEs)Continuously. Record at each visit.
Concomitant Medication ReviewContinuously. Record at each visit.
Laboratory Tests
CBC with Differential, Chemistry Panel, and 
Endocrine TestingXX
C1-C2Must be performed within 3 calendar days prior to dosing for all time points, except C1D1,which does not need to be repeated if performed within 7 days prior to the first dose.
See Section 9.4.4 (Clinical Safety Laboratory 
Assessments) for list of laboratory tests.
Efficacy Assessments
Clinical Breast 
ExaminationXClinical breast examination by palpation ofbreast and axilla.
Revised Protocol No.: 03
Date: 13-Mar-2020 28
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-2: On-treatment Pre-surgery (Neoadjuvant) Procedural Out line (Safety Run-in Phase and Randomized 
Phase; CA2097A8)
ProcedureaNeoadjuvant Treatmentb,c
Cycle 1-5 (1 cycle = 4 weeks)Pre-surgery
(within 7 days 
prior to surgery)Notesd
Day 1 Day 8 Day 15 Day 22
Breast and Axilla 
Ultrasound (Preferred) or 
Mammogram C2D22 (as clinically indicated) XBreast and axilla ultrasound (preferred) or 
mammogram to be done on C2D22 and within 7 
calendar days prior to surgery. Every attempt 
should be made to image each participant using an identical imaging modality and acquisition protocol for all imaging time points.
Documentation of Actual Breast SurgerySee Notes.Record actual type of BC surgery (ie, BCS, mastectomy) on day of or within 7 days after surgery.
Revised Protocol No.: 03
Date: 13-Mar-2020 29
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-2: On-treatment Pre-surgery (Neoadjuvant) Procedural Out line (Safety Run-in Phase and Randomized 
Phase; CA2097A8)
ProcedureaNeoadjuvant Treatmentb,c
Cycle 1-5 (1 cycle = 4 weeks)Pre-surgery
(within 7 days 
prior to surgery)Notesd
Day 1 Day 8 Day 15 Day 22
Study Drug
Randomization XFirst dose to be administered within 3 calendar 
days following randomization (for Randomized Phase ONLY).
IRT Drug Assignment XRegister the visit in the IRT for study drug allocation.
Revised Protocol No.: 03
Date: 13-Mar-2020 30
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-2: On-treatment Pre-surgery (Neoadjuvant) Procedural Out line (Safety Run-in Phase and Randomized 
Phase; CA2097A8)
ProcedureaNeoadjuvant Treatmentb,c
Cycle 1-5 (1 cycle = 4 weeks)Pre-surgery
(within 7 days 
prior to surgery)Notesd
Day 1 Day 8 Day 15 Day 22
Administer Nivolumab 
480 mg (Safety Run-in Cohorts and Arms A and 
B)XTo be administered Q4W IV. First dose to be 
administered within 3 calendar days following randomization.
‚Ä¢Randomized Phase:
‚Ä¢Arm A and Arm B
‚Ä¢Starting at C2D1 for Arm B 
Dispense Anastrozole 1 mg 
and Provide and Review 
Patient Diary (Safety Run-in Cohorts and all Arms)XTo be administered QD PO, with or without food.Review patient diary at each study visit.
Note: Anastrozole given beyond C5 or beyond 
EOT will not be considered as study treatment and must be collected as concomitant medication.
AND
Dispense Abemaciclib and 
Provide/Review Patient 
Diary (Safety Run-in 
Cohort 1)eXTo be administered BID PO with or without 
food. Review patient diary at each study visit.
OR
Dispense Palbociclib and 
Provide/Review Patient 
Diary (Safety Run-in Cohort 2 and Arms A, B, and C)XTo be administered QD PO with food during the first 3 weeks of each cycle (1 week off). Review patient diary at each study visit.
Abbreviations: AE = adverse event; BC = breast cancer; BCS = breast-conserving surgery; BID = twice daily; BP = blood pressure; C = cycle; CBC = complete 
blood count; D = day; ECG = electrocardiogram; ECOG = Eastern Coo perative Oncology Group; eCRF = electronic case report form; EOT = end of treatment; 
; HR = heart rate;  IRT = interactive response 
technology; IV = intravenous; mg = milligram; PE = phy sical examination;  PO = per os, (by mouth );  
PS = per formance status; QD = daily; Q4W = every 4 weeks; SAE = serious  adverse event .
Revised Protocol No.: 03
Date: 13-Mar-2020 31
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
aThe schedule for each procedure should coincide with actual dosi ng.
bParticipants will undergo surgical treatment within  4 weeks of the last dose of neoadjuvant treatmen t (IV or oral, whichever comes later).
cOn-treatment procedures may generally be performed within a ¬±3-day window, unless otherwise specified (eg, breast ultrasound  or mammogram, tumor biopsy).
dSome of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as s afety monitoring by the treating 
physician. Additional testing or assessments may be performed as  clinically necessary or where required by institutional or loc al regulations.
Revised Protocol No.: 03
Date: 13-Mar-2020 32
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2-3: Follow-up Procedural Outline (Safety Run-in Phase and Randomized Phase; CA2097A8)
Procedure30-Day Safety Follow Up
(FU1)a
(¬±7 days)
(All Participants in the 
Safety Run-in Phase and 
the Randomized Phase)100-Day Safety Follow Up
(FU2)a
(¬±7 days)
(All Participants in the 
Safety Run-in Phase and 
Arms A and B Only in the 
Randomized Phase)Notesb
Safety Assessments
Targeted PE, 
Measurements, Vital Signs, 
and ECOG PSXXWeight, BP, HR, temperature, and ECOG PS.
Targeted PE may include ocular examination, if clinically 
indicated.
AE Assessment (including 
SAEs)XXParticipants will be followed for treatment-related toxicities 
until these toxicities resolve, return to baseline, or are deemed 
irreversible.
Note: All AEs will be documented for a minimum of 100 days 
after last dose of nivolumab for Safety Run-in Cohorts and 
Arms A and B, and for 30 days from the last dose of study 
treatment for Arm C.
Concomitant Medication 
ReviewX X Record at each visit.
Subsequent Cancer 
TreatmentXXAt each visit, record any new surgery, radiotherapy, and systemic cancer therapy given for the disease under study.
Laboratory Tests
CBC with Differential, 
Chemistry, and EndocrineXXMust be performed at FU1. If study drug-related toxicities 
persist, must be repeated at FU2.
See Section 9.4.4 (Clinical Safety Laboratory Assessments) for 
list of laboratory tests to conduct.
Abbreviations: AE = adverse event; BP = bl ood pressure; CBC = complete bl ood count; ECOG = Eastern Cooperative Oncology Group; eCRF = elect ronic case 
report form; FU1 = follow-up visit 1; FU2 = follow-up visit 2; HR = heart rate;  IV = intravenous; PE = ph ysical examination; 
 PS = performance status; SAE = serious adv erse event; SOC = standard of care.
aParticipants must be followed for at least 100 days after last dose of nivolumab. FU1 should occur 30 days ( ¬±7 days) from the last dose of any treatment (IV or 
oral whichever comes later). FU2 occurs approximately 100 days ( ¬±7 days) from last dose of nivolumab. Both follow-up visits should be conducted in person.
bSome of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as s afety monitoring by the treating
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or lo cal regulations.
Revised Protocol No.: 03
Date: 13-Mar-2020 33
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
3 INTRODUCTION
CA2097A8 is an open-label, randomized, non-comparative Phase 2 study assessing 
nivolumab, plus palbociclib, and anastrozole as either concurrent  or phased neoadjuvant treatment 
for men and postmenopausal women with primary breast cancer (BC) ‚â•2 cm that are estrogen 
receptor-positive (ER+) and human epidermal growth factor recept or 2-negative (HER2-) with 
safety run-in.
Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype m onoclonal antibody (mAb),
an immuno-oncologic (IO) checkpoint inhibitor that binds progra mmed cell death-1 (PD-1) on 
activated immune cells and disrupts engagement of the receptor with its ligands programmed 
death-ligand 1 (PD-L1; B7-H 1/CD274) and programmed death-ligand  2 (PD-L2; B7-DC/CD273), 
thereby abrogating inhibitory signals and augmenting the host a nti-tumor response. Palbociclib is
an orally bioavailable and highly selective small-molecule inhi bitor against cyclin-dependent
kinases (CDK)4/cyclin-D1 and CDK6/cyclin-D3 enzyme complexes, le ad to reactivation of 
retinoblastoma (Rb) protein, binding back of E2F transcription factor and subsequent cell cycle 
arrest, thus abrogating endocrine-resistant cell proliferation. Anastrozole is a reversible, third-
generation, selective nonsteroi dal aromatase inhibitor (NSAI) th at reduces peripheral estrogen
synthesis by blocking the conversion of androgens to estrogens in  non-ovarian tissues. A detailed 
description of the chemistry, pharmacology, efficacy, and safet y of the study treatments is 
provided i n the Investigator Brochures (IBs) and package inserts.1,2,3,4
The study will assess the efficacy and safety of: i) concurrent therap y with nivolumab in 
combination with palbociclib, and anastrozole (Arm A), ii) phased therapy with one initial priming 
cycle of palbociclib and anastrozole followed by nivolumab in com bination with palbociclib, and 
anastrozole (Arm B), and iii) control tr eatment with palbociclib and anastrozole (Arm C). 
Participants with newly diagnosed, previously untreated primary  ER+ and HER2- BC ‚â•2 cm will 
be subjected to a total 5 cycles (4 weeks per cycle) of neoadjuv ant therapy before definitive 
surgery. Efficacy will be measured by significantly improved re sidual cancer burden (RCB) 0-I 
rate.  
 
3.1 Study Rationale
PD-1 pathway inhibition has demonstrated clinical activity across mult iple tumor types, including
BC.5An accumulatin g body of evidence s upports PD-1/CDK4/6 blockade potential synergy, as it 
has become more apparent that CDK4/6 inhibitors modulate the tu mor immune 
microenvironment6(ie, increases expression of PD-L1,7enhances antigen presentation8and 
secretion of cytokines from both tumor and CD8+ T cells,9,10and suppresses proliferation of 
immunosuppressive regulato ry T cells [Tregs]8). Preliminary clinical data in support of synergistic 
activity of the combination of pembrolizumab and abemaciclib ha s been demonstrated in a 
Phase 1b study on heavily pretr eated participan ts with metastatic hormone receptor-positive 
(HR+), HER2- BC.11Clinical data on combinations of other CDK4/6 inhibitors with PD -(L)1 
Revised Protocol No.: 03
Date: 13-Mar-2020 34
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
blocking agents are being generated in multiple clinical trials spanning from the neoadjuvant to 
metastatic setting (ClinicalTrials.gov: [STUDY_ID_REMOVED], NCT0277868 5, [STUDY_ID_REMOVED]).
Additional treatment benefit (im proved anti-tumor efficacy and c omplete tumor regression) was 
observed in a syngeneic mouse tumor model by priming the anti-ca ncer immune response with 
abemaciclib in a phased administration of abemaciclib and an an ti-PD-L1 therapy.12Therefore, an 
additional phased therapy arm has been added for each CDK4/6 inhibitor to explore possible 
treatment benefit in patients.
The aim of the CA2097A8 study is to assess the potential synerg istic activity of nivolumab, with 
palbociclib, and anastrozole in participants with newly diagnos ed, previously untreated primary 
ER+, HER2- BC ‚â•2 cm, defined by significantly improved RCB (0-I) rate.  
 
 
Additional objectives of the study include char acterization of safety and 
tolerabilit  
.  
3.1.1 Research Hypothesis
The combination of nivolumab, with palbociclib, and anastrozole  is a safe and effective 
neoadjuvant treatment for patients with ER+, HER2- primary BC ‚â•2c m .
3.2 Background
3.2.1 ER+/HER2- Breast Cancer
BC ranks second as a cause of cancer death in women after lung cancer.13An estimated 42,260 
BC deaths (41,760 women) are exp ected in 2019 in the United Sta tes (US). In clin ical pr actice, 
BC tumors are classified by the expression status of estrogen r eceptor (ER), progesterone receptor 
(PgR), and human epidermal growth factor receptor 2 (HER2). The  BC subtypes identified on the 
basis of these receptors have been reported to bear distinct ge ne expression profiles,14,15as well 
as different prognoses and treatm ent vulnerabilities. Seventy p ercent of invasive BC in 
women > 45 years of age express ER and/or PgR, but not HER2, and a re termed hormone 
receptor-positive (HR+), HER2-.16Seminal studies performed with gene expression profiling 
analysis of primary BC samples indicated that the tumors in the  HR+ group are characterized by 
the relatively high expression of genes related to luminal pheno type (ER-responsive genes, luminal 
cytokeratins, and other luminal-associated markers); consequently , HR+, HER2- BC was found to 
be significantly enriched with the so called luminal BC intrins ic subtypes, namely: luminal A 
(50-60% of all BC, showing higher dependence on ER signaling, s lower proliferation rate and 
overall more indolent clinical c ourse) and luminal B (15-20% of  all BC, showing lower 
dependence on ER signaling, higher proliferation rate, and overa ll, a more aggressive clinical 
course and worse prognosis, as compared to their luminal A counterparts).17
Revised Protocol No.: 03
Date: 13-Mar-2020 35
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
3.2.2 Neoadjuvant Endocrine Treatment
While, traditionally, neoadjuvant chemotherapy has been used to d ownstage locally advanced and 
unresectable primary BC, a number of studies have highlighted t he role of neoadjuvant endocrine 
treatment (NET) as an alternative option to chemotherapy in pati ents with HR+, HER2- primary 
tumors,18particularly for postme nopausal women. Available data suggest that NET is associated 
with similar response rates and rates of breast-conserving surg ery (BCS) as neoadjuvant 
chemotherapy, albeit with lower toxicity in postmenopausal women  with HR+ BC.18,19,20,21,22For 
postmenopausal women receiving NET, the administration of an ar omatase inhibitor (AI) is 
recommended instead of tamoxifen, based on evidence suggesting improved outcomes for women 
treated with AIs across clinical trials and meta-analyses.21,23,24,25, 26,27,28,29Similar clinical 
outcomes (rate of BCS) in the neoadjuvant setting among the AIs  were observed in 
377 postmenopausal women with Stag e II or III strongly ER+ BC who were randomly assigned to 
treatment with exemestane, letrozole, or anastrozole for 16-18 weeks before surgery in the 
American College of Surgeons Oncology Group (ACOSOG) Z1031 tria l.28
3.2.3 Nivolumab Mechanism of ActionCancer immunotherapy rests  on the premise that tumors can be recognized as foreign rather than 
as self and can be effectively attacked by an activated immune system. An effective immune 
response in this setting is thought to rely on immune surveilla nce of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune resp onse and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of tra its that allow cancer cells to 
evade immune surveillance and escape effective innate and adapt ive immune responses.
30,31,32
Current immunotherapy efforts attempt to break the apparent tol erance of the immune system to 
tumor cells and antigens by eith er introducing cancer antigens by therapeutic vaccination or by 
modulating regulatory checkpoints of the immune system. T cell stimulation is a complex process 
involving the integration of numerous positive as well as negat ive co-stimulatory signals in 
addition to antigen recognition by the T- cell r eceptor (TCR).33Collectively, these signals govern 
the balance between T-cell activation and tolerance.
PD-1 is a member of the cluster of differentiation 28 (CD28) fam ily of T cell co-s timulatory 
receptors that also includes CD28, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), 
inducible T cell co-stimulator (ICOS), and B- and T-lymphocyte att enuator (BTLA).34PD-1 
signaling has been shown to inhibit CD28-mediated upregulation of interleukin (IL)-2, IL-10, 
IL-13, interferon-Œ≥ (IFN-Œ≥), and B- cell lymphoma-extra large (Bcl-xL). PD-1 expression has also 
been noted to inhibit T cell activation and expansion of previo usly activated cells. Evidence for a 
negative regulatory  rol e of  PD-1 com e s  from  studi es of  PD-1 def icient mice, which develop a 
variety of autoimmune phenotypes.35These results suggest that PD-1 blockade has the potential 
to activate anti-self T-cell res ponses, but these responses are v ariable and dependent upon a h ost 
genetic factors. Thus, PD-1 deficiency or inhibition is not acc ompanied by a universal loss of 
tolerance to self-antigens.
Revised Protocol No.: 03
Date: 13-Mar-2020 36
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affini ty (half-maximal effective 
concentration [EC50] 0.39-2.62 nM), and inhibits the binding of PD-1 to its ligands PD-L1 and 
PD-L2 (half-maximal inhibitory concentration [IC50] ¬±1 nM). Nivolumab binds specifically to 
PD-1 and not to related members of the CD28 family such as CD28 , ICOS, CTLA-4, and BTLA. 
Blockade of the PD-1 pathway by nivolumab results in a reproduc ible enhancement of both 
proliferation and IFN-Œ≥ r elease in the mixed lymphocyte reaction (MLR). Usi ng a cytomegalovirus 
(CMV) re-stimulation assay with human peripheral bl ood m ononuclear cells (PBMCs), the effect 
of nivolumab on antigen-specific recall response indicates that  nivolumab augmented IFN-Œ≥ 
secretion from CMV-specific memory T cells in a dose-dependent manner vs isotype-matched 
control. In vivo blockade of PD-1 by a murine analog of nivolum ab enhances the anti-tumor 
immune response and results in tumor rejection in several immuno competent mouse tumor models 
(MC38, SA1/N, and PAN02).36
3.2.4 CDK 4/6 Inhibitors and Mechanism of Action
Cell cy cle progression is regulated by cyclin-dependent serine-threonine protein kinases. 
Extracellular growth and adhesion signals increase the level an d function of cyclin D pro teins 
within the cell. In turn, the cyclin D proteins associate with and activate CDK4 and CDK6.37CDK4 
and CDK6 phosphorylation leads to inactivation of the Rb protei n and thus releases E2F, which in 
turn leads to the transcription initiation of proteins involved in cell cycle propagation and 
proliferation. 
The luminal A and B subtypes of BC (85% of which are ER+, HER2-) have high rates of 
cyclin D/CDK activation; in the luminal A and B subtypes, cyclin  D1 (CCND1) amplifications 
were observed in 29% and 58%, and CDK4 amplifications were obser ved in 14% and 25%, 
respectively.38,39Luminal A subtype tumors also have loss of CDKN2A, which encode s 
p16INK4A, a CDK inhibitor.40The luminal subtypes also maintain expression of Rb, which is 
essential for benefit from treatment with a CDK4/6 inhibitor.41
Dysregulation of cell cycle ch eckpoints is common in BC, and in  all cancers in general, and may 
have clinical and therapeutic significance. For example, patien ts with HR+ BC exhibiting a gene 
expression signature of Rb loss had a shorter recurrence-free s urvival following adjuvant 
tamoxifen.42A tumor gene e xpression signature of E2F activation is also associated with h igher 
residual tumor cell proliferation following neoadjuvant AI ther apy. Therefore, activation of the 
CDK4/6-Rb-E2F pathway promotes endocrine resistance, and treatm ent with a CDK4/6 inhibitor 
or knockdown of CDK4 expression leads to reactivation of Rb, bi nding back of E2F and 
subsequent cell cycle arrest thus abrogating endocrine-resistan t cell proliferation. A seminal 
preclinical study exploring 47 human BC cell lines reported tha t palbociclib monotherapy was 
active in luminal BC cell lines compared to non-luminal BC cell s lines, and that palbociclib 
potentiated tamoxifen and trastuzumab activity in ER+ and human epidermal growth factor 
receptor 2-positive (HER2+) BC cell lines, respectively.43
Revised Protocol No.: 03
Date: 13-Mar-2020 37
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
3.2.5 Clinical Experience with Nivolumab
The overall clinical safety experience with nivolumab, as eithe r monotherapy or in combination 
with other therapeutics, is based on experience in approximatel y 17,700 participants.3Nivolumab 
monotherapy is approve d in multiple regions, including the US a nd Europe (EU), for unresectable 
or metastatic melanoma, previously treated metastatic non-small  cell lung cancer (NSCLC), 
previously treated advanced renal cell carcinoma (RCC) , previously treated relapsed or refractory 
classical Hodgkin lymphoma, previously treated advanced or meta static urothelial carcinoma, and 
for the treatment of previously treated recurrent or metastatic  squamous cell carcinoma of the head 
and neck (SCCHN); it is also approved for previously treated co lorectal cancer (CRC), previously 
treated hepatocellular carcinoma (HCC), and the adjuvant treatm ent of melanoma in the US. In 
addition, nivolumab has been approved for use in combination wi th ipilimumab for  RCC in the 
US and unresectable melanoma in multiple countries, including t he US and EU.3
In 39 patients with BC, nivolumab alone or in combination with ipilimumab were tolerable without 
additional safety signal detected in the CheckMate 32 study (unp ublished data). In 66 patients with 
metastatic triple negative breast cancer (TNBC), nivolumab with or without various induction 
therapies (radiation therapy, cyclophosphamide, cisplatin, or dox orubicin) demonstrated ORRs
from 17% without induction therapy to 35% with doxorubicin indu ction therapy (TONIC trial).44
An additional 37 clinical trials of nivolumab alone or in combi nation treating patients with BC are 
currently ongoing (eg, ClinicalTrials.gov: [STUDY_ID_REMOVED], NCT037891 10, [STUDY_ID_REMOVED]).
Details on the clinical safety and PK profile of nivolumab, inc luding results from other clinical 
studies, are summarized in the nivolumab IB.3
3.2.6 Clinical Experience with CDK 4/6 Inhibitors and Endocrine TherapyThe clinical development of second generation, CDK4/6-selective  inhibitors, namely palbociclib, 
abemaciclib, and ribociclib, led to practice-changing results in  the setting of advanced HR+, 
HER2- BC. In combination with aromatase inhibitors in the first-l ine setting and fulvestrant in the 
second-line setting, CDK4/6 inhibitors not only significantly inc reased ORR and prolonged
progression-free survival (PFS),
45but also achieved clinically meaningful overall survival (OS) 
benefit from treatment combining palbociclib and fulvestrant, a lbeit not statistically significant.46
In addition, single-ag ent abemaciclib demonst rated an ORR of 19.7% in heavily pretreated patients 
with refractory HR+, HER2- metastatic BC.47Selective CDK4/6 inhibitors are currently assessed 
in early-stage HR+, HER2- primary BC (neoadjuvant and adjuvant s etting) as well as other BC 
subtypes. In the neoadjuvant setting, the combination of palboc iclib and letrozole markedly 
enhanced the suppression of malignant cell proliferation as ass essed by Ki67, a marker of cellular 
proliferation, but did not substantially increase the clinical response of primary ER+ BC over a 
14-week period.48,49Therefore, novel combinations are needed in this setting to opt imize efficacy.
Details on the clinical safety and PK profile of palbociclib, i ncluding results from other clinical 
studies, are summarized in its respective product label.4
Revised Protocol No.: 03
Date: 13-Mar-2020 38
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
3.3 Benefit/Risk Assessment
Based on preclinical and clinical  data, treatment of nivolumab a nd palbociclib in combination with 
endocrine therapy (ET) is expected to be tolerable and toxicitie s of the treatment are expected to 
be manageable and reversible upon dose reduction, treatment int erruption, or discontinuation.
Participants in this study will be carefully monitored for key toxicities. Risks will be further 
minimized by adherence to inclusi on/exclusion selection criteri a (see Section 6 [Study 
Population]), avoidance of prohibited medication (see Section 7.7 [Concomitant Therapy]), close 
safety monitoring (see Section 9.2 [Adverse Events], Section 9.2.9 [Management Algorithms for 
Nivolumab], and Section 9.4 [Safety]), and dose adjustment guidelines (see Section 7.4 [Dosage 
Modification]). These will also be clearly discussed and highlig hted during site visits. 
A Study Steering Committee (SSC; see Section 5.1.4.1 [Study Steering Committee]) will be 
established comprising of Investigators and BMS personnel parti cipating in the trial to ensure 
transparent management of the trial according to the protocol. A BMS Safety Management Team 
will review and evaluate all emerging data across the program for potential safety signal 
assessment in a timely manner.
More d etailed information a bout the known and expected benefits  and risks and reasonably 
anticipated adverse events (AE s) of study treatm ents may be found in the IB,3Patient Information 
Leaflet, Package Insert,1,2,4, 50Development Safety Update Report, or Summary of Product 
Characteristics (SmPC).Due to the need to develop improved therapies to reverse or del ay resistance to current ET in ER+, 
HER2- BC, and on the basis of the clinical and nonclinical data i n support of the current study, 
BMS feels that the benefit-risk profile of nivolumab in combina tion with palbociclib and 
anastrozole in men and postmenopausal women with ER+, HER2- early- stage BC is favorable for 
proceeding with the proposed rando mized Phase 2 clinical trial. As of Protocol Revision 03, the 
benefit-risk profile of the abemaci clib-containing combination i s no longer considered favorable; 
thus BMS will not move forward with randomization to nivolumab in combination with 
abemaciclib and anastrozole (see Section 5.1 ).
3.3.1 Nivolumab Safety Profile
Overall, the safety profile of nivolumab monotherapy is managea ble and generally consistent 
across completed and ongoing clinical trials with no maximum to lerated dose reached at any dose 
tested up to 10 mg/kg. Most AEs were low-grade (Grade 1 to Grad e 2) with relatively few related 
high-grade (Grade 3 to Grade 4) AEs. There was no pattern in th e incidence, severity, or causality 
of AEs with respect to nivolumab dose level.
A pattern of immune-related AEs has been defined, for which mana gement algorithms have been 
developed; these are provided in Appendix 6 . Most high-grade events were manageable with the 
use of corticosteroids or hormone replacement therapy (endocrinopathies) as instructed in these 
algorithms.
Revised Protocol No.: 03
Date: 13-Mar-2020 39
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Additional details on the safety profile of nivolumab, includin g results from other clinical studies, 
are also available in the nivolumab IB.3
3.3.2 CDK 4/6 Inhibitor and Endocrine Therapy Combination Safety Profile
Overall, the safety profile of palbociclib monotherapy, as well as in combination with ET is
manageable and generally consistent across completed and ongoin g clinical trials.
For palbociclib, the most commo n adverse reactions (incidence ‚â•10%) were neutropenia, 
infections, leukopenia, fatigue, nausea, stomatitis, anemia, al opecia, diarrhea, thrombocytopenia, 
rash, vomiting, decreased appetite, asthenia, and pyrexia.4
For anastrozole:
‚Ä¢In the early BC study (ATAC), the most common (incidence of > 10%)  side effects were hot 
flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hy pertension, depression, nausea and 
vomiting, rash, osteoporosis, fractures, back pain, insomnia, h eadache, peripheral edema, and 
lymphedema, regardless of causality.2
‚Ä¢In the advanced BC studies, the most common (> 10%) side effects were hot flashes, nausea, 
asthenia, pain, headache, back pain, bone pain, increased cough , dyspnea, pharyngitis, and 
peripheral edema.2
Extensive details on the safety profile of palbociclib and anast rozole are availab le in the Patient
Information Leaflet, Package Insert, or SmPC.
3.3.3 CDK4/6 Inhibitor and Nivolumab Combination Safety Profile
The safety profile of nivolumab is w ell characterized and manageable when administered alone or 
in combination with other treatments, including regimens where i t is administered in combination 
with chemotherapy, targeted agents, as w ell as additional IO products. In a Phase Ib study, the 
combination of pembrolizumab (a PD-1 inhibitor with similar saf ety profile) and abemaciclib at 
Food & Drug Administr ation (FDA)-approved doses of the respectiv e agents demonstrated a 
manageable safety profile, with a confirmed ORR of  28.6% in 28 h eavily pretreated participants
with metastatic BC (HR+, HER2- subtype)11
In a Phase 2 study of pembrolizu mab, palbociclib  and letrozole ( AI) in patients with metastatic 
ER+, HER2- BC ([STUDY_ID_REMOVED]), of 20 patients treated with the tripl e combination, Grade 3 
pneumonitis was reported in 1 patient during the DLT assessment  period. The median follow up 
for this study was 13.7 months (95% CI 6.4-16.9) and progressio n-free survival (PFS) has not been 
reached.51Also in a phase 1 study exploring safety and efficacy of aveluma b, palbociclib and 
axitinib (tyrosine kinase inhibitor) in patients with advanced n on-small cell lung cancer 
([STUDY_ID_REMOVED]), o f 13 patients treated at 3 dose levels, 1 patie nt with baseline ch ronic obstructive 
pulmonary disease at dose level 3 developed a respiratory failu re event possibly related to study 
treatment and died. No Grade 3 or a bove ILD/pneumonitis events were reported.52A randomized 
Phase 2 trial assessing a triple combination regimen of palbociclib + avelumab (anti-PD-L1 
inhibitor) + fulvestrant (estrogen receptor antagonist) for pat ients with pre-treated metastatic 
Revised Protocol No.: 03
Date: 13-Mar-2020 40
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
ER+/HER2- BC has been ongoing since Aug-2017; no clinical data h ave been reported t o date.
([STUDY_ID_REMOVED]). Thus, the potential benefit of the palbociclib combination therapy appears to 
outweigh the known risks and warrants clinical investigation.
Revised Protocol No.: 03
Date: 13-Mar-2020 41
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
4 OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Primary
‚Ä¢Safety Run-in Phase: Number of participants
with occurrence of DLT.‚Ä¢DLT is defined as TEAE (graded according to the NCI CTCAE v5.0) that occurs during the first 4 weeks after 
treatment start and that meets specific criteria (see Section 5.1.2.1 ).
‚Ä¢Randomized Phase: To assess RCB 0-I rate by 
central assessment of palbociclib plus anastrozole with or w ithout nivol umab in all 
participants with untreated pr imary BC
‚â•2 cm (ER+, HER2-).‚Ä¢RCB 0-I r ate assessed by central assessment at the time 
of definitive surgery.
‚Ä¢RCB is a conti nuous index combining pathological 
measurements of primary tumor (size and cellularity) and nodal metastases (number and size) defined by a point system at surgery (refer to Appendix 7 [RCB Methods]).
Secondary
‚Ä¢To assess the safety and tolerability of 
palbociclib plus anastrozole with or without 
nivolumab.‚Ä¢Incidence of AEs, SAEs, AEs leading to discontinuation, 
immune-related AEs, deaths, and laboratory 
abnormalities in all participants.
‚Ä¢To assess pCR r ate by local assessment of 
palbociclib plus anastrozole with or without nivolumab in participants with untreated 
primary BC ‚â•2 cm (ER+, HER2-).‚Ä¢pCR rate in all participants assessed by the local 
pathologist at the time of definitive surgery.
‚àípCR, defined as no invasive  residual disease in 
breast or lymph nodes (ie, ypT0/is, ypN0) in the 
current AJCC staging system.
‚Ä¢To assess ORR (clinical and radiological 
[ultrasound (preferred) or mammography]) by 
Investigator assessment and BCS rate of palbociclib plus anastrozole with or without nivolumab in participants with untreated 
primary BC ‚â•2 cm (ER+, HER2-).‚Ä¢ORR is defined as the number of participants with a BOR 
of CR or PR divided by the number of randomized 
participants for each treatment group at the end of the study treatment period. 
‚Ä¢BCS rate is defined as the number of participants who undergo BCS after completing the st udy tr eatments 
divided by the number of randomized participants for each treatment group.
Revised Protocol No.: 03
Date: 13-Mar-2020 42
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Abbreviations:  AE = adverse event; AJCC = American J oint Committee on Cancer; 
BC = breast cancer; BCS = breast-conserving surgery; BOR = best overall response; CR = complete response; 
CTCAE = Common Terminology Criteria for Adverse Events; DLT = dose -limiting toxicity;  
 
 HER2- = human epidermal growth factor receptor 2 -negative;  
NCI = National Cancer Institute; ORR = objective response rate; p CR = pathological complete response; 
 
PR = partial response;  
R
CB = residual cancer burden; SAE = serious adverse event;  TEAE = treatment-emergent adverse event; 
TIL = tumor-infiltrating lymphocyte; .
Revised Protocol No.: 03
Date: 13-Mar-2020 43
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5 STUDY DESIGN
5.1 Overall Design
This randomized, open-label Phase 2 study was to evaluate whethe r the combination of nivolumab, 
with abemaciclib or palbociclib, plus anastrozole is a safe and effective neoadjuvant treatment for 
men and postmenopausal women with primary BC ‚â•2 cm that is ER+ and HER2- subtype who 
are suitable to receive NET and willing to undergo SOC breast s urgery after completion of the 
study treatment. 
On 6-Mar-2020, Bristol Myers Squibb (BMS) decided to permanentl y discontinue enrollment and 
dosing in the nivolumab + abemaciclib + anastrozole cohorts of t he CA2097A8 study during the 
Safety Run-in Phase.  
 
 
 
 
At implementation of Revised Protocol 03, the study will only evaluate whether the combination of 
nivolumab, with palbociclib, plus anastrozole is a safe a nd effective neoadjuvant tr eatment for men 
and postmenopausal w omen with primary BC ‚â•2 cm that is ER+ and HER2- subtype who are 
suitable to receive NET and willing to undergo SOC breast surgery  after completi on of the st udy 
treatment. Participants must have histologically confirmed invas ive breast carcinoma meeting the 
characteristics described in Section 6.1 (Inclusion Criteria). Participants in screening and not yet 
treated were offered the option to join the safety lead-in of the nivolumab + palbociclib + 
anastrozole arm. Participants on treatment with nivolumab + abem aciclib + anastrozole were to be 
re-consented and continue on anastrozole alone, OR taken off st udy. In addition, baseline chest X-
ray and periodic pulse oximetry are implemented to monitor ILD/ pneumonitis in patients who will 
be treated with nivolumab + palbociclib + anastrozole.The study is divided into 3 periods: Screening Period, On-treat ment Pre-surgery (neoadjuvant) 
Period (Safety Run-in Phase and Randomized Phase), and Safety F ollow-up Period.
The study started with a Safety Run-in Phase for the combination  of nivolumab, w ith abemaciclib 
or palbociclib, plus anastrozole and will begin the Randomized Ph ase after the regimen is 
determined to be safe. Participants in the Safety Run-in Phase will move to the Safety Follow-up 
Period upon completion of the neoadjuvant treatment or upon dis continuation. Potential needs for 
additional enrollment or for dos e de-escalation w ill be discuss ed with Investigators and BMS 
during the Safe ty Run-in Phase. Once a safe dose for the regimen has been determined by BMS in 
collaboration with Investigators, the Randomized Phase of the s tudy will begin.
In the Randomized Phase, participants will be randomly assigned  by an IRT system to 3 different 
treatment arms and stratified by the following factors:  
Revised Protocol No.: 03
Date: 13-Mar-2020 44
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
 2) evaluation of l ymph nodes (cytologically positiv e vs radiologically or 
cytologically negative); and 3) tumor size (> 3 cm or ‚â§3 cm).
For both the Safety Run-in Phase and Randomized Phase, particip ants will be tr eated for a 
maximum of 5 cycles (1 cycle = 4 weeks). Participants with prog ressive disease prior to 
completion of the 5-cycle study treatment must discontinue all study drugs and proceed to the 
Safety Follow-up Period. Participants who permanently discontin ue the study drugs for any reason 
are considered to have completed the On-treatment Pre-surgery ( neoadjuvant) Period, and hence 
reach end of tr eatment (EOT). After Cy cle 5 or EOT, p articipants must co ntinue to receive 
anastrozole (as concomitant medication and not as study treatme nt) until subsequent SOC breast 
surgery. Followi ng the completion of neoadjuvant tr eatment, all participants who remain operative 
candidates will undergo definitive surgery for BC within 4 week s of the last neoadjuvant tr eatment 
administration. If anastrozole can no longer be administered aft er EOT, participants will go to 
breast surgery right away. Pre-surgical lymph node biopsy is no t allowed. Information on the type 
of the surgery will be collected and recorded in the electronic case report form (eCRF). Surgical
specimens will be collected for the analyses outlined in the pr otocol. Depending on treatment 
assignment, up to 2 safety follow- up visits will be conducted in person. The first safety follow- up 
visit (FU1) will be comp leted for all participants within 30 days ( ¬±7 days) from the last study 
treatment (oral or intravenous [IV ], whichever occurs later). The second safety follow-up visit 
(FU2) will occ ur approximately within 100 days ( ¬±7 days) from the last dose of nivolumab and 
will be required fo r participants in the Safety Run-in Phase and participants rand omized to Arms 
A or B in the Randomized Phase. Further planned treatment of par ticipants in the adjuvant setting 
(ie, radiotherapy, endocrine treatment, chemotherapy or any othe r treatment mod ality) will be at 
the discretion of the treating physician, following local clini cal guidelines, and collected in the 
appropriate eCRF. 
The study design schematic is presented in Figure 5.1-1 .
Revised Protocol No.: 03
Date: 13-Mar-2020 45
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Figure 5.1-1: Study Design Schematic
Abbreviations: Abema = abemaciclib; ANZ = anastrozole; BID = twi ce daily; cm = centimeter; ECOG = Eastern Cooperative Oncology Group; 
ER+ = estrogen-receptor-positive; FU 1 = follow-up visit 1; FU2 = follow-up visit 2; HER2- = human epidermal growth factor recepto r 2-negative;
IV = intravenous; mg = milligram; N = number; Nivo = nivolumab; Palb o = palbociclib;  PO = per os ( by mouth); 
PS = performance status; Q4W = every 4 weeks; QD = once daily; Rand = ra ndomized; wk = week.
aFU1 begins at the end of study treatment.
bCytologically positive vs radiologically or cytologically negat ive.Screening Period Pre-surgery Treatment Period (N = 115~136) Safety Follow-up Period
Key Inclusion 
Criteria
‚Ä¢ Newly diagnosed, 
histologically 
proven ER+, HER2- primary 
breast cancer
‚â• 2 cm
‚Ä¢ Men and 
postmenopausal women
‚Ä¢ ECOG PS 0-1Safety Run-in Phase
(3 + 3 Approach)
(n = 3~24)cRandomized Phase
(n = 110)dFU1a
(All Participants in he 
Safety Run-in Phase and 
the Randomized Phase)FU2
(All Participants in the 
Safety Run-in Phase and 
Arms A and B Only in 
the Randomized Phase)
Investigator‚Äôs Choice
Cohort 1 (n = 3~24)
Nivo 480 mg Q4W IV
+ Abema 150 mg BID PO 
+ ANZ 1 mg QD PO
x 5 cycles
Cohort 2 (n = 3~24)
Nivo 480 mg Q4W IV
+ Pa bo 125 mg QD PO 
3 wks on 1 wk off
+ ANZ 1 mg QD PO
x 5 cyclesArm A (n = 40)
Nivo 480 mg Q4W IV + Palbo 125 mg QD PO 3 wks on 
1 wk off + ANZ 1 mg QD PO x 5 cycles
Arm B (n = 40)
Palbo 125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg 
QD PO x 1 cycle THEN Nivo 480 mg Q4W IV + Palbo
125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg QD PO 
x 4 cycles
Arm C (n = 30)
Palbo 125 mg QD PO 3 wks on 1 wk off + ANZ 1 mg 
QD PO x 5 cycles
Rand
4:4:330-Day Safety 
Follow-up100-Day Safety 
Follow-up
(from last Nivo dose)
30-Day Safety 
Follow-up100-Day Safety 
Follow-up
(from last Nivo dose)
30-Day Safety 
Follow-up
Stratify Randomized 
Phase Participants by:
‚Ä¢ Node (+ or -)b
‚Ä¢ Tumor size
(> 3 cm or ‚â§ 3 cm)
Revised Protocol No.: 03
Date: 13-Mar-2020 46
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
cAt the time of Revised Protocol 03, 2 participants had been trea ted in Cohort 1 (nivolumab + abemaciclib + anastrozole), which was subsequently closed for 
enrollment.
dAt time of Revised Protocol 03, the decision was made to no long er evaluate abemaciclib in combination with nivolumab plus anastr ozole; thus, the abemaciclib-
containing combination arms have been removed from the Randomization Phase of the study.
Revised Protocol No.: 03
Date: 13-Mar-2020 47
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5.1.1 Screening Period
Participants will provide written informed consent to participate in the study be fore completing 
any protocol-specified procedures or evaluations not considered  to be part of the participants‚Äô 
standard care. After signing the informed consent form (ICF), p articipants will be evaluated for 
entry criteria and be enrolled into Interactive Response Techno logy (IRT). The screening 
assessments are shown in Table 2-1 .
Participants must provide a pretreatment (baseline) tumor tissu e, which must be either in FFPE 
tissue block containing 20 mm3 of tissue collected ‚â§90 days prior to enrollment (strongly 
preferred) or unstained tumor tissue sections (22 unstained slide s) sectioned ‚â§60 days prior to 
enrollment from a ti ssue sample collected ‚â§90 days prior to enrollment from primary tumor lesion. 
If a recent tumor specimen is not available, a  fresh tumor biop sy (containing 20 mm3 of tissue) is 
required. At least 15 unstained slides must be submitted for a pa rticipant to be eligible. If < 15
unstained slides are available, the participant is not eligible . Submit samples to the designated 
central laboratory with an associated pathology report.  
Safety Run-in participants: Participant can start study treatme nt before confirmation of receipt of 
the tumor sample by the central laboratory. However, receipt of  the tumor sample by the central 
laboratory must occur within 28 days of the first dose.
Randomized participants:  
 Documen tation of tumor size a nd node status (cytologically positive vs  
radiologically or cytol ogically negative) must be provided to I RT prior to randomization.
 
The Screening Period for each participant ends with the confirmat ion of full eligibility of the 
participant or with the confirmat ion that the participant is a screen failure. This study permits the 
re-enrollment of a participant that has discontinued the study as a pretreatment failure
(ie, participant has not been randomized [or treated in the Safe ty Run-in Phase]). If re-enrolled, 
the participant must be re-consented.
5.1.2 On-treatment Pre-surgery (neoadjuvant) Period
A schedule of on-treatment visi ts and assessments is provided in Table 2-2.
5.1.2.1 Safety Run-in PhaseAs of Revised Protocol 03, Cohort 1 w ill be discontinued. Participants in screening and not yet 
treated were offered the option t o join the nivolumab + palbocic lib + anastrozole arm. Participants 
on treatment were to be re-consented and continue on anastrozole  alone, OR taken off study.
The Safety Run-in Phase will be conducted in advance of the Ran domized Phase to evalu ate the 
safety and tolerability of the combinatio n of nivoluma b, with palbociclib, plus anastrozole, which 
will be administered during the Randomized Phase.
Revised Protocol No.: 03
Date: 13-Mar-2020 48
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Participants will r eceive palbociclib in combination with nivolumab plus anastrozol e (Cohort 2) 
for 5 cycles as neoadjuvant therapy and be followed up for safe ty (see Section 5.1.3 [Safety 
Follow-up Period]). . For the purpose of guiding alternative dos e levels, all AEs will be gra ded 
according to the National Cancer Institute (NCI) Common Termino logy Criteria for Adverse 
Events (CTCAE) v5.0 and dose-limiting toxicities (DLTs) will be defined based on the incidence, 
intensity, and duration of the AEs for which no clear alternati ve cause is identified. For the purpose 
of participant management, any drug-related AE that meets DLT c riteria will lead to 
discontinuation of s tudy treatment.
Participants who have discontinued due to a DLT or who have rec eived 1 dose of nivolumab and 
75% of accumulative  doses of palbo ciclib of the cycle, and have completed the 4-week DLT period 
will be considered as DLT-evaluable participants. Participants w ho withdraw from the study 
during the DLT evaluation period or have received less than 1 dose of nivolumab and 75% of 
accumulative doses of palbociclib of the cycle for reasons othe r than a DLT will not be considered 
as DLT-evaluable participants and may be replaced with new participants at the same dose level. 
Dose De-escalation Rules
For Cohort 2, 3 DLT-evaluable participants will be treated with  the below starting doses:
‚Ä¢Nivolumab: 480 mg every 4 weeks (Q4W) intravenously (IV)
‚Ä¢Palbociclib 125 mg once daily (QD) PO for 3 weeks of each cycle (1 week off)
‚Ä¢Anastrozole: 1 mg QD PO
If no participants (0 of 3 DLT-ev aluable participants) experience  a DLT during the DLT period 
(4 weeks), the Randomized Phase will be initiated at this dose le vel. If 1 evaluable participant
(1 of 3 DLT-evaluable participants) experiences DLT, then the coho rt will be expanded to 
6 DLT-evaluable participants. If no more DLTs are observed (1 of 6  DLT-evaluable participants), 
then the Randomized Pha se will be initiated at the dose level te sted. If 1 or more additional 
evaluable participants (2 of 6 DLT-evaluable participants) experiences DLT during the DLT 
period, a lower dose w ill be tested using the same 3 + 3 schema. See Figure 5.1.2.1-1 for an 
overview of the 3 + 3 approach to be used for the Safety Run-in P hase.
Revised Protocol No.: 03
Date: 13-Mar-2020 49
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Figure 5.1.2.1-1: Schematic of Safety Run-in Phase 3 + 3 Approac h
Abbreviations: DLT = dose-limiting toxicity.
aFor additional details see Section 7.4 (Dosage Modification).
Continuous evaluation of toxicity  events will be  performed. If at any time, the aggregate rate of 
treatment-related  toxicities meeting DLT cr iteria exceeds 33% across participants treated in a 
cohort, the findings w ill be discussed with the Investigators a nd further enrollment may be 
interrupted. A ny toxicities that occur beyond the DLT period will be accounte d for in making final 
dose level decisions.
Generally, if a cohort is discontinued due to DLT of unclear re levance to nivolumab, a lower dose 
level of CDK4/6 inhibitor per product label will be tested in t he next cohort. See Section 7.4
(Dosage Modification) for additional details on permitted dose adjustment. If a cohort is 
discontinued due to DLT related to nivolumab, a different dose or dose schedule will be explored 
per Investigator and Medical Monit or discussion. 
For cohort expansion or dose de-escalation decisions, the available t oxicity information (including
AEs and laboratory abnormalities  that are not DLTs), clinical judgme nt  
will be e valuated by the Investigators a nd BMS study personnel
(including the Medical Monitor and statistician) during a dose d ecision meeting b y teleconference.
Drug administration at the next dose level or proceeding to the Rand omized Phase must not occur 
until the Investigator receives written confirmation from BMS indicati ng that the results of the
previous dose level were evaluated and that it is permissible to proceed.
Revised Protocol No.: 03
Date: 13-Mar-2020 50
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Definition of DLTs : DLTs are defined as any TEAEs specified below that occur during the first 
4 weeks (1 cycle) except those clearly and incontrovertibly due to disease progression or 
extraneous causes.
Gastrointestinal DLTs‚Ä¢Grade 2 colitis that lasts longer than 7 days, despite best suppor tive treatment.
‚Ä¢Grade 3 diarrhea or colitis that lasts longer than 72 hours with  adequate supportive treatment.
‚Ä¢Grade ‚â•4 diarrhea or colitis.
Hepatic DLTs
‚Ä¢Grade 4 elevations in serum transaminases (aspar tate aminotransferase [AST] and alanine 
aminotransferase [ALT], alkaline phosphatase [ALP]) or total bil irubin.
‚Ä¢Grade 3 elevations in serum AST, ALT, or bilirubin.
‚Ä¢Bilirubin > 2 x upper limit of normal (ULN) in the absence of cholestasis.
‚Ä¢Grade 2 elevations in AST or ALT with symptomatic liver inflamm ation (eg, right upper 
quadrant tenderness, jaundice).
‚Ä¢Grade 3 ALP elevation that last longer than 5 days, or is associated with clinical symptoms.
‚Ä¢AST or ALT > 3 √óULN and concurrent t otal bilirubin > 2 √óULN without init ial findings of 
cholestasis (elevated ALP; eg, findings consistent with Hy‚Äôs law  or FDA definition of potential 
drug-induced liver injury [p-DILI]). Note that this specific ca tegory of DLT uses ULN rather 
than NCI CTCAE grade for definition.
Hematologic DLTs
‚Ä¢Grade 4 neutropenia ‚â•7 days in duration.
‚Ä¢Grade 4 thrombocytopenia.
‚Ä¢Grade 3 thrombocytopenia with bleeding or any requirement for pl atelet transfusion.
‚Ä¢Grade 3 hemolysis (ie, requiring transfusio n or medical  interve ntion such as steroids).
‚Ä¢Neutropenic fever of any duration.
‚Ä¢Grade 4 anemia not explained by underlying disease.
Dermatologic DLTs‚Ä¢Grade 4 rash or confirmed Stevens-Johnson Syndrome or Toxic Epid ermal Necrolysis.
‚Ä¢Grade 3 rash if no improvement (ie, resolution to ‚â§Grade 1) after a 1- to 2-week infusion 
omission for nivolumab.
Other DLTs
‚Ä¢Recurrence of same Grade 3 adverse reactions.
Revised Protocol No.: 03
Date: 13-Mar-2020 51
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Any AE that required disconti nuation of nivolumab per approved label.
‚Ä¢Any Grade immune-related encephalitis.
‚Ä¢Any incidence of Grade ‚â•3 prolongation of QT interval corrected using Fridericia's Corre ction 
Formula (QTcF) on electrocardiograms (ECGs).Grade 3 hypersensiti vity reactio n/infusion 
reaction that does not resolve to Grade 1 in < 6 hours.
‚Ä¢Grade 2 pneumonitis that does not respond to dose modification f or nivolumab and systemic 
steroids within 14 days.
‚Ä¢Any death not clearly due to the underlying disease or extraneo us causes.
‚Ä¢Grade 2 uveitis, episcleritis, iritis, eye pain, or blurred vis ion that does not respond to topical 
therapy and does not improve to Grade 1 severity within 2 weeks OR requires systemic 
treatment.
‚Ä¢Grade ‚â•3 electrolyte abnormality associated with clinical symptoms.
‚Ä¢Grade 3 fatigue lasting ‚â•1 week.
‚Ä¢Other Grade 3 ‚â•toxicity will be considered a DLT, except those clearly and inc ontrovertibly 
due to disease progression and extraneous causes. However, the following Grade 3 or 4 events will not be considered DLTs:
‚àíIsolated Grade 3 or 4 electrolyte imbalances/abnorm alities not associated with clinical 
symptoms and either resolve spontaneously or are corrected with 
supplementation/appropriate management within 72 hours of their onset. Confirmatory 
laboratory test is required within 72 hours.
‚àíGrade ‚â•3 amylase or lipase elevation not associated with symptoms or c linical 
manifestations of pancreatitis.
‚àíGrade 3 nausea or vomiting that lasts less than 48 hours and ei ther resolves spontaneously 
or responds to medical intervention. 
‚àíGrade 3 fever not associated with hemodynamic compromise (eg, h ypotension, clinical or 
laboratory evidence of impaired end-organ perfusion).
‚àíGrade 3 endocrinopathy that is well controlled by hormone repla cement.
‚àíGrade 3 tumor flare (defined as pain, irritati on, or rash that localizes t o sites of known or 
suspected tumor).
5.1.2.2 Randomized Phase
The Randomized Phase will start after the combinations tested i n the Safety Run-in Phase are 
confirmed to be safe by BMS in collaboration with Investigators , and the appropriate dose level 
communicated to Investigators. Following confirmation of eligib ility criteria, participants will be 
randomized to either Arm A, Arm B, or Arm C in a 4:4:3 ratio, resp ectively. Participant 
randomizatio n will be stratified using the followi ng factors:
2) Evaluation of lymph nodes (cytologically positive vs radiologi cally or cytologically negative), 
and
3) Tumor si ze (> 3 cm or ‚â§3 cm).
Revised Protocol No.: 03
Date: 13-Mar-2020 52
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
 
 
Treatment must begin wit
hin 3 calendar days followin g randomization.
Participants will be randomly assigned to 1 of the 3 treatment a rms below:
As of Revised Protocol 03, the abemaciclib-containing combinatio n arms have been removed from 
the randomization phase of the study.
1) Arm A (concurrent palbociclib tr eatment arm): nivolumab 480 mg Q4W IV + 
palbociclib 125 mg QD PO for 3 weeks (1 week off) + anastrozole 1  mg QD PO for 5 cycles
2) Arm B (phased palbociclib treatment arm):
a) palbociclib 125 mg QD PO for 3 w eeks of each cycle (1 week off) + anastrozole 1 mg QD 
PO for 1 cycle followed by
b) nivolumab 480 mg Q4W IV + palbociclib 125 mg QD PO for 3 week s (1 week off) + 
anastrozole  1 mg QD PO for 4 cy cles
3) Arm C (control palbociclib arm): palbociclib 125 mg QD PO for 3 w eeks of each cycle (1 
week off) + anastrozole 1 mg QD PO for 5 cycles
5.1.3 Safety Follow-up Period
Depending on the treatment arms, there may be up to 2 in-person  safety follow-up visits. FU1 w ill 
occur 30 days from the last dose ( ¬±7 days) of the study treatment (PO or IV; whichever occurs 
later) for all arms. FU2 occurs approximately 100 days (¬± 7 days) from the last dose of nivolumab 
for Safety Run-in participants and Arms A and B in the Randomized Phase.
5.1.4 External Committees
5.1.4.1 Study Steering CommitteeA SSC will be established to obtain scientific guidance and adv ice on the protocol and conduct of 
the study. The SSC will meet at least annually and on an ad-hoc  basis as necessary. Detailed 
information can be found in the SSC charter.
5.2 Number of Participants
A total of approximately 115~136 participants w ill be tr eated in the study. It is anticipated that 
approximately 3~24 participants (up to approximately 30 screened) will be t reated in each cohort 
in the Safety Run-in Phase. At the time of Revised Protocol 03, 2 participants had been treated in 
Cohort 1 (nivolumab + abemaciclib + anastrozole), which was sub sequently closed for enrollment.
Approximately 138 participants w ill be screened for 110 participants to be treated in the 
Randomized Phase, assuming a screen failure rate of approximate ly 20%. See Section 10.1
(Sample Size Determination) for additional details.
Revised Protocol No.: 03
Date: 13-Mar-2020 53
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5.3 End of Study Definition
The start of the trial is defined as the first participant‚Äôs fi rst visit. End of study is defined as the 
last participant‚Äôs last study visit or scheduled procedure shown in Section 2 (Schedule of 
Activities). Study completion is defined as the final date on w hich data for the primary endpoint 
was or is expected to be collected.
5.4 Early Study Termination Criteria
The Sponsor has the right to terminate this study at any time. Reasons for terminating the study 
may include, but are not limited to, the following:
‚Ä¢The incidence and/or severity of AEs in this or other studies t hat incorporate similar treatment 
arm(s) indicates a potential health hazard to participants.
‚Ä¢Further clinical data that might occur from other studies that i ncorporate s imilar treatment 
arm(s) that indicate a potential  inappropriate benefit-risk balance for participants in the study, 
due to lack of activity.
Such decisions shall be communicated promptly, in order to allo w the termination procedure to be 
properly followed. BMS will also notify Investigators if the st udy is terminated early.
5.5 Scientific Rationale for Study Design
5.5.1 Rationale for the Choice of Patient Population
Men or postmenopausal women with newly diagnosed, histologically  proven ER+, HER2- primary 
BC‚â•2 cm who are eligible for NET will be included in the study p opulation. Due to the low 
pathological complete response (pCR) rate, there remains an unm et medical need in this patient 
population.
Historically, NET has been offered to women with H R+ tumors who are unfit for surgery or refuse 
this procedure, or to elderly women with short life expectancy, as established by a qualified 
specialist and based on a validated geriatric assessment tool. NET has also been used to reduce 
tumor size and third-generation aromatase inhibitors increased l ikelihood of breast conserving 
surgery to 36-45%. In patients with a low recurrence score, NET demonstrated a clinical response 
rate of 59% and a BCS rate of 91%. NET not only confers clinical benefit to patients with HR+, HER2 - BC but also provides important 
prognostic information and is an excellent platform for the development of investigational drugs, 
triaging of novel combinations,  and disco very of mechanisms of drug 
resistance. Several key mechanisms of action have been assessed  in the neoadjuvant space in an 
exploratory setting, where results from metastatic trials mirro r those from their respective 
neoadjuvant trials (ie, mammalian target of rapamycin [mTOR] block ade + endocrine therapies,
53
phosphoinositide-3 kinase (PI3K) blockade + endocrine therapies,54,55and CDK4/6 blockade plus 
endocrine therapies49,56,57,58). Those examples suggest that know ledge gained from NET studie s 
provide information to predict if a new combination is likely t o be successful in large adjuvant or 
metastatic Phase 3 trials. We anticipate that the current study may help to focus the development 
Revised Protocol No.: 03
Date: 13-Mar-2020 54
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
of the combination of nivolumab, palbociclib, and anastrozole fo r use in patients with BC that is 
ER+ and HER2-.
5.5.2 Rationale for Choice of Endpoint (Residual Cancer Burden 0-I Rate)
There are lack of clinical endpoints predictive of event-free sur vival after NET in the HR+, HER2-
primary BC setting, since pCR is uncommon and is not an effective  surrogate of long-term 
outcome for this tumor type. Failure to achieve a pCR does not imply poor patient outcome since 
these patients still receive 5-10 years of adjuvant ET. Additio nally, many patients with HR+, 
HER2- BC are likely cured with local treatment and standard adju vant ET, which is also informed 
by several well validated prognostic gene signatures. For patients who did not achieve pCR, RCB 
is a type of pathological response quantification for the exten t of residual disease with the RCB 
index evaluating 5 post-treatment variables: 2-dimensional tumo r bed, cellularity, percentage of 
carcinoma in situ, number of metastatic lymph nodes, and the di ameter of the largest nodal 
metastases. The RCB index classifies the surgical specimen into 4 categories that include RCB-0
(pCR), RCB-I (minimal residual disease), RCB-II (moder ate residual dis ease), and RCB-III 
(extensive residual disease), a nd predicts risk of relapse after  neoadjuvant chemotherapy to be 
highest for RCB-III (53.6%), wh ile s imilar for RCB-0 and RCB-I ( 2.4% and 5.4%, 
respectively).59,60RCB (0-I) determined by local site pathologists was also prognostic fo r better 
long-term survival after neoadjuvant chemotherapy in all subtyp es of BC.61,62Hence, RCB index 
is increasingly used in NET studies  
. In addition, a RCB (0-I) rate endpoin t can be assessed within several 
months of initiation of an investigational drug in the neoadjuvant setting that could potentially address an unmet need in a far shorter time frame than would be required via the conventional 
approach to BC drug development. Use of this surrogate endpoint is expected to innovate the 
development of novel therapies for BC.
5.5.3 Rationale for CDK 4/6 Plus PD-1 Inhibition
PD-1 inhibition prevents interaction with the receptors PD-1 and  B7-1 (a costimulatory 
cell-surface protein), reversing T- cell s uppression and leading to tumor response. The PD-1 
inhibitor pembrolizumab as a single agent led to ORR of 12% (3/ 25) in heavily pretr eated p atients 
with ER+ BC that was also PD-L1 positive. In combination with che motherapy, pembrolizumab 
improved pCR rates in all HER2- BCs in the neoadjuvant setting.
5Several preclinical studies point 
towards PD-1/CDK4/6 blockade synergy as it has become more appa rent that CDK4/6 inhibitors 
affect the tumor immune microenvironment.6Within tumor cells, selective CDK4/6 inhibitors 
increase expression of PD-L1 th rough the E3 ligase adapter prot ein, Speckle-type POZ protein 
(SPOP),7and enhance antigen presentation via reduced activity of the E2 F target, 
deoxyribonucleic acid (DNA) methyltransferase 1 (DNMT).8Secretion of cytokines from both 
tumor and CD8+ T cells is also enhanced with CDK4/6 inhibitor t reatment,9,10whereas 
proliferation of immunosuppressive Tregs is suppressed.8In murine models of BC, selective 
CDK4/6 inhibitors promote anti-tumor immunity via indirect stimulation of type III interferon 
(IFN) production and enhancing tumor antigen presentation, plus suppression of the proliferation 
Revised Protocol No.: 03
Date: 13-Mar-2020 55
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
of Tregs.8,10In addition, tr eatment with the CDK4/6 inhib itor abemaciclib alone resulted in tumor 
growth delay that was associated with an increased T-cell infla mmatory signature in tumors. 
Combination of a CDK4/6 inhibitor with an anti-PD-(L)1 therapy led to complete tumor regression 
and immunological memory, accompanied by enhanced antigen prese ntation, a T- cell inf lamed 
phenotype, and enhanced cell-cycle control.63
Clinically, in a Phase Ib study, the combination of pembrolizum ab and abemaciclib demonstrated 
a confirmed ORR of 28.6% in heavily pretreated participants with  metastatic HR+, HER2- BC.11
In agreement with the previously mentioned preclinical data indicating CDK4/6 blockade as a 
mediator of the cancer immunity, ab emaciclib alone or in combi nation with anast rozole has been 
associated with upregulation of gene expression signatures related to T-cell immune response and 
antigen presentation in the neoMONARCH study, where 10-16 paired samples in each arm were 
examined in the  primary disease setting.11Clinical data on combinations of other CDK4/6 
inhibitors with PD-(L)1 blocking agents are being generated in multiple clinical trials spanning 
from the neoadjuvant to metastatic settings (ClinicalTrials.gov:  [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED]) .
The aim of CA2097A8 is to assess the potential synergistic acti vity of nivolumab, with palbo ciclib,
and anastrozole in participants with newly diagnosed, previously  untreated primary HR+, HER2-
BC‚â•2 cm, defined by significantly improved RCB (0-I) rate.  
 This trial is part of a broader effort to esta blish nivolumab as a SOC for the 
treatment of HR+, HER2- BC.
5.5.4 Rationale for Phased Therapy (Arm B)
Strategies to render the tumor micro-environment (TME) more susceptible to anti-PD(L)1 therapy 
has been investigated in a phase 2 study (TONIC trial) of 50 pa rticipants with metastatic TNBC 
who received palliative chemotherapy.44Priming the anti-cancer immune response with low-dose 
chemotherapy for 2 weeks or radiation therapy before starting n ivolumab resulted in a best 
objective response rate (ORR) of 24%. In CT26 syngeneic mouse t umor model, a phased 
administration of abemaciclib and an anti-PD-L1 therapy improve s anti-tumor efficacy and 
induced complete tumor regression.12In the same animal model, abemaciclib monotherapy 
induced intra-tumor immune inflammation on D13 and D20. In agre ement with the previously 
mentioned preclinical data indicating CDK4/6 blockade as a medi ator of cancer immunity, 
abemaciclib in combination with anastrozole has been associated  with upregulation of gene 
expression signatures related to T- cell imm une response and antigen presen tation in the 
neoMONARCH study, where 10-16 paired samples in each arm were e xamined in the primary 
disease.49We therefore chose to test a phased therapy approach in Arm B to  investigate whether 
additional treatment benefit will be  observed with these regimens.
Revised Protocol No.: 03
Date: 13-Mar-2020 56
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 57
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5.6 Justification for Dose
5.6.1
Justification for Dose of Nivolumab
Nivolumab 480 mg Q4W infused over 30 minutes was FDA approved i n Mar-2018 for the majority 
of the nivolumab approved indications. The European Medicines A gency‚Äôs (EMA‚Äôs) Committee 
for Medicinal Products for Human Use has also recommended addin g  th e  opti o n  of  a  4 -week 
dosing schedule to the label for nivolumab for the treatment of  patients with advanced melanoma 
and previously treated RCC.
Nivolumab 480 mg Q4W infused ove r 30 minutes will be examined in combination with 
palbociclib and anastrozole in this study.5.6.2 Justification for Dose of CDK4/6 Inhibitors
Abemaciclib 150 mg BID PO or palbociclib 125 mg QD PO for 3 wee ks of each cycle (1 week 
off) were a pproved by FDA in Sep-2017 and Feb-2015 , respectively, and by EMA in Sep-2018 
and Nov-2016, respectively, in combination with ET for ER+, HER2 - BC, based on clinical safety 
and efficacy.
Abemaciclib 150 mg BID PO or palbociclib 125 mg QD PO for 3 week s of each cycle (1 week 
off) will  be examined in combination with nivolumab and anastroz ole in this study.
As of Revised Protocol 03, examination of abemaciclib + nivolumab + anastrozole will not be 
continued in this study.
Revised Protocol No.: 03
Date: 13-Mar-2020 58
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5.6.3 Justification for Dose of Anastrozole
Anastrozole 1 mg QD PO was approved by FDA and in Europe in Jan -1996 and Aug-1995, 
respectively, for BC.
Anastrozole 1 mg QD PO will be examined in combination with niv olumab and palbociclib in this 
study.6 STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Participants must have signed and dated an Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC)-approved written ICF in accordance with r egulatory and 
institutional guidelines. This must be obtained before the perf ormance of any 
protocol-related procedures that are not part of normal patient  care.
b) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests, t umor biopsies , and other requirements of the  study.
2) Type of Participant and Target Disease Characteristics
a) Participants must have histologically confirmed unilateral inv asive breast carcinoma, with 
the following characteristics:
i) Primary tumor ‚â• 2 cm in largest diameter (cT1-3) by US/mammog ram. In the case of 
a multifocal tumor (defined as the presence of two or more foci  of cancer within the 
same breast quadrant), the largest lesion must be ‚â• 2 cm and de signated as the ‚Äútarget‚Äù 
lesion for all subsequent tumor evaluations. Please note: N3 di sease (defined so either 
clinically or radiologically) is excluded.
ii) In participants where there may be a reasonable suspicion of  advanced disease 
(eg, large tumors, clinically posit ive axillary lymph nodes, sig ns and symptoms), 
documentation confirming the absence of distant metastasis (M0)  as determined by 
institutional practice is required (staging imaging reports).
iii)Not applicable per Revised Protocol 03.
b) Participants must have ER+ and HER2- BC meeti ng below characteristics:
i) ER+ BC and with or without progesterone-receptor (determined on the most recently 
analyzed tissue sample and tested by a local laboratory as defi ned in the relevant 
American Society of Clinical Oncology [ASCO]-College of American  Pathologists
[CAP] Guidelines).
72
ii) HER2- BC defined as a negative in situ hybridization test or a n IHC status of 0, 1+, or 
2+. If IHC is 2+, a negative in situ hybridization (fluorescenc e in situ hybridization 
[FISH], chromogenic in situ hybridization [CISH], or silver in s itu hybridization 
[SISH]) test as defined in the  relevant ASCO-CAP Guidelines73is required (tested by 
a local laboratory).
c) Participants must have neoadjuvant endocrine monotherapy deem ed to be a suitable 
therapy.
Revised Protocol No.: 03
Date: 13-Mar-2020 59
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
d) Participants must agree to provide tumor tissue at baseline, o n-treatment, and at surgery. 
The tumor tissue at baseline must be either in FFPE tissue block ( 20 mm3) collected within 
90 days prior to enrollment or unstained tumor tissue sections (22 slides sectioned within 
60 days prior to enrollment from a tissue sample collected withi n 90 days prior to 
enrollment) from primary tumor lesion. If a recent tumor specimen is not available, a fresh 
tumor biopsy (containing 20 mm3 of tissue) collection is required. At least 15 unstained 
slides must be submitted for a participant to be eligible. If <  15 unstained slides are 
available, the participant is not eligible.  
 
 
e
) Participants must have the  ability to sw allow oral med ication.
f) Participants must have a performance status (PS) ‚â§1 on the Eastern Cooperative Oncology 
Group (ECOG) scale.
g) Participants must be deemed eligible for surgery and must agre e to undergo surgery after 
completion of neoadjuvant therapy.
h) Re-enrollment: This study permits the re-enro llment of a participant that has discontinued 
the study as a pretr eatment failure (ie, participant has not been rando mized (or treated in 
the Safety Run-in Phase). If re-enrolled, the participant must be re-consented and 
inclusion/exclusion criteria reassessed.
3) Age and Reproductive Status
a) Women not of childbearing potential (WNOCBP; refer to Appendix 4 ) and Men, ages 18 
or local age of majority and older, inclusive.
b) Women participants must have documented proof that they are n ot of childbearing 
potential including postmenopausal status defined as:
i) Women over age 55 years who, in the absence of other biologic al or physiolog ical 
causes, have 12 months of amenorrhea.
ii) Age 55 or younger with no menses (eg, spontaneous or secondar y to hysterectomy) for 
at least 12 months prior to enrollment (in the absence of chemo therapy, tamoxifen, 
toremifen, or ovarian s uppression) and with a documented serum follicle stimulating 
hormone (FSH) lev el > 40 mIU /mL and estradiol level in the postmenopausal range 
according to local instituti onal/laboratory standard; or
iii) Age ‚â•18 with documented bilateral oophorectomy at least 28 days prio r to D1 of 
treatment.Note: For women with therapy-induced amenorrhea, serial measure ments of FSH 
and/or estradiol are needed to ensure postmenopausal status. Ov arian radiation or 
treatment with a luteinizing hormone-releasing hormone agonist (LH-RHa; goserelin 
acetate or le uprolide acet ate) is not permitted for induction o f ovarian suppression in 
this trial.
c) Women who are not of childbearing potential are exempt from co ntraceptive requirements.
Revised Protocol No.: 03
Date: 13-Mar-2020 60
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
d) Men who are sexually active with WOCBP must agree to follow in structions for method(s) 
of contraception and fetal protection ( Appendix 4) for the duration of treatment with study 
treatment(s) plus 5 half-lives of the study treatment plus 90 da ys (duration of sperm 
turnover) for a total of 7 months post-treatment completion. In  addition, male pa rticipants 
must be willing to refrain from sperm donation during this time.
e) Azoospermic men are not exempt from contraceptive requirements,  even if the participant 
has undergone a successful vasectomy or if the partner is pregn ant.
6.2 Exclusion Criteria
1) Medical Conditions
a) Women who are of childbearing potential or breastfeeding
b) The following BC characteristics:
i) History of ipsilateral invasive BC, regardless of treatment, or ipsilater al ductal 
carcinoma in situ treated with ra diotherapy or contralateral inv asive BC at any time.
ii) Definitive clinical or radiologic evidence of metastatic dis ease.
iii)Inflammatory/inoperable BC.
iv) Multicentric BC (the presence of more than 1 tumor in differen t quadrants of the 
breast).
v) Bilateral invasive BC.
c)Not applicable per Protocol Revision 03.
d) Participants with a history of or active, known or suspected au toimmune disease, or other 
syndrome that requires systemic steroids above physiological replacement dose or 
autoimmune agents for the past 2 years, except :
i) Participants with type I diabetes mellitus, hypothyroidism onl y requiring hormone 
replacement, skin disorders (such as vitiligo, psoriasis, or al opecia) not requiring 
systemic treatment, or conditions not exp ected to recur in the absence of an external 
trigger are permitted to enroll.
ii) Inhaled or topical steroids, and adrenal rep lacement steroid doses up to physiolog ical 
replacement dose, are permitted in the absence of active autoim mune disease.
e) Known human immunodeficiency virus (HIV) positive with an AID S defining 
opportunistic infection within the  last year, or a current CD4 count <350 cells/uL. NOTE: 
Testing for HIV must be performed at sites where mandated local ly (refer to Appendix 9 ).
f) Prior malignancy active within the previous 3 years except fo r locally curable cancers that 
have been apparently cured, such as basal or squamous cell skin  cancer, superficial bladder 
cancer, or carcinoma in situ of the prostate, cervix, or breast.
g) Participants with serious or uncontrolled medical disorders.
h) Personal history of any of the following conditions: syncope of either unexplained or 
cardiovascular etiology, ventr icular arrhythmia (including but not limited to ventricular 
tachycardia and ventricular fibrillation), long or short QT syn drome, Brugada syndrome, 
or known history of corrected QT pr olongation, Torsade de Point es, or sudden cardiac 
arrest. Exception: participants with controlled atrial fibrillat ion for > 30 days prior to study 
treatment are eligible.
Revised Protocol No.: 03
Date: 13-Mar-2020 61
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
i) Other nonmalignant systemic disease that would preclude the parti cipant from receiving
study treatment or woul d prevent required follow up such as:
i) Active infection or chronic infection requiring c hronic s uppressive antibiotics.
ii) Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of
the stomach or small bowel, or other disease or condition signific antly affecting GI 
function.
iii) Chron ic daily tr eatment with cor ticosteroids at a  dose above physiolo gical replacement 
dose (excluding inhaled steroids).
iv) Seizure disorders requiring medication.
v) History of interstitial lung disease or pneumonitis. 
j) Class III or Class IV myocardial disease as described by the New Yor k Heart Association
(refer to Appendix 11 )74; a recent history (within 6 months prior to enrolment) of
myocardial infarction, or symptomatic arrhythmia at the time of rand omization/treatment.
k) Any psychological, familial, sociolog ical, or geo graphical condition potentially hampering 
compliance with the study protocol and follow-up schedule. 
2) Prior/Concomitant Therapy
a) Any treatment, including radiotherapy, chemotherapy, and/or t argeted therapy, 
administered for the currently d iagnosed BC prior to enrollment .
b) Surgical axillary staging procedure prior to enrollment (with  exception of fine-needle 
aspiration or core biopsy).
c) Surgical excisional biopsy of primary tumor.
d) Participants for whom upfront chemotherapy is clinically judge d appropriate as optimal 
neoadjuvant treatment
e) Prior ET or CDK4/6 inhibitors for BC within 5 years.
Note: Participants who received ‚â§7 days of letrozole or anastrozole for current disease 
prior to randomization/treatment are eligible.
f) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or  anti-CTLA-4 antibody, or 
any other antibody or dr ug specifically targeting T-cell co-stimulation or checkpoint 
pathways.
g) Use of any medication or substances that are strong inhibitor s or inducers of cytochrome 
p-450 (CYP)3A isoenzymes, or CYP3A substrates with narrow therapeutic index (see 
Section 7.7 [Concomitant Therapy]). 
h) Treatment with botanical preparations (eg, herbal supplements or traditional Chinese 
medicines) intended for general health support or to treat the disease under study within 
2 weeks prior to randomization/treatment. See S ection 7.7 fo r prohibited therapies.
i) Participants who have received a live/attenuated vaccine within 30 days before first 
treatment.
j) Concurrent use (defined as use within 4 weeks prior to baseli ne tissue sample being taken) 
of hormone replacement therapy or any other estrogen-containing  medication (including 
vaginal estrogens).
3) Physical and Laboratory Test Findings
a) White blood cells < 2000/ŒºL
Revised Protocol No.: 03
Date: 13-Mar-2020 62
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
b) Neutrophils < 1500/ŒºL
c) Platel ets < 100 √ó103/ŒºL
d) Hemoglobin < 10.0 g/dL
e) Serum creatinine > 1.5 √óULN, or estimated creatinine clearance < 60 mL/min (as 
calculated using the method standard for the institutions)
f) AST/ALT: > 1.5 √óULN
g) Total bilirubin > ULN or > 1.5 √óULN in participants with Gilbert Syndrome or similar 
syndrome involving slow conjugation of bilirubin
h) ALP > 1.5 √óULN
i)Not applicable per Protocol Revision 03.
j) Have corrected QT interval of > 470 milliseconds on screening  ECG.
k) International normalized ratio must be within normal limits o f the local laboratory ranges. 
l) Serologic evidence of chronic hepatitis B virus (HBV) infectio n with an HBV viral load 
above the limit of quantification. Patients with chronic HBV in fection must be on 
concurrent viral suppressive therapy.
m) Serologic evidence of current h epatitis C virus (HCV) infectio n with an HCV viral load 
above the limit of quantification.
4) Allergies and Adverse Drug Reaction
a) History of allergy or hypersen sitivity to study drug componen ts.
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated.  (Note: under certain specific 
circumstances, and only in countries where local regulations perm it, a person who has been 
imprisoned may be included or permitted to continue as a partic ipant. Strict conditions 
apply and BMS written a pproval is required).
b) Participants who are compulsorily detained for tr eatmen t of either a psychiatric or physical 
(eg, infectious disease) illness.
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
6.3.1 Meals and Dietary Restrictions for CDK 4/6 Inhibitor
‚Ä¢Participants must avoid consumption of grapefruit, grapefruit hy brids, pummelos, star-fruit, 
Seville oranges, pomegranates, or products containing the juice of each during the entire study 
treatment and preferably 7 days before the first dose of study medications, as they affect CYP
and P-glycoprotein (Pg P) activity and have a potential to increas e exposure to palbociclib 
(NOTE: Oranges and orange juice are allowed.)
‚Ä¢Herbal or dietary supplements known as strong inhibitors or inducers of CYP3A4 (refer to 
Appendix 10 [Concomitant Medications]) are prohibited. 
Revised Protocol No.: 03
Date: 13-Mar-2020 63
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
6.4 Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but who 
are not subsequently randomized in the study/included in the anal ysis population. A min imal set 
of screen failure information is required to ensure transparent  reporting of screen failure 
participants, to meet the Consolidated Sta ndards of Reporting T rials (CONSORT) publishing 
requirements, as applicable, and to respond to queries from regul atory authorities. Minimal 
information includes date of consent, demography, screen failur e details, eligibility criteria, and 
any serious AEs.
6.4.1 Retesting During Screening or Lead-In Phase
Participant Re-enrollment: This study permits the re-enrollment of a participant that has 
discontinued the study as a pretreatment f ailure (ie, participant has not been randomized/has not 
been treated). If re-enrolled, the participant must be re-conse nted.
Retesting of laboratory parameters and/or other assessments wit hin any single Screening or Safety 
Run-in Phase will be permitted (in addition to any parameters th at require a confirmatory value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participant‚Äôs most current, clin ical state.
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo, or 
medical device intended to be administered to a st udy participant acc ording to the st udy 
randomizatio n or treatment allocation.
Study treatment includes both Inve stigational [Medicinal] Produc t (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and ca n consist of the following:
‚Ä¢BMS-936558 (nivolumab)
‚Ä¢Abemaciclib
‚Ä¢Palbociclib
‚Ä¢Anastrozole
An IP, also known as an IMP in some regions, is defined a pharma ceutical form of an active 
substance or placebo being tested or used as a reference in a c linical study, including products 
already with a marketing author ization but used or assembled (f ormulated or packaged) differently 
than the authorized form, or used for an unauthorized indicatio n, or when used to gain further 
information about the authorized form.
Description and storage information for the 4 drugs used in thi s open-label study are provided in
Table 7-1.Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the SOC for a given diagnosis, may be considered as non-IPs.
Revised Protocol No.: 03
Date: 13-Mar-2020 64
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Premedications or med ications used to treat i nfusion-related reactions s hould be sourced by the 
investigative sites if available and permitted by local regulat ions.
Revised Protocol No.: 03
Date: 13-Mar-2020 65
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 7-1: Study Treatments for Study Number CA2097A8
Product Description/ 
Class and Dosage 
FormPotency IP/Non-IMPBlinded or 
Open LabelPackaging/ 
AppearanceStorage Conditions
(per label)
Nivolumab Injectiona10 mg/mL;
100-mg fill volume
and
10 mg/mL;
40-mg fill volumeIP Open Label VialsRefer to the label or container and/or 
Pharmacy Manual
Abemaciclib Tabletsb150 mg, 100 mg, and 50 mg IP Open Label TabletsRefer to the label or container and/or 
Pharmacy Manual
Palbociclib Capsulesb125 mg, 100 mg, and 75 mg IP Open Label CapsulesRefer to the label or container and/or 
Pharmacy Manual
Anastrozole Tabletsb1 mg IP Open Label TabletsRefer to the label or container and/or 
Pharmacy Manual
Abbreviations: IP = investigational product; IMP, investigation al medicinal product; mg = milligram; mL = milliliter; SmPC = s ummary of product characteristics.
aMay be labeled as either ‚Äú BMS-936558-01‚Äù or ‚ÄúNivolumab".
bThese products may be obtained by the investigational sites as local commercial product in certain countries if allowed by local regulations. In these cases, 
products may be a different pack s ize/potency than listed in th e table. These products should be prepared/stored/administered in accordance with the package 
insert or SmPC or according to institutional standards.
Revised Protocol No.: 03
Date: 13-Mar-2020 66
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
7.1 Treatments Administered
The selection and timing of dose for each participant are shown in Table 7.1-1 and Table 7.1-2.
Table 7.1-1: Selection and Timing of Dose - Safety Run-in Phase
CohortStudy 
TreatmentDosage Levela Frequency of
AdministrationStart and Duration 
of TreatmentRoute of 
Administration
1Nivolumab 480 mg Q4W Cycle 1-5 IV
Abemaciclib 150 mg BID Cycle 1-5PO (with or 
without food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
2Nivolumab 480 mg Q4W Cycle 1-5 IV
Palbociclib 125 mgQD √ó3w e e k so n
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Abbreviations: BID = twice daily; EOT  = end of treatment; IV = intravenous; mg = milligram; PO = per  os (by mouth); 
Q4W = every 4 weeks; QD = once daily.
Note: At the time of Revised Prot ocol 03, 2 participants had bee n treated in Cohort 1 (nivolumab + abemaciclib + 
anastrozole), which was subsequently closed for enrollment.
aFor abemaciclib and palbociclib, this is the starting dose leve l. Dose levels may be reduced per Section 7.4 (Dosage 
Modification).
bAfter 5 cycles or EOT, all participants should continue to recei ve anastrozole until breast surgery. Anastrozole is 
not considered study therapy beyond completion of Cycle 5 or EO T.
Table 7.1-2: Selection and Timing of Dose - Randomized Phase
ArmStudy 
TreatmentDosage Levela Frequency of
AdministrationStart and Duration 
of TreatmentRoute of 
Administration
ANivolumab 480 mg Q4W Cycle 1-5 IV
Palbociclib 125 mgQD √ó3 weeks on 
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
BPalbociclib 125 mgQD √ó3 weeks on 
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Nivolumab 480 mg Q4W Cycle 2-5 IV
Revised Protocol No.: 03
Date: 13-Mar-2020 67
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 7.1-2: Selection and Timing of Dose - Randomized Phase
ArmStudy 
TreatmentDosage Levela Frequency of
AdministrationStart and Duration 
of TreatmentRoute of 
Administration
CPalbociclib 125 mgQD √ó3 weeks on 
(1 week off)Cycle 1-5 PO (with food)
Anastrozole 1 mg QD Cycle 1-5b PO (with or 
without food)
Abbreviations: BID = twice daily; EOT  = end of treatment; IV = intravenous; mg = milligram; PO = per  os (by mouth); 
Q4W = every 4 weeks; QD = once daily.
Note: As of Revised Protocol 03, the abemaciclib-containing combination arms have been removed from the 
Randomization Phase of the study.
aFor palbociclib, the starting dose level will be the safe dose determined upon completion of the Safety Run-in 
Phase.
bAfter 5 cycles or EOT, all participants should continue to recei ve anastrozole until breast surgery. Anastrozole is 
not considered study therapy beyond completion of Cycle 5 or EOT .
Randomized participants should begi n study treatment within 3 c alendar days of rando mization.
7.1.1 Nivolumab Dosing (Safety Run-in Cohorts and Randomized Phase 
Arms A and B)
Participants are to start nivolumab within 3 calendar days of r andomization.Participants will 
receive nivolumab at a dose of 480 mg as a 30-mi nute IV infusio n for a maximum of 5 cycles 
(maximum 4 cycles for Arm B).
Doses of nivolumab may be interrupted, omitted, or discontinued , depending on how well the 
participant tolerates the treatment. There w ill be no dose escalations or reductions of nivolumab 
allowed. For Q4W dosing cycles, participants may be dosed within a ¬±3-day window. 
If a participant cannot receive nivolumab within a ¬±3-day window, nivolumab must be omitted 
(skipped) for that cycle. If nivolumab is omitted, the other st udy medications may continue. If a 
participant discontinues nivolumab, the entire study treatment (CDK4/6 inhibitor and anastrozole) 
must be discontinued.When nivolumab is scheduled to be administered on the same day with palbociclib plus
anastrozole, nivolumab dosing should be started > 1 hour after palbociclib plus anastrozole 
ingestion. If nivolumab can not be given within 3 days of palboc iclib plus anastrozole 
administration for a given cycle, nivolumab must be omitted for t hat cycle. 
Premedications are not recommended for the first dose of nivolu mab.
Participants should be carefully monitored for infusion reactio ns during nivolumab a dministration. 
If an acute infusion reaction is noted, participants should be managed according to Section 7.4.4.3
(Treatment of Nivol umab Infusion Reaction). 
Instructions for dilution and infusion of nivolumab injection m ay be provided in the clinical 
protocol, pharmacy binder, or pharmacy reference sheet. Care mu st be taken to assure sterility of 
Revised Protocol No.: 03
Date: 13-Mar-2020 68
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
the prepared solution, as the product does not contain any anti microbial preservative or 
bacteriostatic agent.
7.1.2 CDK4/6 Inhibitors and Anastrozole Dosing
Premedications are not recommended for the first dose.
In the Safety Run-in Phase, participant assignment to abemacicl ib or palbociclib will be carefully 
managed by the study team with the Investigator. The selected CD K4/6 inhibitor cannot be 
changed or switched to another one once the study treatment has  been initiated. At implementation 
of Revised Protocol 03, the study will only evaluate the combin ation of nivolu mab with palbociclib 
plus anastrozole. Patients in screening and not y et treated were offered the option to join the nivolumab 
+ palbociclib + anastrozole arm. Patients on treatment were to b e re-consented and continue on 
anastrozole alone, OR taken off study. 
Study treatment must be taken within 3 calendar days following randomization.
In the Randomized Phase, participants will be randomly assigned by an IRT system.
Palbociclib should be taken together with anastrozole as follows :
‚Ä¢Palbociclib is dosed QD PO for the first 3 weeks of the cycle ( with the 4th week off). 
Anastrozole is dosed continuously, BID and QD PO, respectively.
‚Ä¢On scheduled visit days, partici pants must hold taking study tr eatments at home. They must 
take them in the clinic under the supervision of the Investigat or or designee after all st udy 
procedures for the visit have been completed. On all other days, participants may take st udy 
treatments at home.
‚Ä¢Participants should be instructed  to take palbociclib and anastr ozole with a large glass of water 
(~250 mL or ~8 oz) at the same time each day.
‚Ä¢Palbociclib should be administered with food. Anastrozole can b e administered either with or 
without food.
‚Ä¢Participants should be instructed to swallow the tablets whole a nd not to chew, crush, or open 
them.
‚Ä¢If vomiting occurs during the course of treatment, no re-dosing  of the participant is allowed 
before the next scheduled dose. The occurrence and frequency of  any vomiting during a 
treatment cycle must be noted i n the AEs secti on of the  eCRF. 
‚Ä¢Any doses that are missed (not taken within 6 hours of the inte nded time) s hould be s kipped 
and should not be replaced or made up on a subsequent day.
‚Ä¢Multivitamins, glucosamine, probiotics, and fish oil are permit ted. 
‚Ä¢After 5 cycles or EOT, all participants should continue to rece ive anastrozole until subsequent 
breast surgery. If anastrozole can no longer be administered af ter EOT (ie, due to related 
toxicities), breast surgery w ill be performed right away. Anastrozole is not considered stud y 
therapy beyond com pletion of Cycle 5 or EOT.
Revised Protocol No.: 03
Date: 13-Mar-2020 69
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
7.2 Method of Treatment Assignment
Before the study is initiated, each user wi ll receive log-in in formation and directions on how to 
access the IRT. Each participant will be assigned a unique part icipant number after signing the 
ICF. Participant numbers will be used on all participants‚Äô stud y information. Participant numbers 
will not be reassigned. The Investigator or designee will regis ter the participant for enrollment by 
following the enrollment procedures established by BMS.
The following information is required for enrollment in the IRT:
‚Ä¢Date that informed consent was obtained
‚Ä¢Year of birth
‚Ä¢Gender at birth
Safety Run-in participants who have met all eligibility criteri a will be enro lled in the IRT.  
After the Safety Run-in Phase is complete (safet y of the combination is c onfirmed), randomization 
of participants to Arms A, B, and C can begin. 
The following information is required for participant randomiza tion:
‚Ä¢Participant number
‚Ä¢Year of birth
‚Ä¢Tumor characteristics (involvement of lymph nodes, tumor size at  baseline)
Participants meeting all eligibility criteria w ill be randomized in a 4:4:3 ratio and stratified by  
 2) involvement of lym ph node
(cytologically positive vs radiologically or cytologically nega tive), and 3) tumor size (> 3 cm or 
‚â§3c m ) .
The exact procedures for usi ng the IRT will be  detailed in the I RT manual. Study treatment w ill 
be dispensed at the study visits as listed in Section 2 (Schedule of Activities).
7.3 Blinding
This is a randomized, non-comparative, open-label study; blinding procedures are not applicable.
7.4 Dosage Modification
When assessing AEs, the Investigator must assign drug causality  to each study drug for each AE. 
If a reasonable determination cannot be made, then the AE shoul d be considered related to each of 
the study drugs. IO agents are associated with AEs that can diff er in severity and duration from 
AEs caused by other therapeutic classes. No dose re-escalation w ill be allowed.
Please refer to individual approved drug labels for recommendat ions on dose reduction, 
interruption or discontinuatio n of individual st udy drug s in the  management of study drug-related 
Revised Protocol No.: 03
Date: 13-Mar-2020 70
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
adverse reactions. C linical judgment of the  treating physician s hould guide the management plan 
of each participant based on i ndividual benefit-risk assessment. However, for events requiring a 
discontinuation, treatment must be discontinued. Any changes to t he dose must be recorded on the
appropriate eCRF.
7.4.1 Dose Modifications for Abemaciclib
At the implementation of Revised Protocol 03, abemaciclib dosin g will be discontinued in all 
patients. 
7.4.2 Dose Modifications for Palbociclib
Palbociclib can be interrupted, reduced, or discontinued both with in a cycle and between cycles.
The dose modifications permi tted fo r palbociclib in combination with anastrozole are based on the 
dose level changes outlined in Table 7.4.2-1.
Table 7.4.2-1: Dose Levels for Palbociclib
Dose Level Oral Dose Frequency
Starting dose 125 mg QD √ó3 weeks on (1 week off)
First dose reduction 100 mg QD √ó3 weeks on (1 week off)
Second dose reduction 75 mg QD √ó3 weeks on (1 week off)
Third dose reduction Discontinue Not applicable
Abbreviations: mg = milligram; QD = once daily.
7.4.3 Dose Modification for Anastrozole
No dose modification f or anastrozole is listed per full prescribing information.
7.4.4 Dose Modifications for Nivolumab
Participants who require a dose omission for nivolumab should b e re-evaluated and resume 
treatment at the next cycle when re-treatment criteria are met.  Drug-drug interaction between 
nivolumab and palbociclib are not expected. Nivolumab is a mono clonal antibody given IV, and 
is unlikely to cause any cytokine mediated changes in CYP isoen zymes.
7.4.4.1 Dose Omission Criteria for Nivolumab
Nivolumab administration should be omitted for the following:
‚Ä¢Grade 2 non-skin, drug-related AE, with the exception of fatigu e.
‚Ä¢Grade 2 drug-related creatinine, AST, ALT, and/or total bilirubi n abnormalities.
‚Ä¢Grade 3 skin, drug-related AE.
‚Ä¢Grade 3 drug-related laboratory abnormality, with the following  exceptions:
‚àíGrade 3 lymphopenia or asymptomatic amylase or lipase does not require dose omission.
‚àíGrade ‚â•3 AST, ALT, total bilirubin will require dose discontinuation ( see Section 8.1.1
[Nivolumab Dose Discontinuation]).
Revised Protocol No.: 03
Date: 13-Mar-2020 71
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Any AE, laboratory abnormality, or intercurrent illness which, in the  judgment of the 
Investigator, warrants an omissio n of the  dose.
For the nivolumab omission criteria and criteria to resume trea tment, please refer to the nivolumab 
dose delay criteria in Appendix 6.
7.4.4.2 Criteria to Resume Treatment with Nivolumab
Participants may resume treatment with study treatment when the  drug-related AE(s) resolve to 
Grade ‚â§1 or baseline value, with the following exceptions:
‚Ä¢Participants may resume treatm ent in the presence of Grade 2 fa tigue.
‚Ä¢Participants who have not experienced a Grade 3 drug-related sk in AE may resume treatment 
in the presence of Grade 2 skin toxicity.
‚Ä¢For participants with Grade 2 AST, ALT, and/or total bilirubin a bnormalities, dosing may 
resume when laboratory values return to baseline and management  with corticosteroids, if 
needed, is complete.
‚Ä¢Drug-related pulmonary tox icity, dia rrhea or co litis must have r esolved to baseline before 
treatment is resumed. Participants with persistent Grade 1 pneu monitis after completion of a 
steroid taper over at least 1 month may be eligible for retreat ment if discussed with and 
approved by Med ical Monit or (or designee).
Participants with drug-related endocrinopathies adequately cont rolled with only  physiologic 
hormone replacement may resume treatment after consu ltation with the Medical Monitor (or 
designee). Adrenal insufficiency  requires discontinuation regar dless of control with hormone 
replacement.
7.4.4.3 Treatment of Nivolumab Infusion Reaction
Since nivolumab contains only human immunoglobulin protein sequ ences, it is unlikely to be 
immunogenic and induce infusion or hypersensi tivity reactions. However, if such a reaction were 
to occur, it might manifest with fever, chills, rigors, headach e, rash, pruritus, arthralgias, 
hypotension, hypertension, bronchospasm, or other allergic-like reactions. All Grade 3 or 4 
infusion reactions should be re ported within 24 hours to the st udy Medical Moni tor and reported  
as a serious adverse event (SAE) if it meets the criteria. Infus ion reactions should be graded 
according to NCI CTCAE v5.0 guid elines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms (mild reaction; i nfusion interruption not indicated; intervention not 
indicated):
‚Ä¢Remain at bedside and monitor participant until recovery from sy mptoms occurs. The 
following prophylactic pre -medications are r ecommended for futu re infusions: 
Revised Protocol No.: 03
Date: 13-Mar-2020 72
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/para cetamol 325 to 1000 mg at 
least 30 minutes before subsequent nivolumab administrations.
For Grade 2 symptoms: (moderate reaction required therapy or i nfusion inte rruption but responds 
promptly to symptomatic treatment [eg, antihis tamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for 
‚â§24 hours):
‚Ä¢Stop the study drug i nfusion, begin an IV infusio n of normal saline, and tr eat the participant
with diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 
1000 mg; remain at bedside and monitor participant un til resolution of symptoms. 
Corticosteroid and/or bronchodilator therapy may also be admini stered as appropriate. If the 
infusion is interrupted, then restart the i nfusion at 50% of the original infusion r ate when 
symptoms resolve; if no further complications ensue after 30 min utes, the rate may be 
increased to 100% of the original infusion rate. Monitor partic ipant closely. If symptoms recur, 
then no further study medication will be administered at that v isit.
‚Ä¢For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equiv alent) and/or acetaminophen/para cetamol 325 to 1000 mg 
should be administered at least 30 minutes before nivolumab inf usions. If necessary, 
corticosteroids (up to 25 m g of hydrocortis one or equiv alent) may be used.
For Grade 3 or 4 symptoms : (severe reaction, Grade 3: prolonged [ie, not rapidly respons ive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improv ement; hospi talization indi cated for other clinical sequelae [eg, renal impairment, 
pulmonary infiltrates]. Grade 4: Life threatening; pressor or v entilatory support indicated):
‚Ä¢Immediately discontinue infusion of study d rug. Begin an IV i nfusion of normal saline and 
treat the participant as follows: Recommend bronchodilators, epi nephrine 0.2 to 1 mg of a 
1:1000 solution for subcutane ous administrati on or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 5 0 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Partici pant should be monitored 
until the Investigator is comfortable that the symptoms will no t recur. Study drug w ill be 
permanently discontinued. Investigators should follow their ins titutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor partici pant until recovery of the 
symptoms.
In case of late-occurring hypersen sitivity symptoms (eg, appear ance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the Investigator to ensure that IP is only dispensed to study p articipants. The IP must be dispensed 
only from official study sites by authorized personnel accordin g to local regulations.
Revised Protocol No.: 03
Date: 13-Mar-2020 73
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental c onditions (temperature, light, and humidity) as determined by B MS. If 
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment 
should not be dispensed and BMS should be contacted immediately .
Study treatment not supplied by BMS will be stored in accordance with the package insert.
IP documentation (whether supplied by BMS or not) must be maint ained that includes all processes 
required to ensure drug is accurately administered. This includ es documentation of drug storage, 
administration and, as applicable, storage temperatures, recons titution, and use of required 
processes (eg, required diluents, administration sets).
Further guidance and information for final disposition of unuse d study treatment are provided in 
Appendix 2 (Study Governance Considerations).
7.5.1 Retained Samples for Bioavailability/Bioequivalence/Biocomparability
Not applicable.
7.6 Treatment Compliance
Study treatment compliance will be periodically monitored by dr ug accountability, dosing diary 
cards, participant‚Äôs medical r ecords, and eCRF. On the day of a s cheduled visit, study drug will be 
administered in the clinic by trained site pers onnel and drug ac countability should be reviewed by 
the site study staff. Sites should di scuss discrepancies with th e participant at each scheduled visit.
7.7 Concomitant Therapy
Concomitant medications, all forms of premed ications, and supportive care are recorded at 
baseline and throughout st udy tr eatment and safety follow-up in the appropriate section of the 
eCRF at each visit.
All medications (prescription and over-the-counter), vit amin and mineral s upplements, and/or 
herbs taken by the participant from Screening th rough the Safety Follow-up Period w ill be 
documented and recorded, including start and stop date, dose an d route of administration, 
frequency, and indication. Medications taken for a procedure (e g, biopsy) should also be included.
Anastrozole administered after completion of 5 cycles of neoadj uvant treatment (or EOT) up to 
subsequent breast surgery must be collected as concomitant medication.
Any subsequent anti-cancer therapy (ie, adjuvant treatment, rad iotherapy) will be recorded up to 
100 days after last dose of nivolumab or 30 days after last dos e of study treatment (Arm C), in the 
appropriate section of the eCRF.7.7.1 Prohibited and/or Restricted Treatments for Nivolumab
The following medications are prohibited during the study (unle ss utilized to treat a drug-related 
AE):
‚Ä¢Any live/attenuated vaccine (eg, varicella, zoster, yellow feve r, rotavirus, oral polio, and 
measles, mumps, rubella [MMR]) during treatment and until 100 d ays post last dose.
‚Ä¢Immunosuppressive agents.
Revised Protocol No.: 03
Date: 13-Mar-2020 74
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Supraphysiological doses of systemic corticosteroids.
‚Ä¢Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormo nal therapy, immunotherapy, 
extensive, non-p alliative rad iation therapy , or standa rd or investigational agents for treatment 
of ER-, HER+ BC).
‚Ä¢Any botanical preparation (eg, herbal supplements or traditional  Chinese medicines) intended 
to treat the disease under s tudy or provide supportive care. Us e of marijuana and its derivatives 
for treatment of symptoms related to cancer or cancer treatment  are permitted if obtained by 
medical prescription or if its use (even without a medical pres cription) has been legalized 
locally.
7.7.2 Prohibited and/or Restricted Treatments for Abemaciclib and 
Palbociclib
‚Ä¢Anticancer agents: No additional investigational or commercial anticancer agents (i ncluding 
specifically aromatase inhibitors, anti-estrogens other than fu lvestrant, chemotherapy, and 
immunotherapy) other than those mentioned in this study w ill be permitted during the 
On-treatment Pre-s urgery (neoadjuvant) Period. In general, any drugs containing ‚Äúfor the 
treatment of breast cancer‚Äù on the product insert are not permi tted on the study. Additionally, 
use of megestrol acetate as an appetite stimulant is not permit ted.
‚Ä¢Strong CYP3A inhibitors/inducers and CYP substrates (refer to Appendix 10
[Concomitant Medications]): The results from human disposition (I3Y-MC-JPBD) and 
in vitro human r ecombinant CYP phenotyping studies indicate that  abemaciclib is extensively 
metabolized pr imarily via CYP3A. Co-administration with drugs that are CYP3A i nhibitors 
and inducers may change the plasma concentrations of abemacicli b in humans. 
‚àíCo-administration with  strong CYP3A inhibitors and strong induce rs should be avoided 
while on treatment. Par ticipants treated with those drugs within  the last 5 days prior to 
randomization/study t reatment cannot be included in the tr ial. 
‚àíCo-administration with moderate CYP3A inhibitors and moderate inducers should also be 
avoided if possible, or otherwise be subject to caution (eg, inc reased frequency of safety 
monitoring).
‚àíCYP substrates: In vitro studies in cultured human hepatocytes indicate that ab emaciclib 
and its major metabolites LSN2839567 and LSN3106726 downregulate messenger ribonucleic acid (mRNA) of CYPs at clinically relevant concentrations. The mechanism of 
downregulation and its clinical relevance are presently not understood. Therefore, care 
should be taken when co-administering substrate drugs of CYPs ( CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A) with narrow therapeutic margi n. Participants
treated on CYP3A Substrates with Narrow Therapeutic Index (NTI) ca n only be included 
in the trial after discontinuation of the drug for longer than 5  half-lives prior to 
randomization/study treatment. 
‚Ä¢Herbal/alternative remedies: Participants are to avoid Seville oranges and grapefruit and 
grapefruit juice, as they affect CYP and PgP activity.
Revised Protocol No.: 03
Date: 13-Mar-2020 75
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Chronic immunosuppressive therapies: Chronic immunosuppressive therapies should be 
avoided, including systemic corticosteroids. Steroids given for  physiolo gical rep lacement, as 
anti-emetics, or inhaled, as well as s hort courses of ora l/topical steroids given for allergic 
reactions or asthma flares are allowed.
‚Ä¢Erythropoietin: Erythropoietin is  not to be used. Any potential indication should be discussed 
with the Investigator and the Sponsor.
7.7.3 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with  either corticosteroids at above 
physiolog ical replacement dose or other immunosuppressive medications within 14 d ays of 
randomization/study treatment are excluded.
7.7.3.1 Imaging Restriction and Precautions
It is the local imagi ng facility‚Äôs respons ibility to determine,  based on participant attributes 
(eg, allergy history, diabetic history , renal status), the a ppropriate imaging mo dality and contrast 
regimen per imaging study. Imaging contraindications and contrast risks are to be considered in 
this assessment. Participants with renal insufficiency are to be assessed as to whether or not they should receive contrast and, if so, which contrast agent and dos e is appropriate. Specific to 
magnetic resonance imaging (MRI), participants with severe rena l insufficiency (ie, estimated 
glomerular filtration rate < 30 mL/min/1.73 m
2) are at increased ris k of nephrogenic systemic 
fibrosis; therefore, M RI contrast is contraindicated. In addition , participants may be excluded from 
MRI if they have tattoos, metallic implants, pacemakers, etc. 
Gentle hydration before and after IV contrast should follow loc al SOC. The ultimate decision to 
perform MRI in an individual participant in this study rests wi th the site radiologist, the 
Investigator, and standards set by the local IEC.
7.7.4 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-ar ticular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). A brief (le ss than 3 weeks) course of 
corticosteroids for prophylaxis (eg, contrast dye allergy) or f or treatment of non-autoimmune 
conditions (eg, delayed-type hypersensitivity reaction caused by  a contact allergen) is permitted.
7.8 Treatment After the End of the StudyAt the end of the study, BMS will not continue  to provide BMS-s upplied study treatment to 
participants/Investigators unless BMS chooses to extend the stud y. The Investigator should ensure 
that the participant receives appropriate SOC to treat the condi tion under study.
BMS reserves the right to terminate access to BMS-supplied stud y treatment if a ny of the following 
occur:
1) The study is terminated due to safety concerns.
2) The development of the study tr eatment is termin ated for other reasons, including but not 
limited to lack of efficacy and/or n ot meeting the study  object ives.
Revised Protocol No.: 03
Date: 13-Mar-2020 76
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
3) The participant can obtain medicatio n from a government-s ponsored or private h ealth program. 
In all cases BMS will follow local regulations.
8 DISCONTINUATION CRITERIA
Reasons for discontinuation (of treatment vs from study): Participants are expected to complete 
5 cycles of neoadjuvant therapy except in the event of disease progression, death, unacceptable 
toxicity, symptomatic deterioration, Investigat or‚Äôs decision to discon tinue treatment, the 
participant‚Äôs decision to discontinue treatment or withdraw consent, the participant being lost to 
follow-up, or BMS decides to terminate the study.
8.1 Discontinuation from Study Treatment
Participants MUST discontinue IP (and non-IP at the discretion of  the Investigator) for any of the 
following reasons:
‚Ä¢Participant‚Äôs request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for pr otocol specified 
follow-up procedures. The only exception to this is when a part icipant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provide this information
‚Ä¢Any clinical AE, laboratory abnorm ality or intercurrent illness which, in the opinion of the 
Investigator, indicates that continued participation in the stu dy is not in the best interest of the 
participant
‚Ä¢Termination of the study by BMS
‚Ä¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of eit her a psychiatric or physical (eg, infectious dis ease) illness. (Note: Under 
specific circumstances, and only in countries where local regul ations permit, a participant who 
has been imprisoned may be permitted to continue as a participan t. Strict conditions apply and 
BMS approval is required.)
‚Ä¢Disease progression
Refer to Section 2 (Schedule of Activities) for data to be collected at the time of  treatment 
discontinuation and follow-up and for any further evaluations t hat can be completed.
All participants who disc ontinue study treatment s hould comply with protocol specified follow-up 
procedures as outlined in S ection 2 (Schedule of Activities). The only exception to this re quirement 
is when a participant withdraws consent for all study proce dures including post-treatment study 
follow-up or los es the ability to consent freely (ie, is impris oned or involuntarily incarcerated for 
the treatment of either a psyc hiatric or physical illness).
If study treatment is discontinued prior to the participant‚Äôs co mpletion of the study, the reason for 
the discontinuation must be documented in the participant‚Äôs med ical records and en tered on the 
appropriate eCRF page.
Revised Protocol No.: 03
Date: 13-Mar-2020 77
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
8.1.1 Nivolumab Dose Discontinuation
If a participant discontinues nivolumab, the entire study treatment (CDK4/6 inhibitor and 
anastrozole) must be discontinued.
Nivolumab treatment should be permanently discontinued for the following:
‚Ä¢Any Grade 2 drug-related uveitis, eye pain, or blurred vision th at does not respond to topical 
therapy and does not improve to Grade 1 severity within the re- treatment period OR requires 
systemic treatment.
‚Ä¢Any Grade 3 non-skin, drug-related AE lasting > 7 days or recur s, with the following 
exceptions for laboratory abnormalities, drug-related uveitis, pneumonitis, bronchospasm, 
neurologic toxicity, hypersensitivity reactions, infusion react ions, and endocrinopathies:
‚àíGrade 3 drug-related uveitis, pne umonitis, bronchospasm, neurol ogic toxicity, 
myocarditis, hypersensitivity reaction, or infusion reaction of  any duration requires 
discontinuation.
‚àíGrade 3 drug-related endocrinopathies, adequately controlled wi th only physiologic 
hormone replacement do not require discontinuation. Adrenal ins ufficiency requires 
discontinuation regardless of c ontrol with hormone replacement.
‚àíGrade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except:
‚ô¶Grade 3 drug-related thrombocytopenia > 7 days or associated wi th bleeding requires 
discontinuation.
‚ô¶Grade ‚â•3 drug-related AST, ALT, or total bilirubin requires discontinua tion (see 
below).
‚ô¶Concurrent AST or ALT > 3 √óULN and total bilirubin > 2 √óULN.
NOTE: In most cases of Grade 3 AST or ALT elevation, study trea tment will be permanently 
discontinued. If the Investigator determines a possible favorable benefit-risk ratio that warrants 
c o n t i n u a t i o n  o f  s t u d y  t r e a t m e n t ,  a  d i s c u s s i o n  b e t w e e n  t h e  I n v e s tigator and the Medical 
Monitor/designee must occur.
‚Ä¢Any Grade 4 drug-related  AE or laboratory abnorm ality (including, but not limited to,
creatinine, AST, ALT, or total bilirubin), except for the follo wing events which do not require 
discontinuation:
‚àíGrade 4 neutropenia ‚â§7 days.
‚àíGrade 4 lymphopenia or leukopenia or asymptomatic amylase or li pase elevation.
‚àíIsolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset.
‚àíGrade 4 drug-related endocrinopathy AEs, such as, hyper- or hypot hyroidism, or glucose 
intolerance, which resolve or are adequately controlled with ph ysiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose-cont rolling agents, 
respectively, may not require discontinuation afte r discussion with an d approval from the 
Medical Monitor.
Revised Protocol No.: 03
Date: 13-Mar-2020 78
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Any event that leads to a dose omission lasting > 10 weeks from t he previous dose requires 
discontinuation, with the following exceptions:
‚àíDose omissions to allow for prolonged steroid tapers to manage drug-related AEs are 
allowed. 
‚àíDose omissions lasting > 10 weeks from the previous dose that oc cur for non-drug-related 
reasons may be allowed if approved by the Medical Monitor (or d esignee).
‚àíNOTE: Prior to re -initiating tr eatment in a particip ant with a dose omission lasting 
> 10 weeks, the Medical Monitor (or designee) must be consulted. Tumor assessments 
should conti nue per protocol, even if a  dose is omitted. Periodic study visits to assess safety 
and laboratory studies s hould also continue Q4W or more fre quently if clinically indicat ed 
during such dose omissions.
‚Ä¢Any AE, laboratory abnormality, or intercurrent illness which, in the  judgment of the 
Investigator, presents a substantial clinical risk to the partic ipant with continued nivolumab 
dosing.
8.1.2 Abemaciclib Dose Discontinuation
At the implementation of Revised Protocol 03, abemaciclib dosing  will be discontinued in all 
patients. 
8.1.3 Palbociclib Dose Discontinuation
Scenarios in which palbociclib shoul d be discontinued are included in the dose modif ication details 
provided in Section 7.4.2 (Dose Modifications for Palbociclib). If palbociclib needs to be 
discontinued, the participant may continue nivolumab and anastr ozole.
8.1.4 Anastrozole Dose DiscontinuationIf anastrozole needs to be discontinued, the participant must a lso stop the other study treatments
and subsequent breast surgery must be performed right away.
8.1.5 Post-study Treatment Study Follow-up
Participants who discontinue st udy treatment must continue to b e followed per Table 2-3.
8.2 Discontinuation from the Study
Participants who request to discontinue study treatment will rem ain in the study and must continue 
to be followed for protocol sp ecified follow-up procedures. The  only exception to this is when a 
participant specifically withdraws consent for any further cont act with him/her or persons 
previously authorized by parti cipant to provide this information . 
‚Ä¢Participants should notify the Investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
‚Ä¢The withdrawal of consent shoul d be explained in detail in the m edical rec ords by the 
Investigator, as to whether the withdrawal is from further trea tment with study treatment only 
or also from study proce dures and/or post-treatment study follow-up, and entered on the  
appropriate eCRF page.
Revised Protocol No.: 03
Date: 13-Mar-2020 79
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
‚Ä¢If the participant wit hdraws consent for disclosure of future i nformation, the Sponsor may 
retain and continue to use any data collected before such a wit hdrawal of consent.
8.3 Lost to Follow-up
‚Ä¢All reasonable efforts must be made to locate participants to d etermine and report their ongoing 
status. This include s follow-up with pers ons authorized by the participant.
‚Ä¢Lost to follow-up is defined by the inability to reach the part icipant after a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in th e participant‚Äôs medical records.
‚Ä¢If it is determined that the participant has died, the site will  use permissible local methods to 
obtain the date and cause of death.
‚Ä¢If the Investigator‚Äôs use of a third-party representative to as sist in the follow-up portion of the 
study has been included in the participant‚Äôs informed consent, then the Investigator may use a 
Sponsor-retained third-party representative to assist site staf f with obtaining participant‚Äôs 
contact information or other public vital s tatus data n ecessary to complete the follow-up 
portion of the study. 
‚Ä¢The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, in order to obtain updated contact in formation.
‚Ä¢If after all attempts, the participant remains lost to follow-u p, then the last known alive date as 
determined by the Investigator should be reported and documente d in the participant‚Äôs medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
‚Ä¢Study procedures and timing are summarized in Section 2 (Schedule of Activities).
‚Ä¢Protocol waivers or exemptions are not allowed.
‚Ä¢All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
‚Ä¢Adherence to the study design requirements, including those spe cified in Section 2 (Schedule 
of Activities), is essential and required for study conduct.
‚Ä¢All screening evaluations must be completed and reviewed to con firm that potential 
participants me et all elig ibility criteria before tr eatment assignment. T he Investigator will 
maintain a screening log to record details of all participants screened and to confirm eligibility 
or record reasons for screening failure, as applicable.
‚Ä¢Procedures conducted as part of  the participant‚Äôs routine clini cal management (eg, blood count) 
and obtained before signing of  informed consent may be utilized  for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in Section 2 (Schedule of Activitie s).
Revised Protocol No.: 03
Date: 13-Mar-2020 80
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating ph ysician. Additional testing or 
assessments may be performed as clinically necessary  or where required by institutional or lo cal 
regulations.
9.1 Efficacy Assessments
9.1.1 Blinded Independent Pathology Review
Blinded independent pathology review will be established for ce ntral review and central
assessment of RCB. Tumor and lymph node collection from definiti ve surgical resection  
 should be perform ed on the day of surgery. 
Processing of the remainder of the specimens for histopathologi c analysis should be performed 
within 72 hours of the procedure. Sections w ill be used for central pathology review assessing 
pathologic response. All hematoxylin and eosin (H&E) slides pre pared from the specimens that 
are reviewed locally must be sent for central pathology review,  along with a c opy of the comp leted 
pathology report. Diagnostic H&E slides are preferred, but recu t sections from all the tissue blocks 
are acceptable. Pathology samples acquisition guidelines and su bmission process will be outlined 
in the laboratory manual.
9.1.2 Pathologic Assessment of Effect
9.1.2.1 RCB DeterminationCentral RCB will be assessed from  routine pathologic sections o f the primary breast tumor site 
and the regional lymph nodes right after surgery . Five variables are included in 
a calculation formula, which includes the following:
1) The primary tumor bed area in its 2 dimensions. For multifocal  tumors (defined as the presence 
of 2 or more foci of cancer within the same breast quadrant), th e largest lesion must be ‚â•2 cm 
and designated as the ‚Äútarget‚Äù lesion for the RCB determination .
2) The overall cancer cellularity (percentage of area).
3) The percentage of cancer that is in situ disease (percentage of area).
4) The number of positive lymph nodes.5) The diameter of the largest lymph node metastasis.
The calculated RCB index value can also be categorized as 1 of 4 RCB classes. The calculation 
formula and detailed description can be found at a dedicated we bsite: 
http://www.mdanderson.org/breastcancer_RCB. The 4 RCB classes ar e the following:
1) RCB 0: no residual disease
2) RCB-I: minimal residual disease3) RCB-II: moder ate residual disease
4) RCB- III: extensive residual disease
Revised Protocol No.: 03
Date: 13-Mar-2020 81
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Detailed procedures are provided in Appendix 7 (Detailed Pathology Methods For Using Residual 
Cancer Burden).
9.1.2.2 Pathological Complete Response Determination
The determination of pCR will be performed by the local patholo gist following examination of 
tissue (breast and nodes) removed at the time of surgery. 
Criteria for evaluation of pCR includes the following: 
‚Ä¢pCR in breast and axillary lymph nodes as well as non-axillary s entinel node (pCR breast and
nodes).
‚Ä¢No histologic evidence of invasive tumor cells in the surgical breast specimen or axillary nodes 
after neoadjuvant treatment. 
‚Ä¢pCR in the breast (pCR breast). No histological evidence of inva sive tumor cells in the 
surgical breast.
9.1.3 C
linical Response Assessments
For the purposes of this study , all clinical res ponse assessments, including 1) clinical breast 
examination by palpati on of breast a nd axilla, and 2) imaging assessment of breast and axilla via
ultrasound (preferred) or mammography, will be assessed by the Investigator and performed 
locally. Every attempt should be made to image each participant using an identical imaging 
modality and acquisition protocol for all imaging time points. Tumor measurements s hould be 
Revised Protocol No.: 03
Date: 13-Mar-2020 82
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
made by the same Investigator or Imager for each assessment, wh enever possible. Tumor 
assessments for all participants should continue per protocol, even if dosing is delayed or 
discontinued. The longest diameter (LD) of the initial lesion(s) wi ll be reported as the baseline 
measurement and used as reference to characterize the objective tumor response. The LD of the 
same lesion(s) will be measured during subsequent imaging studie s.
A best overall response of stable disease requires a minimum of 49 days on study from the first 
dose of treatment.
Screening and on-study images should be acquired as outlined in  Section 2 (Schedule of 
Activities). Tumor assessments at other time points may be perf ormed if clinically indicated.
Bone scans and other SOC imaging, including pathologic examinatio n of suspicious lesions, may 
be acquired per local standards, as clinically indicated.At the Sponsor‚Äôs discretion, images may be collected for review .
9.1.3.1 Objective Response Rate Assessed by Imaging
ORR will be assessed at the end of  the neoadjuvant treatment pri or to Surgery.
For the purposes of this study, tumor response assessments will  be performed by bilateral breast
and axilla ultrasound (preferred) or mammography. Changes in tum or measurements and tumor 
responses will be assessed by th e same Investigator or designee . The timepoint of tumor
assessments will be reported on the eCRF based on the Investigator‚Äôs assessment.
Radiographic Response Assessments:
‚Ä¢Radiographic complete response: Disappearance of the target les ion.
‚Ä¢Radiographic partial response (PR): At least a 30% decrease in the LD of the target lesion
taking as reference the baseline LD.
‚Ä¢Radiographic progression (PD): At l east a 20% increase in the L D of target lesion taking as
references the baseline LD or the appearance of one or more new  lesions.
‚Ä¢Radiographic stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for PD taking as reference the baseline LD.
Note:
1) Target lesions should be selected on the basis of their size ( lesions with the longest diameter)
and should lend themselves to repr oducible repeated measurements. Up to 2 lesions in the 
breast may be identified as target lesions. Per this protocol, target lesion #1 must be ‚â•2 cm
and, if selected, target lesion #2 must be ‚â• 10 mm. A sum of the diameters of all target lesions
will be calculated and reported as the bas eline sum of d iameters. The baseline sum of diameters
will be used as a reference to  further characterize any objecti ve tumor regression in the
measurable dimension of the disease. Lesions that meet the crit eria for radiographically defined
simple cysts should not be considered malignant lesions (neithe r target nor non-target) since
Revised Protocol No.: 03
Date: 13-Mar-2020 83
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
they are, by definition, simple cysts. Pathologic axillary lymph  nodes are not to be designated
at target lesions, and lymph node measurements are not to be in cluded in the sum of diameters.
2) Target Lesions that become too small to measure: all lesions recorded at baseline should have
their actual measurements recorded at each subsequent evaluatio n, even when very small (e.g.,
2 mm). However, somet imes lesions that are rec orded as target lesions at baseline become so
faint on imaging that the radiologist may not feel comfortable assigning an exact measure and
may report them as being too small to measure. When this occurs , it is important that a value
be recorded on the eCRF as follows:
‚àíIf it is the opinion of the radiologist that the lesio n has likely disappeared, the measurement
should be recorded as 0 mm.
‚àíIf the lesion is b elieved to be present and is faintly seen but too small to accu rately measure,
too small to measure should be indicated.
3) Assessments of partial respons e and complete response do not require confirmation. A best 
objective response of stable disease requires a minimum of 42 d ays on study from 
randomizatio n to the date of the follow- up imaging assessment.
For further information please refer to Appendix 8 (RECIST v1.1).
9.1.4 Breast Conserving Surgery Rate
BCS rate is defined as the number of participants who undergo BCS after completing the study 
treatments divided by the number of randomized participants for  each treatment group.
For this study, planned breast surgery (mastectomy or BCS) at t he time of diagnosis or baseline 
and the actual surgery patient undergo after completion of the study treatment will be captured on 
the eCRF to assess BCS rate with palbociclib plus anastrozole w ith or without nivolumab in 
participants with untreated primary BC ‚â•2 cm (ER+, HER2-).
Revised Protocol No.: 03
Date: 13-Mar-2020 84
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
9.2 A
dverse Events
The definitions of an AE or SAE can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally a uthorized repre sentative).
The Investigator and any designees are responsible for detecting, documenting, and re porting 
events that meet the definition of an AE or SAE and remain respo nsible for following up AEs that 
are serious, considered related to the study treatment or the s tudy, or that caused the participant to 
discontinue before completing the study.
Contacts for SAE reporting specified in Appendix 3.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
Sections 5.6.1 and 5.6.2 in the IB represent the Reference Safet y Information to determine 
expectedness of SAEs for expedited reporting.
All SAEs must be collected from the time of signing the consent , including those thought to be 
associated with protocol-specif ied procedures and for a minimum of 100 days of discontinuation 
of nivolumab dosing. For particip ants randomized in Arm C, SAEs s hould be collected for 30 days 
from the date of last dose. For participants randomized/assigne d to treatment and never treated 
with study drug, SAEs s hould be collect ed for 30 days from the d ate of randomization/tr eatment 
assignment.
Revised Protocol No.: 03
Date: 13-Mar-2020 85
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
The Investigator must report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure (eg, a  follow-up skin biopsy).
‚Ä¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF m odule.
‚Ä¢All SAEs will be recorded and reported to the Sponsor or design ee within 24 hours, as indicated 
in Appendix 3 .
‚Ä¢The Investigator will submit any updated SAE data to the Sponso r or designee within 24 hours
of updated information being available.
Investigators are not obligated  to actively seek AEs or SAEs in  former study participants. 
However, if the Investigator learns of any SAE, including a dea th, at any time after a participant 
has been discharged from the study, and he/she considers the eve nt reasonably related to the study 
treatment or study participation, the Investigator must promptl y notify the Sponsor.
The method of evaluating, and assessing caus ality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
AEs can be spontaneously re ported or elicited during open-ended questioning, examination, or 
evaluation of a participant. Care should be taken not to introduce bias when collecting AEs and/or 
SAEs. Inquiry about specific AEs should be guided by clinical judgement in the context of known 
AEs, when appropri ate for the program or protocol.
All non-serious AEs (not only those deemed to be treatment-rela ted) should be collected 
continuously during the On-tr eatment Pre-s urgery (neoadjuvant) Period and for a minimum of 
100 days following discontinuation of nivolumab. For participants  randomized in Arm C, non-
serious AEs should be collected for 30 days from the date of la st dose.
Every AE must be assessed by the Investigator with regard to whether it is considered 
immune-mediated. For events which  are potentially immune-mediat ed, additional information will 
be collected on the participant‚Äôs eCRF.
9.2.3 Follow-up of AEs and SAEs
‚Ä¢Non-serious AEs should be followed to resolution or stabilizati on, or reported as SAEs if they 
become serious (refer to Appendix 3).
‚Ä¢Follow-up is also required for non-serious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treat ment as appropriate.
‚Ä¢ All identified non-serious AEs must be recorded and described on the non-serious AE page of 
the eCRF (paper or electronic). Completion of supplemental eCRF s may be requested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study.
After the initial AE/SAE re port, the Investigator is required to proactively follow each p articipant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of  special interest (as defined in 
Revised Protocol No.: 03
Date: 13-Mar-2020 86
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Section 9.2 [Adverse Events]) will be followed until resolution, until the condition stabilizes, until 
the event is otherwise explaine d, or until the participant is l ost to follow-up (as defined in 
Section 8.3 [Lost to Follow-up]).
Further informatio n on follow- up procedures is given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
‚Ä¢Prompt notification by the Investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
‚Ä¢An Investigator who receives an Investigator Safety Report desc ribing SAEs or other specific 
safety information (eg, su mmary  or listing of SAEs) from the S ponsor w ill file it along with 
the IB and will notify the IRB/IEC, if appropriate according to local requirements.
The Sponsor or designee will be reporting AEs to regulatory autho rities and IECs according to 
local applicable laws including European Directive 2001/20/EC a nd FDA Code of Federal 
Regulations 21 CFR Parts 312 a nd 320. A SUSAR  (Suspected, Unexp ected Serious Adverse 
Reaction) is a subset of SAEs and will be reported to the appro priate regulatory authorities and 
Investigators following local and global guidelines and require ments.
9.2.5 Pregnancy
Protocol-required procedures fo r study disconti nuation and foll ow-up must be performed on the 
participant.
Any pregnancy that occurs in a female partner of a male study p articipant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collec t any pregnancy surveillance 
information from the female partne r, the fe male pa rtner must si gn an informed consent form for 
disclosure of this information. Information on this pregnancy w ill be collected on the Pregnancy 
Surveillance Form.In cases where a study drug can be present in seminal fluid, at  exposures sufficient to potentially 
cause fetal toxicity, and if any sexual activity (eg, vaginal, a nal, oral) has occurred between a male 
participant and a pregnant WOCBP partner(s), the information sh ould be reported to the Sponsor 
or designee, even if the male participant has undergone a successful vasectomy. In order for 
Sponsor or designee to  collect any pregnancy surveillance infor mation from the f emale part ner, 
the female partner(s) must sign an informed consent form for di sclosure of this information. 
Information on the pregnancy will  be collected on the Pregnancy  Surveillance Form.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be ca ptured on the non-serious AE eCRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
‚Ä¢Any laboratory test result that is clinically significant or mee ts the definition of an SAE.
Revised Protocol No.: 03
Date: 13-Mar-2020 87
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Any laboratory test result abnormality that required the partic ipant to have study treatment
discontinued or interrupted.
‚Ä¢Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting Investigator (eg, anemia vs low hemoglobin value).
9.2.7 Potential Drug-Induced Liver Injury
Wherever possible, t imely confirmation of initial liver-related  laboratory abnormalities s hould 
occur prior to the reporting of a p-DILI event. All occurrences  of p-DILIs, meeting the defined 
criteria, must be reported as SAEs (see Section 9.2 [Adverse Events] and Appendix 3 for reporting 
details).
p-DILI is defined as:
1) Aminotransaminase (AT; ALT or AST) elevation > 3 √óULN,
AND2) Total bilirubin > 2 √óULN, without initial findings  of cholestasis (elevated serum ALP),
AND
3) No other immediately apparent possible causes of AT elevation  and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, ECG, x-ray 
filming, any other potential safety assessment required or not required by protocol should also be 
recorded as a non-serious or serious AE, as appropriate, and re ported accordingly.
9.2.9 Management Algorithms for Nivolumab
IO agents are associated with IMAEs that can differ in severity  and duration from AEs caused by 
other therapeutic classes. Nivolumab is considered an IO agent in this protocol. Early recognition 
and management of IMAEs associate d with IO agents may mitigate severe toxicity. Management 
algorithms have bee n developed from extensive exper ience with nivolu mab to assist Investigators 
in assessing and managing the following groups of IMAEs:
‚Ä¢GI
‚Ä¢Renal
‚Ä¢Pulmonary
‚Ä¢Hepatic
‚Ä¢Endocrinopathies
Revised Protocol No.: 03
Date: 13-Mar-2020 88
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
‚Ä¢Skin
‚Ä¢Neurological
‚Ä¢Myocarditis
The algorithms reco mmended for the management of IMAEs in this protocol are in Appendix 6 .
Please note that for this protocol, nivolumab delay means nivol umab omission.
‚Ä¢Checkpoint inhibitor molecules have been uncommonly associated with ocular drug-r elated 
AEs. Inflammation of components within the eye (eg, episcleriti s, uveitis) are uncommon 
events of nivolumab monotherapy (< 1% of cases). These events a re usually of low or 
intermediate grade, reversible, detected early in the course of  therapy, and manageable with 
topical or systemic steroids.
‚àíRoutine eye examinations should be performed in participants re ceiving immune 
checkpoint inhibitors ( Section 2 [Schedule of Activities]). Upon clinical suspicion of an 
ocular event consider ophthalmic consult, dose omission, or dos e discontinuation.
‚àíPermanently discontinue for clinically significant or severe im mune-mediated adverse 
reactions. Initiate systemic c orticosteroids for severe immune- mediated adverse reactions.
‚àíPermanently discontinue for immune-mediated ocular disease that  is unresponsive to local 
immunosuppressive therapy.
‚àíAdminister corticosteroid eye drops to participants who develop  uveitis, iritis, or 
episcleritis.
9.3 Overdose
An overdose is defined as the accidental or intentional adminis tration of any dose of a product that 
is considered both excessive and medically important. Overdoses  that meet the regulatory 
definition of SAE will be reported as an SAE (refer to Appendix 3).
All instances of accidental overdose and/or dosing errors shoul d be reported on the Dosage 
Administration Record eCRF.
For this study, any dose of nivolumab, abemaciclib, palbociclib , or anastrozole that is greater than 
the scheduled dose within a 24-hour time period will be consider ed an overdose.
In the event of an overdose the Investigator should:1) Contact the Medical Monitor immediately.
2) Closely monitor the participant for AEs/SAEs and laboratory a bnormalities until study 
treatment ca n no longer be detected  systemically (at least 5 days for abemac iclib or palbociclib, 
and at least 10 days for anastrozole).
3) Document the quantity of the excess dose as well as the durat ion of the overdosing in the eCRF.
Decisions regarding dose interruptions or modifications will be  made by the Investigator in 
consultation with the Medical Monitor based on the clinical eva luation of the participant.
Revised Protocol No.: 03
Date: 13-Mar-2020 89
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
9.4 Safety
Planned time points for all safety assessments are listed in Section 2 (Schedule of Activities).
9.4.1 Physical Examinations
Refer to Schedule of Activities (Section 2).
9.4.2 Vital Signs
Refer to Schedule of Activities (Section 2).
9.4.3 Electrocardiograms/ECHO (preferred) or MUGA
Refer to Schedule of Activities (Section 2).
9.4.4 Clinical Safety Laboratory Assessments
Investigators must document their review of each laboratory saf ety report.
Results of clinical laboratory t ests (performed by local labora tory) must be available within 
3 calendar days prior to dosing. Complete bl ood c ounts must be performed within 7 days prior to 
the first dose.
A list of the clinical laboratory analyses to be tested is prov ided below in Table 9.4.4-1.
Table 9.4.4-1: Clinical Safety Laboratory Assessments
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)Total bilirubin
Alkaline phosphatase (ALP)
Lactate dehydrogenase (LDH)
Creatinine or creatinine clearance (as calculated using
the method standard for the institutions)
Blood urea nitrogen (BUN) or serum urea
glucose
Lipase and amylase (if pancreatitis is suspected)Albumin - screening only
Sodium
Potassium
Chloride
Calcium
Phosphorus
TSH, free T3 and free T4 - screening
TSH, with reflexive fT3 and fT4 if TSH is abnormal -
on-treatment and follow-up
Serology
Hepatitis B/C, (HBVsAG, HCV antibody or HCV RNA) - screening onl y
Other Analyses
FSH screening - only required to confirm menopause in women ‚â§ age  55
Revised Protocol No.: 03
Date: 13-Mar-2020 90
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 9.4.4-1: Clinical Safety Laboratory Assessments
Estradiol level - only required to confirm menopause in women ‚â§ age 55
INR
Abbreviations: FSH = follicle stimulating hormone; HBV sAG = hepat itis B surface antigen; HCV  = hep atitis C virus; 
INR = international normalized ratio; RNA = ribonucleic acid; T SH = thyroid-stimulating hormone.
Revised Protocol No.: 03
Date: 13-Mar-2020 91
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 92
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 93
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 94
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 95
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 96
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 97
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 98
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 99
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Econom ics parameters w ill not be 
evaluated in this study.
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
A total of approximately 115~136 pa rticipants will be tr eated in the st udy. A pproximately 3~24
participants will be t reated in the Safety Run-in Phase in each cohort (Cohort 1: nivolumab + 
abemaciclib + anastrozole for 5 cycles; n = 3 ‚àº6 per dose level of abemaciclib; Cohort 2: nivolumab 
+ palbociclib + anastrozole for 5 cycles; n = 3 ‚àº6 per dose level of palbociclib). At the time of 
Revised Protocol 03, 2 participants had been treated in Cohort 1  (nivolumab + abemaciclib + 
anastrozole), which was subsequently closed for enrollment. Appr oximately 110 participants are 
planned to be randomized  in this study at a 4:4:3 ratio into Arm  A (nivolumab + palbociclib + 
anastrozole for 5 cycles; n = 40), Arm B (palbociclib + anastroz ole for 1 cycle, followed by 
nivolumab + palbociclib + anastrozole for 4 cycles; n = 40), an d Arm C (palbociclib + anatrozole 
for 5 cycles;  n = 30), respectively. No stratification variable s will be included for formal analysi  
 
.
Revised Protocol No.: 03
Date: 13-Mar-2020 100
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 101
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
10.2 Populations for Analyses
Populations for purposes  of analysis are defined in Table 10.2-1 b elow.
Table 10.2-1: Populations for Analyses
Population Description
All Enrolled All participants who signed an ICF and were registered into the IRT.
All Randomized All participants who were randomized to any treatment arm in the study. Participants 
are grouped within the All Randomized population by the treatment to which they 
were randomized.
This is the primary analysis set for demography, protocol deviations, baseline 
characteristics, and primary efficacy analyses.
All Treated All randomized participants who receive at least 1 dose of study drug. Participants are grouped within the All Treated population according to the treatment they actually received. This is the analysis set for all safety analyses and study drug administration.
All Treated from Safety Run-in PhaseAll enrolled participants who received at least 1 dose of study  drug in the Safety Run-
in Phase. Participants are grouped within the All Treated from Safety Run-in Phase 
population according to the treatment and dose level they actua lly received. This is 
part of the analysis set for all safety analysis and study drug administration. 
All RCB Evaluable All Treated participants who have an RCB of 0, I, II, or III fr om both the Safety 
Run-in Phase and Randomized Phase.
Abbreviations: ICF = informed consent form; IRT = Interactive R esponse Technology;  
RCB = residual cancer burden.
10.3 Statistical Analyses
The statistical analysis plan (SAP) w ill be developed and fin alized before database lock and will 
describe the selection of participants to be included in the an alyses, and procedures for accounting 
for missing, unused, and spurious data. Below is a summary of p lanned statistical analyses of the 
primary and secondary endpoints.
A description of the participant population will be included in  a statistical output report, including 
subgroups of age, gender, and race.
Revised Protocol No.: 03
Date: 13-Mar-2020 102
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
10.3.1 Efficacy Analyses
Statistical analyses for efficacy are shown in Table 10.3.1-1.
Table 10.3.1-1: Efficacy - Statistical Analyses
Endpoint Statistical Analysis Methods
Primary
‚Ä¢RCB (0-I) rate per central assessment Estimates of response rate and corresponding exact 90% 
and 95% CIs will be generated for each arm in the Randomized Phase. CIs will be constructed using the Clopper-Pearson method.
Secondary
‚Ä¢pCR per local assessment
‚Ä¢ORR by Inves tigator assessment
‚Ä¢BCSEstimates of response rate and corresponding exact 95% CIs will be generated for each arm. CIs will be constructed using the Clopper-Pearson method.
Abbreviations: BCS = breast-conserving surgery; CI = confidence i nterval;  ORR = objective 
response rate; pCR = pathological complete response;  RCB = residual cancer 
burden.
After review of the efficacy data in each arm and upon agreemen t of the study team, efficacy 
endpoints might also be estimated based on pooled arms (eg, RCB [0-I] rate in Arm A and Arm B), 
when appropriate. Details of the analyses will be defined in th e SAP. 
10.3.2 Safety Analyses
Statistical analyses for safety are shown in Table 10.3.2-1 .
Revised Protocol No.: 03
Date: 13-Mar-2020 103
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 10.3.2-1: Safety - Statistical Analyses
Endpoint Statistical Analysis Methods
Primary
‚Ä¢Number of participants with occurrence of 
DLT (Time frame: from start of study treatment up to 4 weeks).‚Ä¢DLT rate by treatment and dose level in the Safety Run-in 
Phase.
Secondary
‚Ä¢Incidence of AEs, SAEs, immune-related 
AEs, AEs leading to discontinuation, and death.
‚Ä¢Laboratory abnormalities.AEs will be graded according to NCI CTCAE v5.0.Frequency 
distribution of treated participants with AE using the worst 
CTC grade. Participants will only be counted (1) once at the PT level, (2) once at the sy stem organ class level, and (3) 
once in the ‚Äútotal participant‚Äù row at their worst CTC grade, regardless of system organ class or PT.
Laboratory values will be graded according to NCI CTCAE 
v5.0.
Laboratory shift table using the worst CTC grade on treatment 
per participant.
Abbreviations: AE = adverse ev ent; DLT = dos e-limiting toxicity ; CTC = Common Terminology Criteria; 
CTCAE = Common Terminology Criteria for Adverse Events; NCI = Nati onal Cancer Institute; PT = preferred term; 
SAE = serious adverse event.
Revised Protocol No.: 03
Date: 13-Mar-2020 104
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 105
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
10.3.4 Interim Analysis
Not applicable.
Revised Protocol No.: 03
Date: 13-Mar-2020 106
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
11 REFERENCES
1Nivolumab (Opdivo) US Prescribing Information. Bristol-Myers Squibb Company; Revised 
January 2018.
2Anastrozole (Arimidex) US Pr escribing Information. ANI Pharmace uticals, Inc.; Revised 
December 2018.
3Nivolumab (BMS-936558) Investigator Brochure Version 17. Bristo l-Myers Squibb 
Company, 2018. 
4Palbociclib (Ibrance) US Prescribing Information. Pfizer; Revis ed April 2019.
5Nanda R, Liu MC, Yau C, et al. Pembrolizumab Plus Standard Neoa djuvant Therapy for High-
risk Breast Cancer (BC): Results from I-SPY 2. Journal of Clini cal Oncology: Official Journal 
of the American Society of Clinical Oncology 2017; 35(15_suppl) : 506-.
6Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resi stance and Alterations in 
the Tumor Immune Microenvironment. Clinical Cancer Research: An  Official J ournal of the 
American Association for Cancer Research 2019;25(3): 921-927.
7Zhang J, Bu X, Wang H, et al. Cy clin D-CDK4 Kinase Destabilizes  PD-L1 Via Cullin 3-SPOP 
to Control Cancer Immune Surveillance. Nature 2018; 553(7686): 91-5.
8Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 Inhibition Triggers  Anti-tumour Immunity. 
Nature 2017; 548(7668): 471-5.
9Vilgelm AE, Johnson CA, Prasad N, et al. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. Journal of the National Cancer Institute 
2016; 108(6): djv406.
10Deng J, Wang ES, Jenkins RW, et al. CDK4/6 Inhibition Augments Antitumor Immunity by 
Enhancing T-C ell A ctivation. Cancer Discovery 2017: CD-17-0915.
11Tolaney SM, Kabos P, Dickler MN, et al. Updated Efficacy, Safet y, & PD-L1 Status of Patients 
with HR+, HER2- Metastatic Breas t Cancer Administered Abemacicli b Plus Pembrolizumab. 
Journal of Clinical Oncology: Off icial J ournal of the American Society of Clinical Oncology 
2018; 36(15_suppl): 1059-.
12Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 Inhibitor  Abemaciclib Induces a 
T Cell Inf lamed Tumor Microenvironment and Enhances the Efficacy of PD-L1  Checkpoint 
Blockade. Cell Reports 2018; 22(11): 2978-94.
13Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA: A C ancer Journal for Clinicians 
2019; 69(1): 7-34.
14Sotiriou C, Pusztai L. Gene-Expression Signatures in Breast Can cer. The New England Journal 
of Medicine 2009; 360(8): 790-800.
Revised Protocol No.: 03
Date: 13-Mar-2020 107
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
15Perou CM, Sorlie T, Eisen MB, et al. Molecular Portraits of Huma n Breast Tumours. Nature 
2000; 406(6797): 747-52.
16Huang H, Groth J, Sossey-Alaoui K, et al. Aberrant Expression o f Novel and Previously 
Described Cell Membrane Markers in Human Breast Cancer Cell Lin es and Tumors. Clinical 
Cancer Research: An Official Journal of the American Associatio n for Cancer Research 2005; 
11(12): 4357-64.
17Yersal O, Barutca S. Biological S ubtypes of Breast Cancer: Prog nostic and Therapeutic 
Implications. World Journal of Clinical Oncology 2014; 5(3): 412-24.
18Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 Random ized Trial of Primary 
Endocrine Therapy Versus Chemotherapy in Postmenopausal Patient s with Estrogen 
Receptor-positive Breast Cancer. Cancer 2007; 110(2): 244-54.
19Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) Versus Ho rmone Therapy (HT) as 
Neoadjuvant Treatment in Luminal Breast Cancer: A Multicenter, Randomized Phase II Study 
(GEICAM/2006-03). Journal of Clinical Oncology 2010; 28(15_supp l): 500-.
20Palmieri C, C leator S, Kilburn LS, et al. NEOCENT: A Randomised Feasibility and 
Translational Study Comparing Neoadjuvant Endocrine Therapy Wit h Chemotherapy in ER-
rich Postmenopausal Primary Breast Cancer. Breast Cancer Resear ch and Treatment 2014; 
148(3): 581-90.
21Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant Endocrine T herapy for Estrogen 
Receptor-positive Breast Cancer : A Systematic Review and Meta-analysis. JAMA Oncology 
2016; 2(11): 1477-86.
22Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and Hormo notherapy (HT) as 
Neoadjuvant Treatment in Luminal Breast Cancer Patients: Result s From the 
GEICAM/2006-03, A Multicenter, Randomized, Phase-II Study. Annal s of Oncology: Official 
Journal of the European Society for Medical Oncology 2012; 23(1 2): 3069-74.
23Ellis MJ, Ma C. Letrozole in the Neoadjuvant S etting: The P 024 Trial. Breast Cancer Research 
and Treatment 2007; 105 Suppl 1: 33-43.
24Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative Treat ment of Postmenopausal 
Breast Cancer Patients with Letrozole: A Randomized Double-blin d Multicenter Study. 
Annals of Oncology: Official J ournal of the European Society fo r Medical Oncology 2001; 
12(11): 1527-32.
25Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant Treatment of P ostmenopausal Breast 
Cancer with Anastrozole, Tamoxifen, or Both in Combination: The  Immediate Preoperative 
Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) Mul ticenter Double-blind 
Randomized Trial. Journal of Clin ical Oncology: Official J ournal of the American Society of 
Clinical Oncology 2005; 23(22): 5108-16.
Revised Protocol No.: 03
Date: 13-Mar-2020 108
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
26Cataliotti L, Buzdar AU, Noguchi S, et al . Comparison of Anastrozole Versus Tamoxifen as 
Preoperative Therapy in Postmenopausal Women with Hormone Recep tor-positive Breast 
cancer: The Pre-Operative "Arimidex" Compared to Tamoxifen (PRO ACT) Trial. Cancer 
2006; 106(10): 2095 -103.
27Leal F, Liutti VT, Antunes dos Santos VC, et al. Neoadjuvant En docrine Therapy for 
Resectable Breast Cancer: A Systematic Review and Meta-analysis . Breast (Edinburgh, 
Scotland) 2015; 24(4): 406-12.
28Ellis MJ, Suman VJ, H oog J, et al. Rando mized Phase II Neoadjuvant Comparison Between 
Letrozole, Anastrozole, and Exemestane for Postmenopausal Women  with Estrogen Receptor-
rich Stage 2 to 3 Breast Cancer: Clin ical and Bio marker Outcomes and Predictive Value of the 
Baseline PAM50-based Intrinsic Subtype-ACOSOG Z1031. Journal of  Clinical Oncol ogy: 
Official Journal  of the American Society of Clin ical Oncology 2011; 29(17): 2342-9.
29Seo JH, Kim YH, Kim JS. Meta-analysis of Pre-operative Aromatas e Inhibitor Versus 
Tamoxifen in Postmenopausal Woman with Hormone Receptor-positiv e Breast Cancer. 
Cancer Chemotherapy and Pharmacology 2009; 63(2): 261-6.
30Pardoll D. Does the Immune System See Tumors as Foreign or Self ? Annual Review of
Immunology. 2003;21:807-39.
31Zitvogel L, Tesniere A, Kroemer G. Cancer Despite Immunosurveil lance: Immunoselection 
and Immunosubversion. Nature Rev iews Immunology. 2006; 6:715-27.
32Dunn GP, Bruce AT, Ikeda H, et al. Cancer Immunoediting: From I mmunosurveillance to 
Tumor Escape. Nature Immunology. 2002; 3:991-8.
33Greenwald RJ, Freeman GH, Sharpe AH. The B7 Family Revisited. A nnual Review of
Immunology. 2004; 23:515-48.
34Freeman GJ, Long AJ , Iwai Y, et al. Engagement of the PD-1 Immu noinhibitory Receptor by 
a Novel B7 F amily Member Lead s to Negative Regulatio n of Lym phocyte Activa tion. Journal 
of Experimental Medicine. 2000; 192(7): 1027-34.
35Sharpe AH, Wherry EJ, Ahmed R, et al. The Function of Programme d Cell Death 1 and its 
Ligands in Regulating Autoimmunity and Infection. Nature Immuno logy. 2007; 8:237-45.
36Wolchok JD, Hoos A, O‚ÄôDay S, et al. Guidelines for the Evaluati on of Immune Therapy 
Activity in Solid Tumors: Immune-related Response Criteria. Cli nical Cancer Research. 2009;
15:7412-20.
37Musgrove EA, Caldon CE, Barraclough J, et al. Cyclin D as a the rapeutic target in cancer. Nat 
Rev Cancer. 2011 Jul 7;11(8):558-72.
38Holm K, Staaf J, Jonsson G, et al. Characterisation of amplific ation patterns and target genes 
at chromosome 11q13 in CCND1-a mplified sporadi c and familial br east tumours. Breast 
Cancer Res Treat. 2012 Jun;133(2):583-94.
Revised Protocol No.: 03
Date: 13-Mar-2020 109
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
39Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. 
Nature. 2012 Oct 4, 490(7418):61-70.
40Beroukhim R, Mermel CH, Porter D, et al. The landscape of somat ic copy-number alteration 
across human cancers. Nature. 2010 Feb 18;463(7283):899-905.
41Thangavel C, Dean, JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle 
control in endocrine therapy-res istant breast cancer. Endocr Rel at Cancer. 2011 Apr 
28;18(3):333-45.
42Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle. 2007 Mar 15;6(6):667-71.
43Finn RS, Dering J, Conklin D, et al. PD 0332991, A S elective Cycl in D Kinase 4/6 Inhibitor, 
Preferentially Inhibits Proliferation of Luminal Estrogen Recep tor-positive Human Breast 
Cancer Cell Lines in Vitro. Breast Cancer Research: BCR 2009; 1 1(5): R77-R.
44Kok M, Voorwerk L, Horlings H, et al. Adaptive phase II randomi zed trial of nivolumab after 
induction treatment in triple negative breast cancer (TONIC tri al): Final response data stage I 
and first translational data. J Clin Oncol. 2019;36(15_suppl):1 012-1012.
45Zardavas D, Pond√© N, Tryfonidis K. CDK4/6 Blockade in Breast Ca ncer: Current Experience 
and Future Perspectives. Expert Opinion on Investigational Drug s 2017; 26(12): 1357-72.
46Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine 2018; 3 79(20): 1926-36.
47Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2-
Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-522 4.
48Johnston S, Puhalla S, Wheatley D, et al. Randomized Phase II S tudy Evaluating Palbociclib 
in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Rec eptor-positive Early Breast 
Cancer: PALLET Trial. Journal of Clinical Oncology: Official Jo urnal of the Amer ican Society 
of Clinical Oncology 2019; 37(3): 178-89.
49Hurvitz SA, Schilder JM, Frenzel M, et al. Abstract CT092: A Ph ase II Study of Neoadjuvant 
Abemaciclib (LY2835219) in Postmenopausal Women with Hormone Re ceptor Positive 
(HR+), Human Epidermal Growth Factor Receptor 2 Neg ative (HER2-) Breast Cancer 
(neoMONARCH). Cancer Research 2016; 76(14 Supplement): CT092-CT .
50Abemaciclib (Verenzio) US Prescribing Information. Eli Lilly an d Company; Revised August 
2018.
51Yuan Y, Yost SE, Lee JS, et al. Abstract P3-11-04: A phase II s tudy of pembro lizumab, 
letrozole and palbo ciclib in patients with metastatic estrogen receptor positive breast cancer. 
Cancer Research 2020; 80(4 Supplement): P3-11-04-P3-11-04.
Revised Protocol No.: 03
Date: 13-Mar-2020 110
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
52Solomon B, Callejo A, Bar J, et al. Survival prolongation by ra tionale innovative genomics 
(SPRING): An international WIN consortium phase I study explori ng safety and efficacy of 
avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with 
integrated genomic and transcriptomic correlates. Annals of Onc ology 2019;30:v648.
53Baselga J. Targeting the Phosphoinositide-3 (PI3) Kinase Pathwa y in Breast Cancer. 
Oncologist 2011; 16 Suppl 1: 12-9.
54Azambuja ED, Saura C, Oliveira M, et al. LORELEI: A Phase II Ra ndomized, Double-blind 
Study of Neoadjuvant Letrozole Plus Taselisib (GDC-0032) Versus  Letrozole Plus Placebo in 
Postmenopausal Women with ER-positive/HER2-negative, Early-stag e Breast Cancer. Journal 
of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015; 
33(15_suppl): TPS627-TPS.
55Saura C, de Azambuja E, Hlauschek D, et al. LBA10_PR - Primary Re sults of LORELEI: A 
Phase II Randomized, Double-blind Study of Neoadjuvant Letrozole (LET) Plus Taselisib  
Versus LET Plus Placebo (PLA) in Postmenopausal Patients (pts) with ER+/HER2-negative 
Early Breast Cancer (EBC). Annals of Oncology 2017; 28(suppl_5) : mdx440.001-
mdx440.001.
56Ma C, Gao F, Northfelt D, et al. Abstract S6-05: A Phase II Tri al of Neoadjuvant Palbociclib, 
a Cyclin-dependent Kinase (CDK) 4/6 Inhibitor, in Combination w ith Anastrozole for Clinical 
Stage 2 or 3 Estrogen Receptor Positive HER2 Negative (ER+HER2- ) Breast Cancer (BC). 
Cancer Research 2016; 76(4 Supplement): S6-05.
57Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-
Positive, Advanced Breast Cancer. The New England Journal of Me dicine 2016; 375(18): 
1738-48.
58Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. The 
New England Journal of Medicine 2016; 375(20): 1925-36.
 
 
 
 
 
 
 
 
Revised Protocol No.: 03
Date: 13-Mar-2020 111
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
63Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 Inhibitor  Abemaciclib Induces a 
T Cell Inf lamed Tumor Microenvironment and Enhances the Efficacy of PD-L1  Checkpoint 
Blockade. Cell Reports 2018; 22(11): 2978-94.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72Hammond ME, Hayes DF, Wolff AC, et al. American Society of Clin ical Oncology/College 
of American Pathologists Guideline Recommendations for Immunohi stochemical Testing of 
Estrogen and Progesterone Recept ors in Breast Cancer. Journal o f Oncology Practice 2010;
6(4):195-7.
73Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growt h Factor Receptor 2 
Testing in Breast Cancer: American Society of Clinical Oncology /College of American 
Pathologists Clinical Practice Gu ideline Focuse d Update. Journal of Clinical Oncology. 2018;
36(20):2105 -2122.
74Bennett JA, Riegel B, Bittner V, et al. V alidity and Reliability of the NYHA Classes for 
Measuring Research Outcomes in Patients with Cardiac Disease. H eart & Lung: The Journal 
of Critical Care 2002; 31(4):262‚Äì270.
Revised Protocol No.: 03
Date: 13-Mar-2020 112
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
 
Revised Protocol No.: 03
Date: 13-Mar-2020 113
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
12 APPENDICES
Revised Protocol No.: 03
Date: 13-Mar-2020 114
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
¬∞C degrees Celsius
ŒºL microliter
Abema abemaciclib
ACOSOG American College of Surgeons Oncology Group
ADL activities of daily living
AE adverse event
AI aromatase inhibitor
AIDS acquired immunodeficiency syndrome
AJCC American Joint Committee on Cancer
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANZ anastrazole
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
AT aminotransaminases
BC breast cancer
Bcl-xL B-cell lymphoma-extra large
BCS breast-conserving surgery
BID bis in die, twice daily
BMS Bristol-Myers Squibb
BOR best overall response
BP blood pressure
BTLA B- and T-lymphocyte attenuator
BUN blood urea nitrogen
C cycle
CAP College of American Pathologists
Revised Protocol No.: 03
Date: 13-Mar-2020 115
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
CBC complete blood count
CCND1 cyclin D1
CD28 cluster of differentiation 28
CDK cyclin-dependent kinase
CFR Code of Federal Regulations 
CI confidence interval
CISH chromogenic in situ hybridization
Cm Centimeter
CMV Cytomegalovirus
CONSORT Consolidated Standards of Reporting Trials
CR complete response
CRC colorectal cancer
CRF case report form
CRO contract research organization
CTAg Clinical Trial Agreement
CTCAE Common Terminology Criter ia for Adverse Events
CTLA-4 cytotoxic T-lymphocyte-associated protein-4
CYP cytochrome p-450
DD ay
dL deciliter
DLT dose-limit ing toxicity
DNA deoxyribonucleic acid
DNMT DNA methyltransferase 1
EC50 half-maximal effective concentration
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
eg exempli gratia (for example)
Revised Protocol No.: 03
Date: 13-Mar-2020 116
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
EMA European Medicines Agency
EOT end of treatment
ER estrogen receptor
ER+ estrogen receptor-positive
ET endocrine therapy
etc et cetera
EU Europe
 
FDA Food and Drug Administration
FFPE formalin-fixed, paraffin-embedded
FISH fluorescence in situ hybridization
FSH follicle-stimulating hormone
FU1 follow-up visit 1
FU2 follow-up visit 2
gg ram
GCP Good Clinical Practice
GI Gastrointestinal
H&E hematoxylin and eosin
HBsAg hepatitis B surface antigen
HCC hepatocellular carcinoma
HCV hepatitis C virus
HER2 human epidermal growth factor receptor 2
HER2+ human epidermal growth factor receptor 2-positive
HER2- human epidermal growth factor receptor 2-negative
HIV Human Immunodeficiency Virus
HR heart rate
HR+ hormone receptor-positive
Revised Protocol No.: 03
Date: 13-Mar-2020 117
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
HRT hormone replacement therapy
IB Investigator Brochure
INR international normalized ratio
IC50 half-maximal inhibitory concentration
ICF informed consent form
ICH International Conference on Harmonisation 
ICOS inducible T cell co-stimulator
ie id est (that is)
IEC Independent Ethics Committee
IFN interferon
IFN-Œ≥ interferon-Œ≥
IHC Immunohistochemistry
IL Interleukin
IMAE immune-mediate adverse event
IMP investigational medicinal product
IND Investigational New Drug
IO immuno-oncologic
IP investigational product
IRB Institutional Review Board
IRT Interactive Response Technology
IU International Unit
IV Intravenous
kg kilogram
LDH lactate dehydrogenase
LH-RHa luteinizing hormone-releasing hormone agonist
LLN lower limi t of normal
mAb monoclonal antibody
MD medical doctor
MDSC myeloid-derived suppressor cells
Revised Protocol No.: 03
Date: 13-Mar-2020 118
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
mg Milligram
min minute
mL Milliliter
MLR mixed lymphocyte reaction
m2meters squared
mm3cubic millimeters
MMR measles, mumps, rubella
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
msec milisecond
mTOR mammalian target of rapamycin
MUGA multiple gated acquisition
N number of subjects or observations
NCI National Cancer Institute
NET neoadjuvant endocrine treatment
Nivo Nivolumab
nM Nanomolar
NSAI nonsteroid al aromatase inhibitors
NSCLC non-small cell l ung cancer
ORR objective response rate
OS overall survival
oz ounce
Palbo Palbociclib
pCR pathological complete response
PD-1 programmed cell death-1
p-DILI potential drug-induced liver injury
PD-L1 programmed death-ligand 1
Revised Protocol No.: 03
Date: 13-Mar-2020 119
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
PD-L2 programmed death-ligand 2
PE physical examination
PFS progression-free survival
PgP P-glycoprotein
PgR progesterone receptor
PI3K phosphoinositide-3 kinase
PK Pharmacokinetics
PO per os (by mouth route of administration)
PPK populatio n pharmacokinetics
PR partial response
 
PS performance status
PT preferred term
Q4W every 4 weeks
QD, qd quaque die, once daily
QTc corrected QT interval
QTcF Fridericia's Correction Formula
Rand Randomized
Rb retinoblastoma
RCB residual cancer burden
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
RFS relapse-free survival
RNA ribonucleic acid
SAE serious adverse event
SAP statist ical analysis plan
Revised Protocol No.: 03
Date: 13-Mar-2020 120
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Term Definition
SCCHN squamous cell carcinoma of the head and neck
SISH silver in situ hybridization
SmPC summary of product characteristics
SOC standard of care
SOP Standard Operating Procedures
SPOP speckle-type POZ protein
SSC Study Steering Committee
SUSAR Suspected, Unexpected Serious Adverse Reaction
TCR T cell receptor
TEAE treatment-emerge nt adverse event
TIL tumor-infiltrating lymphocyte
TME tumor microenvironment
TNBC triple-negative breast cancer
Treg regulatory T cell
TSH thyroid-stimulating hormone
ULN upper limit of normal
US United States
USP United States Pharmacopeia
vs versus
WHO World Health Organization
Wk week
WOCBP women of childbearing potential
WNOCBP women notof childbearing potential
Revised Protocol No.: 03
Date: 13-Mar-2020 121
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS
The term ‚ÄòParticipant‚Äô is used i n the protocol to refer to a person who has consented to participate 
in the clinical research study. The term ‚ÄòSubject‚Äô used in the eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
‚Ä¢Consensus ethical principles derived from international guideli nes including the Declaration 
of Helsinki and Council for International Organizations of Medi cal Sciences (CIOMS) 
International Ethical GuidelinesGood Clinical Practice (GCP), 
‚Ä¢as defined by the International Council on Harmonisation (ICH)
‚Ä¢in accordance with the ethical principles underlying European U nion Directive 2001/20/EC
‚Ä¢United States Code of Federal Regulations, Title 21, Part 50 (2 1CFR50) 
‚Ä¢applicable local requirements.
The study will be conducted in compliance with the protocol. Th e protocol and any amendments 
and the participant informed consent will r eceive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regula tory authorities according to 
applicable local regu lations prior to i nitiation of the study.
All potential serious breaches must be reported to the Sponsor or designee immediately. A 
potential serious breach is de fined as a Quality Issue (eg, pro tocol deviation, etc) that is likely to 
affect, to a significant degree, one or more of the following: (1) the phys ical, safety, or mental 
integrity of one or more subjects /participants; or (2) the scie ntific value of the trial (eg, reliability 
and robustness of generated data). Items (1) or (2) can be asso ciated with either GCP Regulation(s) 
or Trial protocol(s).
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant re cruitment materials 
(eg, advertisements), and any other written information to be pr ovided to subjects/participants. The 
investigator or BMS s hould also provide the IRB/IEC with a copy of the Investigator Brochure or 
product labeling information to be provided to subjects/partici pants and any updates. 
Revised Protocol No.: 03
Date: 13-Mar-2020 122
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and admi nistrative letters) according to 
regulatory requirements or institution procedures.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change t o the protocol without prior 
review and documented approval/favorable opinion of an amendmen t from the IRB/IEC (and if 
applicable, also by local health authority) except where necess ary to eliminate an immediate 
hazard(s) to study subjects/participants. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation  or change will be submitted, as 
soon as possible to:
‚Ä¢IRB/IEC
‚Ä¢Regulatory Authority(ies), if applicable by local regulations (p er national requirements)
Documentation of approval/favorable opinion signed by the chair person or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority  must be sent to BMS.
If an amendment substantially alters the study design or increa ses the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be us ed to obtain consent from 
subjects/participants currently enrolled in the study if they ar e affected by the amendment; and (3) 
the new form must be used to obtain consent from new subjects/p articipants prior to enrollment.
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclosure statements to th e appropriate h ealth aut horities. 
Investigators are responsible fo r providing information on financial interests during the course of 
the study and for 1 year after  completion of the study.
INFORMED CONSENT PROCESSInvestigators must ensure that subjects/participants are clearly and fully informed a bout the 
purpose, potential risks, and other critical issues regarding clinical studies in which they volunteer 
to participate. 
In situations where consent cannot be given by subjects/partici pants, their legally acceptable 
representatives (as per country guidelines) are clearly and ful ly informed about the purpose, 
potential risks, and other critical issues regarding clinical s tudies in which the participant 
volunteers to participate. 
Revised Protocol No.: 03
Date: 13-Mar-2020 123
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Sponsor or designee will provide the investigator with an appro priate (ie, Global or Local) sample 
informed consent form w hich will include all elements required by ICH, GCP and applicable 
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Investigators must:
‚Ä¢Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical stud y participation. The language must 
be non-technical and easily understood. 
‚Ä¢Allow time necessary for participant or participant's legally a cceptable representative to 
inquire about the details of the study.
‚Ä¢Obtain an informed consent signed and personally dated by the participant or the participant's 
legally acceptable representative and by the person who conduct ed the informed consent 
discussion. 
‚Ä¢Obtain the IRB/IEC‚Äôs written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects/partic ipants, pri or to the beginning of 
the study, and after any revisions are completed for new inform ation.
If informed consent is initially given by a participant‚Äôs legal ly acceptable representative or legal 
guardian, and the participant subsequently becomes capable of m aking and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a p erson designated by the investigator, 
should fully inform the participant or the participant's legall y acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the stud y. This commun ication should be 
documented. The confidentiality of records that could identify subjects/par ticipants must be protected, 
respecting the privacy and confidentiality rules applicable to regulatory requirements, the 
subjects'/participants‚Äô signed ICF and, in the US, the subjects‚Äô signed HIPAA Authorization.The consent form must also include a statement that BMS and reg ulatory authorities have direct 
access to participant records. 
Subjects/participants unable to gi ve their written consent (eg, stroke or subjects/participants with 
or severe dementia) may only be enrolled in the study with the consent of a legally acceptable 
representative. The participant must also be informed about the  nature of the study to the extent 
compatible with his or her understanding, and should this partic ipant become capable, he or she 
should personally sign and date the consent form as soon as pos sible. The explicit wish of a 
participant who is unable to give his or her written consent, b ut who is capable of forming an 
opinion and assessing information to refuse participation in, or to be withdrawn from, the clinical 
study at any time should be considered by the investigator.
Revised Protocol No.: 03
Date: 13-Mar-2020 124
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
The rights, safety, and well-being of the study subjects/partic ipants are the most important 
considerations and should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data are hand-written on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vend ors, or the site) must substantiate 
study treatment integrity and traceability from receipt, prepar ation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
Revised Protocol No.: 03
Date: 13-Mar-2020 125
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
If Then
Supplied by BMS (or its vendors): Records or logs must comply wi th applicable 
regulations and guidelines and should include:
‚Ä¢amount received and placed in storage area
‚Ä¢amount currently in storage area
‚Ä¢label identif ication number or batch number
‚Ä¢amount dispensed to and returned by each 
participant, including unique participant 
identifiers
‚Ä¢amount transferred to another area/site for 
dispensing or storage
‚Ä¢nonstudy disposition (eg, lost, wasted) 
‚Ä¢amount destroyed at study site, if applicable
‚Ä¢amount returned to BMS
‚Ä¢retain samples for bioavailability/bioequivalence/biocomparability, if applicable 
‚Ä¢dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
Sourced by site, and not supplied by 
BMS or its vendors (examples include IP 
sourced from the sites stock or 
commercial supply, or a specialty 
pharmacy)The investigator or desi gnee accepts r esponsibility 
for documenting traceability and study treatment 
integrity in accordance with requirements applicable 
under law and the SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory cont rol if the investigational site does 
not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other d ata pertinent to the investig ation on each individual treated 
or entered as a control in the investigation. Data that are der ived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs a nd/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture  tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields specif ic to SAEs and pregnancy, which will 
Revised Protocol No.: 03
Date: 13-Mar-2020 126
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
be reported on the electronic SAE form and Pregnancy Surveillan ce form, respectively. If 
electronic SAE form is not av ailable, a paper SAE form can be u sed. 
The confidentiality of records that could identify subjects/par ticipants must be protected, 
respecting the privacy and confidentiality rules in accordance with the applicable regulatory 
requirement(s).
The investigator will maintain a s ignature sheet to document si gnatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by the 
investigator or qualified physician who is a sub-investigator a nd who is delegated this task on the 
Delegation of Authority Form. Sub-investigators in Japan may not be delegated the CRF approval 
task for electronic CRFs, review and approval/signature is comp leted electroni cally through the 
BMS electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically si gning electronic CRFs must mee t Sponsor or designee training 
requirements and must only access the BMS electronic data captu re tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individualsMONITORING
Sponsor or designee representativ es will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity . On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable Certain CRF pages and/or electroni c files may serve as the source 
documents:
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by regulatory aut horities, 
and promptly forward copies of inspection reports to Sponsor or  designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or d esignee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.
Revised Protocol No.: 03
Date: 13-Mar-2020 127
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inv estigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vend or or sourced by the investigator) 
such as partially used study treatment containers, vials and sy ringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including 
its vendorsAny unused study treatments supplied by BMS can only be destroyed after being inspected and 
reconciled by the responsible Study Monitor 
unless study treatments containers must be immediately destroyed as required for safety, or to meet local regulations (eg, cytotoxics or 
biologics).
If study treatments will b e returned, the return 
will be arranged by th e responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include study treatments sourced from the sites stock 
or commercial suppl y, or a specialty 
pharmacy)It is the investigator‚Äôs or designee‚Äôs responsibility to dispose of all containers according to the institutional guidelines and procedures.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been established according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The following minimal standards must be met:
‚Ä¢On-site disposal practices must not expose humans to risks from  the drug.
‚Ä¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled o r hazardous substances.
‚Ä¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the site‚Äôs SOPs and a copy  provided t o BMS upon request.
‚Ä¢Records are maintain ed that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
‚Ä¢Accountability and disposal records are complete, up-to-date, and available for the Monitor to review throughout the clinical trial period.
Revised Protocol No.: 03
Date: 13-Mar-2020 128
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
It is the investigator‚Äôs or designee‚Äôs responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stud y Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors) . Destruction of non- study 
treatments s ourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.CLINICAL STUDY REPORT
A Signatory Investigator must be selected to sign the clinical study report. 
For each CSR r elated to this protocol, the following criteria will be used to  select the signatory 
investigator:
‚Ä¢External Principal Investigator designated at protocol developm ent
‚Ä¢National Coordinating Investigator 
‚Ä¢Participant recruitment (eg, among the top quartile of enroller s)
SCIENTIFIC PUBLICATIONS
The data collected during this study are confident ial and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study s ite or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to s ubmission or presentation and 
otherwise within the time period set forth in the CTAg.
Scientific Publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effor t between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
principal investigator, sub-investigator or any other member of  the study staff without the prior 
written consent of the Sponsor. 
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship sele ction is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors mu st meet all 4 ICMJE criteria for 
authorship:1) Substantial int ellectual contri bution to the conception or de sign of the work; or the acquisition 
of data (ie, evaluable subjects with qualit y data), analysis , or interpretation of data for the work 
(eg, problem solving, advice, evaluation, insights and conclusi on); AND
2) Drafting the work or revising it critically for important int ellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all asp ects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriat ely investigated and resolved.
Revised Protocol No.: 03
Date: 13-Mar-2020 129
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Those who make the most significant contributions, as defined a bove, will be considered by BMS 
for authorship of the primary publication. Sub-investigators wi ll generally not be considered for 
authorship in the primary publication. Geographic representatio n will also be considered.
Authors will be lis ted by order of significant contributions (highest to lowest), with the exception 
of the last author. Authors i n first and last positi on have provided the most signif icant contributions 
to the work. 
For secondary analyses and rel ated publications, author list an d author order may vary from 
primary to reflect additional contributions.
Revised Protocol No.: 03
Date: 13-Mar-2020 130
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation parti cipant administered study treatment 
and that does not necessarily have a causal relationship with t his treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
‚Ä¢Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc a n s ,  v i t a l  s i g n s  
measurements), including those that worsen from bas eline, considered clinically significant 
in the medical and scie ntific judgment of the investigator. Note  that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
‚Ä¢Exacerbation of a chronic or intermittent pre-existing conditio n including either an increase 
in frequency and/or intensity of the condition.
‚Ä¢New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
‚Ä¢Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
‚Ä¢Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by the investigator), 
shoul d not be reported as an AE/SAE unless it is an intentional  overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported  regardless of sequelae and 
should specify "intentional overdose" as the verbatim term
Events NOT Meeting the AE Definition
‚Ä¢Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
‚Ä¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospital).
Revised Protocol No.: 03
Date: 13-Mar-2020 131
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of deat h at the time 
of the event; it does not refer to an event which hypotheticall y might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of ex isting hospitalization (see NOTE 
below)
NOTE: The following hospitalizations are not  considered SAEs in BMS clinical studies: 
‚Ä¢a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
‚Ä¢elective surgery, planned prior to signing consent
‚Ä¢admissions as per protocol f or a planned med ical/surgical procedure
‚Ä¢routine health assessment requi ring admission for baseline/tren ding of health status 
(eg, routine colonoscopy)
‚Ä¢medical/surgical admission other  than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
‚Ä¢admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical inte rvention (eg, lack of hous ing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
‚Ä¢admission for administr ation of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Revised Protocol No.: 03
Date: 13-Mar-2020 132
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospitalization but, based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above.) Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospitalization.) Potential drug indu ced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Pregnancy and potential drug induced liver injury (DILI) must f ollow the same transmission timing 
and processes to BMS as used for SAEs (see Section 9.2.5 for reporting pregnancies).
Any component of a study endpoint that is considered related to  study therapy should be reported 
as SAE (eg, death is an endpoint, if death occurred due to anap hylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
‚Ä¢The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE.
‚Ä¢A ‚Äúreasonable possibility‚Äù of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled out.
‚Ä¢The investigator will use clinical judgment to determine the re lationship.
‚Ä¢Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.
‚Ä¢The investigator will also consult the Investigat or‚Äôs Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
‚Ä¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
‚Ä¢There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that the 
investigator always make an assessment of causality for every e vent before the initial 
transmission of the SAE data to Sponsor.
‚Ä¢The investigator may change his/her opinion of causality in lig ht of follow-up information 
and send a SAE follow-up report with the updated causality asse ssment.
‚Ä¢The causality assessment is one  of the criteria used when deter mining regulatory reporting 
requirements.
Revised Protocol No.: 03
Date: 13-Mar-2020 133
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Follow-up of AEs and SAEs
If only limited information is i nitially available, follow- up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initi ally reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy treatment or if new 
information becomes available, the SAE report must be updated a nd submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmit ting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
‚Ä¢SAEs, whether related or not r elated to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
‚Ä¢SAEs must be recorded on the SAE Report Form.
‚àíThe required method for SAE data reporting is through the eCRF.
‚àíThe paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for tr ansmission of the eCRF 
to BMS (or designee).
‚ô¶In this case, the paper form is transmitted via email or confir med facsimile (fax) 
transmission
‚ô¶When paper forms are used, the original paper forms are to remain on site
‚Ä¢Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
SAE Telephone Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
Information list
Revised Protocol No.: 03
Date: 13-Mar-2020 134
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
‚Ä¢Premenarchal
‚Ä¢Premenopausal female wi th 1 of the following:
‚àíDocumented hysterectomy
‚àíDocumented bilateral salpingectomy
‚àíDocumented bilateral oophorectomy
Note: Documentation can come from the site personnel‚Äôs review of  the participant‚Äôs medical 
records, medical examinatio n, or medical history interview.
‚Ä¢Postmenopausal female
‚àíA postmenopausal state is defined as 12 months of amenorrhea in  a woman over age 
45 years in the absence of other biological or physiological cau ses. In addition, females 
under the age of 55 years must have a serum follicle stimulatin g hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement thera py, (HRT) are likely to have artificially 
suppressed FSH levels and may re quire a washout period in order to obtain a  physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the inves tigators should use their 
judgement in checking serum FSH levels. 
‚Ä¢1 week minimum for vaginal hormonal products (rings, creams, gels)
‚Ä¢4 week minimum for transdermal products
‚Ä¢8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the  woman can be considered 
postmenopausal.
Revised Protocol No.: 03
Date: 13-Mar-2020 135
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potentia l are eligible to participate if they 
agree to the following during the treatment and until the end o f relevant systemic exposure.
‚Ä¢Inform any and all partner(s) of their participation in a clini cal drug study and the need to 
comply with contraception instructions as directed by the inves tigator.
‚Ä¢Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study tre atment.
‚Ä¢Female partners of males participating in the study to consider  use of effective methods of 
contraception until the end of relevant systemic exposure, defi ned as 7 months after the end of 
study treatment in the male participant.
‚Ä¢Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each epi sode of penile penetration 
during the treatment and until 7 months after the end of study t reatment.
‚Ä¢Refrain from donating sperm for the duration of the study treat ment and until 7 months after 
the end of study treatment p lus an additional 90 days.
COLLECTION OF PREGNANCY INFORMATIONGuidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follow -up and Reporting.
Revised Protocol No.: 03
Date: 13-Mar-2020 136
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 5 ECOG PERFORMANCE STATUS
ECOG PERFORMANCE STATUSa
0 Fully active, able to carry on all pre-disease performance wit hout restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair mor e than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
aOken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET,  and Carbone PP. Toxicity and Response 
Criteria of the Eastern Cooperative Oncology Group. Am J Clin O ncol 1982; 5: 649-655.
Revised Protocol No.: 03
Date: 13-Mar-2020 137
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 6 NIVOLUMAB MANAGEMENT ALGORITHMS
These general guidelines constitu te guidance to the Investigato r and may be supplemented by 
discussions with the Medical Monitor representing the Sponsor. The guidance applies to all 
immuno-oncology agents and regimens.
A general principle is that differential diagnoses should be di ligently evaluated according to 
standard medical practice. N on-inflammatory etiologies s hould be cons idered and appropriately 
treated.Corticosteroids are a primary t herapy for immuno-oncology drug- related adverse events. The oral 
equivalent of the recommended IV doses may be considered for am bulatory patients with low-
grade toxicity. The lower bioavailability of oral corticosteroi ds should be taken into account when 
switching to the equivalent dose of oral corticosteroids.Consultation with a medical or surgical specialis t, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.The frequency and severity of the related adverse events covere d by these algorithms will depend 
on the immuno-oncology agent or regimen being used.
Revised Protocol No.: 03
Date: 13-Mar-2020 138
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 139
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 140
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 141
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 142
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 143
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 144
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 145
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 146
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 7 DETAILED PATHOLOGY METHODS FOR USING RESIDUAL 
CANCER BURDEN
Residual cancer burden (RCB) is estimated from routine patholog ic sections of the primary breast 
tumor site and the regional lymph nodes (LNs) after the complet ion of neoadjuvant therapy. 
Six variables are included in a calculation formula. The calcula ted RCB index value can also be 
categorized as 1 of 4 RCB classes. The calculation formula (see  image below) and detailed 
description can be found at a dedicated website: http://www.mdan derson.org/breastcancer_RCB.
Relevant information can be in cluded within a pathology report (diagnoses or comment) without 
a need for reporting calculated RCB index results. An example o f relevant information from a 
report would be:
‚Ä¢Residual invasive carcinoma with chemotherapy effect
‚Ä¢Residual carcinoma measures 2.4 √ó1.8 cm (d1 √ód2) and contains approximately 10% cancer 
cellularit y (proporti on of cancer; %CA)
‚Ä¢Residual intraductal carcinoma, solid type with necrosis, compr ising 5% of the residual 
carcinoma (proportion of in situ com ponent; %CIS)
‚Ä¢Metastatic carcinoma involving 3 of 14 axillary LNs (3/14)
‚Ä¢The largest metastasis measures 4 mm in greatest dimension (diam eter of the largest nodal 
metastasis ; dmet)
Revised Protocol No.: 03
Date: 13-Mar-2020 147
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
From the results above, one c ould calculate RCB using these resu lts: d1 = 24 mm; d2 = 18 mm; 
%CA = 10%; %CIS = 5%; LN = 3; dmet = 4 mm.
Primary Tumor Bed
In general terms, pathologic evaluation of the primary tumor be d in the breast requires that the 
pathologist make 3 judgments about the primary tumor bed:
1) Identify the cross-sectional dimensions of the residual tumor  bed (d1 and d2).
2) Estimate of the proportion of that residual tumor bed area th at is involved by cancer (%CA). 
3) Estimate the proportion of the cancer that is in situ compone nt (%CIS).
Defining the Tumor Bed
In cases of multicentric diseas e, the RCB measur ements a re from the largest residual tumor bed. 
In cases where the extent of residual cancer under the microscope does not correlate with the gross 
measurement of the residual tum or be d, the tumor bed d imensions are to be revised according to 
the microscopic findings. 
Schematic diagrams are shown below to illustrate how gross resi dual tumor bed dimensions are 
first estimated from the gross findings (pink area) but may be revised after review of the slides 
from the gross tumor bed area according to the extent of residu al cancer (blue).
Revised Protocol No.: 03
Date: 13-Mar-2020 148
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
In the diagrams above, the macroscopic tumor bed dimensions in ex amples A, C, and D also define 
the final dimensions of the residual tumor bed after microscopic  review. However, the macroscopic 
tumor bed dimensions in examp le B overestimate the extent of re sidual cancer, and so the 
dimensions of the residual tum or bed (d1 and d2) would be revised af ter microscopic evaluation 
of the extent of residual cancer in the corresponding slides fro m the gross tumor bed. In a different 
example (E), microscopic residual cancer extends beyond the con fines of the macroscopic tumor 
bed. Again, the dimensions of the residual tumor bed (d1 and d2 ) would be revised after 
microscopic evaluation of the recognizable extent of residual ca ncer beyond the macroscopic 
tumor bed.
This approach accounts for differences in the concentration and  distribution of residual cancer 
within a tumor bed. In the illustration above, the estimated %C A in example A would be high (in 
a small area), whereas the estimated %CA for examples C and D would be lower (in a larger area). 
In examples C and D, the estimated %CA would likely be similar, even though the distribution of cancer within the residual tumor bed is different in those 2 exa mples.
Revised Protocol No.: 03
Date: 13-Mar-2020 149
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Estimating Cellularity within the Tumor Bed
The %CA and the %CIS are estimated from microscopic evaluation o f the slides from the residual 
tumor bed area. The most effective way to ob tain this information is to measure and submit for 
histology the largest cross-sectional area of residual tumor be d, and to designate in the report which 
slides represent the cross section of tumor bed. After reviewing those slides, the pathologist can 
estimate the average cellularity in the tumor bed on each slide in order to e stimate the overall 
average cellularity of the tumor bed area, as illustrated below .
The key is to simply:
1) Define the gross tumor bed as the largest cross-sectional are a.
2) Submit sections representing that tumor bed area as individua l slides.
3) Review those slides to estimate the %CA and %CIS within the residual tumor bed.
A practical way to estimate %CA in a slide is to encircle with ink dots the tumor bed on each slide 
from the grossly defined residual tumor bed (eg, slides A1-A5 in  the example above). Then use 
the microscope to estimate the cellularity in each microscopic field across the area of tumor bed. 
In each microscopic field, %CA can be estimated by comparing th e proporti on of residual tumor 
bed area containing cancer (invasive or in sit u). Estimate an average of the readings for %CA in 
the cross-sectional area. The same can be done for %CIS. Estima tes are to the nearest 10%, but 
include 0%, 1%, and 5% for areas with low cellularity. The aver age cellularity within the tumor 
Revised Protocol No.: 03
Date: 13-Mar-2020 150
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
bed from each slide across the tumor bed can then be estimated, as illustrated above. The website 
provided a bove contains computer-generated diagrams of % cellularity per area to assist 
pathologists with accurately estimating the cellularity of a mic roscopic field. Those diagrams are 
provided at the end of this Appendix.
Regional Lymph Nodes: Pathologic evaluation of the primary tumor bed in the breast re quires 
that the pathologist make 2 judgments:
1) Count the number of positive LNs.
2) Measure the dmet.
Revised Protocol No.: 03
Date: 13-Mar-2020 151
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Footnotes
Inoperable or Progressive Disease
The RCB index cannot be accurately calculated for patients whos e disease remains inoperable at 
the completion of the neoadjuvant treatment course (eg, requiri ng subsequent additional tr eatments 
before surgical resection is possible), or those who experience  disease progression and so do not 
undergo surgical resection at the completion of the neoadjuvant  treatment course. For those 
patients, RCB is assigned as extensive (ie, RCB-III).
Internal Mammary Lymph Node Metastasis
There were no examples of internal mammary nodal metastasis in the published study that 
evaluated the prognostic value of RCB. However, it is reasonabl e to include internal mammary 
nodes with the other regional (axillary) nodes in the assessment of RCB.
Pre-treatment Sentinel Lymph Node Biopsy
Surgical excision of a  positive sentinel LN  before the neoadjuv ant treatment would invalidate the 
accuracy of measuring RCB after the treatment to assess respons e. If all sentinel LNs were negative 
before treatment began, this would not affect the assessment of RCB after treatment ended.
Summary of Key Points for Pathologic Assessment of the Primary Tumor Bed
Define the dimensions of residual tumor bed and estimate the pe rcent of that area that is cancer.
3)GROSS. Identify the residual tumor bed and describe this macroscopic finding:
a) Report the measurements of the largest gross dimensions (prefer 3 d imensions, but 
minimum is 2 dimensions).
b) Submit the largest cross-sectional area for histology and spe cifically describe those blocks 
in the Section Code:
i) Try to indicate how they are oriented by photography, or a scheme or intelligent 
description (eg, ‚Äúblocks B1 ‚Äì B7 cross section of tumor bed in r ows from 
antero-superior to postero-inferior‚Äù).
ii) If additional blocks are from surrounding tissues, then desc ribe those as well.
iii) Five representative sections from a bi g, obvious tumor bed should be sufficient.
4)MICROSCOPY. Review the slides that correspond to the tumor bed ( ¬±surrounding tissues):
a) Estimate the extent of spread of residual cancer relative to the gross tumor bed:
i) If similar to the gross description, then keep the original measurements.ii) If obviously different, then revise the d imensions of the tumor bed based on the 
microscopic review of the tumor bed.
iii) S uggestion: Dotting the perimeter of cancer in each slide can be helpful to reconstruct 
the tumor extent across multiple slides (see point 1) b) i)).
b) Using the microscope, make visual snapshots of cancer cellularity as you go from f ield to 
field across the defined tumor bed from one end to the opposite  (eg, left to right, then top 
to bottom) to estimate the:
Revised Protocol No.: 03
Date: 13-Mar-2020 152
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
i) Average cancer cellularity (%) across the entire tumor bed. C onsidering both invasive 
and in situ components.
ii) Average percent of the cance r within the tumor bed that is i n situ.
iii) Cellularity es timates are to the nearest 10%, with additional selections of 1 % and 5% 
for very low cellularity. For reference, there are images of co mputer generated 
examples at the following website: http://www.mdanderson.org/br eastcancer_RCB.
iv) The usual misunderstanding is to only make estimates in foci  of the tumor bed that 
contain lots of cancer. The estimates are supposed to represent  the average across the 
entire residual tumor bed area.
Revised Protocol No.: 03
Date: 13-Mar-2020 153
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 154
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 155
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Revised Protocol No.: 03
Date: 13-Mar-2020 156
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 8 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
GUIDELINES (VERSION 1.1) 
1 EVALUATION OF LESIONS
Solid tumors will be evalu ated using Response Evaluation Criteria In Solid Tumors version  1.1 
(RECIST 1.1) guideline .1
At baseline, tumor lesions/lym ph nodes will be categorized as measurable or non-measurable as 
follows:
2 MEASURABLE
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
‚Ä¢10 mm by CT/MRI scan (scan slice thickness no greater than 5 mm), or ‚â•2x slice thickness if 
greater than 5mm.
Malignant lymph nodes: To be considered pat hologically enlarged and measurable, a lymp h node 
must be ‚â•15 mm in short axis when assessed by CT/MRI scan (scan slice thickness recommended 
to be no greater than 5 mm).
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet th e criterion of a short axis of 
‚â•15 mm by CT/MRI scan. Only the short axis of these nodes will co ntribute to the baseline sum. 
The short axis of the node is the diameter normally used by rad iologists to judge if a node is 
involved by solid tumor. Nodal size is normally reported as two  dimensions in the plane in which 
the image is obtained (for CT scan this is almost always the ax ial plane; for MRI the plane of 
acquisition may be axial, sagittal or coronal). The smaller of these measures is the short axis. For 
example, an abdominal node which is reported as being 20 mm x 3 0 mm has a short axis o f 20 mm 
and qualifies as a malignant, measurable node. In this example,  20 mm should be recorded as the 
node measurement. All other pathological nodes (those with shor t axis ‚â•10 mm but < 15 mm) 
should be considered non-target lesions. Nodes that have a shor t axis < 10 mm are considered 
non-pathological and should not be recorded or followed.Note: Lesions on X-Ray are not to be selected as Target or Non- Target Lesions.
3 NON-MEASURABLE
All other lesions are considered non-measurable, including smal l lesions (l ongest d iameter 
< 10mm or pathological lymph nodes with ‚â•10 to < 15 mm short axis) as w ell as truly 
non-measurable lesions. Lesions considered truly non-measurable  include: leptomeningeal 
disease, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses/abdominal organomegaly identified by physical exam that is not measurable by 
reproducible imaging techniques.
Revised Protocol No.: 03
Date: 13-Mar-2020 157
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.
3.1 Special Considerations Regarding Lesion Measurability
3.1.1 Bone Lesions
‚Ä¢Bone scan, PET scan and plain films are notconsidered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
‚Ä¢Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components , that 
can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered 
as measurable lesions if the soft tissue component meets the definition of measurability 
described above.
‚Ä¢Blastic bone lesions are non-measurable.
4 BASELINE DOCUMENTATION OF ‚ÄòTARGET‚Äô AND ‚ÄòNON-TARGET‚Äô 
LESIONS
When more than one meas urable lesion is present at baseline all  lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) represen tative of all involved organs should 
be identified as target lesions  and will be recorded and measure d at baseline (this means in 
instances where patients have only one or two organ sites invol ved a maximum of two and four 
lesions respectively will be recorded).
Note: A maximum of two lesions can be selected per organ system . For example, a maximum of 
two lung lesions can be selected (selected from one lung or one  lesion from each). A maximum of 
two lymph nodes can be selected at baseline, as the lymphatic system is considered one organ.
Target lesions should be selected on the basis of their size (l esions with the longest diameter), be 
representative of all involved organs, but in addition should b e those that lend themselves to 
reproducible repeated measurements. It may be the case that, on  occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstan ce the next largest lesion which 
can be measured reproducibly should be selected.
A sum of the diameters (longest for non-nodal lesions, short ax is for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis i s added into the sum. The baseline 
sum diameters will be used as reference to further characterize  any objective tumor regression in 
the measurable dimension of the disease.
All other lesions (or sites of disease) including pathological lymph nodes s hould be identified as 
non-target lesions and should also be recorded at baseline. Mea surements are not required and 
these lesions should be followed as ‚Äòpresent‚Äô, ‚Äòabsent‚Äô, or in rare cases ‚Äòunequivocal progression‚Äô 
(more details to follo w). In addition, it is  possible to record  multiple non-target lesions involving 
the same organ as a single item on the case record form (eg, ‚Äòmu ltiple enlarged pelvic lymph nodes‚Äô 
or ‚Äòmultiple liver metastases‚Äô).
Revised Protocol No.: 03
Date: 13-Mar-2020 158
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
5 RESPONSE CRITERIA
5.1 Evaluation of Target Lesions
‚Ä¢Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nod es 
(whether target or non-target) must have reduction in short axi s to < 10 mm.
‚Ä¢Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesio ns, 
taking as reference the baseline sum diameters.
‚Ä¢Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesio ns, 
taking as reference the smallest sum on study (this includes th e baseline sum if that is the 
smallest on study). In addition to the relative increase of 20% , the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: the appearance of  one or more new lesions is also 
considered progression).
‚Ä¢Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient i ncrease to 
qualify for PD, taking as reference the smallest sum diameters while on study.
‚Ä¢Not Evaluable (NE): If one or more target lesions cannot be measured or adequately assessed 
as either fully resolved or too sm all to measure (due to missi ng or poor quality i mages), and 
the sum of diameters of the remaining measured target lesions ( if any) has not increased 
sufficiently to meet Progressive Disease as defined above. 
5.1.1 Special Notes on the Assessment of Target Lesions
5.1.1.1 Lymph Nodes
Lymph nodes identified as target lesions s hould always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline  examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nod es are included as target lesions, 
the ‚Äòsum‚Äô of lesions may not be zero even if complete response criteria are met, since a normal 
lymph node is defined as having a short axis of < 10 mm. Case r eport forms or other data collection 
methods may therefore be designed to have target nodal lesions recorded in a s eparate section 
where, in order to qualify f or CR, each node m ust achieve a sho rt axis < 10 mm. For PR, SD and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.
5.1.1.2 Target Lesions that Become ‚Äòtoo Small to Measure‚Äô
While on study, all lesions (nodal and non-nodal) r ecorded at baseline s hould have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as  target lesions at baseline 
become so faint on CT scan that the radiologist may not feel co mfortable assigning an exact 
measure and may report them as being ‚Äòtoo small to measure‚Äô. Wh en this occurs it is important 
that a value be recorded on the case report form. If it is the opinion of the radiologist that the lesion 
has likely disappeared, the meas urement should be recorded as 0  mm. If the lesion is believed to 
be present and is faintly seen but too small to measure, a defa ult value of 5 mm should be assigned 
as the reference diameter. (Note: It is less likely that this ru le will be used for lymph nodes since 
they usually have a definable size when normal and are frequent ly surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be pre sent and is faintly seen but too 
Revised Protocol No.: 03
Date: 13-Mar-2020 159
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
small to measure, a default value of  5 mm s hould be assigned in this circumstance as well). This 
default value is derived from the 5 mm CT slice thickness (but should not be changed with varying 
CT slice thickness). The measurement of these lesions is potent ially non-reproducib le, therefore 
providi ng this default value will prevent false responses or progressions based upon measurement 
error. To reiterate, however, if the radiologist is able to pro vide an actual measure , that s hould be 
recorded, even if it is below 5 mm.
5.1.1.3 Lesions that Split or Coalesce on Treatment
When non-nodal lesions ‚Äòfragment‚Äô, the longest diameters of the  fragmented portions should be 
added together to calculate the target lesion sum. Similarly, a s lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diam eter measurements of each 
individual lesion. If the lesions have truly coalesced such tha t they are no longer separable, the 
vector of the longest diameter in this instance should be the m aximal longest diameter for the 
‚Äòcoalesced lesion‚Äô.
5.2 Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to d etermine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitative ly at the time points specified in 
the protocol.
‚Ä¢Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must be 
non-pathological in size (< 10mm short axis). 
‚Ä¢Non-CR/Non-PD: Persistence of one or more non-target lesion(s)
‚Ä¢Progressive Disease (PD): Unequivocal progression of existing non-target lesions.
5.2.1 Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-target disease requires addit ional explanation as follows:
5.2.1.1 When the Patient also has Measurable DiseaseIn this setti ng, to achieve ‚Äòunequi vocal progression‚Äô on the basis of the no n-target disease, there 
must be an overall level of substantial worsening in non-target  disease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has inc reased sufficiently to merit 
discontinuation of therapy A modest ‚Äòincrease‚Äô in the size of o ne or more non-target lesions is 
usually not sufficient to  qualify for unequivocal p rogression status. Pleural effusions, pericardial 
effusions and ascites will not be  followed as target or non-tar get lesions and will not contribute to 
response or progression. The designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease wi ll therefore be extremely rare.
5.2.1.2 When the Patient has Only Non-Measurable Disease
This circumstance arises in some trials when it is not a criterion of study entry to have measurable 
disease. The same general concepts apply here as noted above, h owever, in this instance there is 
no measurable disease assessment to factor into the inte rpretati on of an increase in non- measurable 
Revised Protocol No.: 03
Date: 13-Mar-2020 160
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: 
if all lesions are truly non-measurable) a useful test that can  be applied when assessing patients for 
unequivocal progressi on is to consider if the increase in overall disease burden bas ed on the change 
in non-measurable disease is comparable in magnitude to the inc rease that would be required to 
declare PD for measurable disease: ie, an increase in tumor bur den representing an additional 73% 
increase in ‚Äòvolume‚Äô (which is equivalent to a 20% increase dia meter in a measura ble lesion). 
Examples include, an increase in lymphangitic disease from loca lized to widespread, or may be 
described as ‚Äòsufficient to require a change in therapy‚Äô. If ‚Äòu nequivocal progression‚Äô is seen, the 
patient should be considered to have had overall PD at that poi nt. While it would be ideal to have 
objective criteria to apply to non-measurable disease, the very  nature of that disease makes it 
impossible to do so; therefore the increase must be substantial .
5.2.2 New Lesions
The appearance of new malignant  lesions denotes disease progres sion; therefore, some comments 
on detection of new lesions are important. There are no specifi c criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion should be unequi vocal: ie, not 
attributable to differences in scanning technique, change in im aging modality or findings thought 
to represent something other than tumor (for example, some ‚Äònew ‚Äô bone lesions may be simply 
healing or flare of pre-existing lesions). This is particularly  important when the patient‚Äôs baseline 
lesions show partial or complete response. For example, necrosi s of a liver lesion may be reported 
on a CT scan report as a ‚Äònew‚Äô cystic lesion, which it is not.
NOTE: Fluid collections (pleural effusions, pericardial e ffusions, and ascites) w ill not be 
considered new lesions and will not contribute to response or p rogression. In the event a new fluid 
collection is seen on a post-baseline imagi ng exam, a comment m ay be made, but the appearance 
of a new fluid collection alone should not result in an assessm ent of Progressive Disease (PD). A 
lesion identified on a follow-up study in an anatomical locatio n that was not scanned at baseline 
is considered a new lesion and will indicate disease progressio n. An example of this is the patient 
who has visceral disease at baseline and while on study has a CT or MRI brain ordered which 
reveals metastases. The patient‚Äôs brain metastases are consider ed to be evidence of PD even if 
he/she did not have brain imaging at baseline. A lesion identif ied on Chest X-Ray that was not 
present in prior CT can be considered a new lesion and will res ult in Progressive Disease (PD).
If a new lesion is equivocal, for example because of its small size, continued follow-up evaluation 
will clarify if it represents truly new disease. If repeat scans conf irm there is definitely a new 
lesion, then progression should be  declared using the date of t he initial scan. While FDG-PET 
response assessments need additi onal study, it is sometimes rea sonable to incorporate the use of 
FDG-PET scanning to complement CT scanning in assessment of pro gression (particularly 
possible ‚Äònew‚Äô disease). New lesions on the basis of FDG-PET im aging can be identified according 
to the following algorithm:1) Negative FDG-PET at baseline, with a positive FDG-PET at follo w-up is a sign of PD based 
on a new lesion.
Revised Protocol No.: 03
Date: 13-Mar-2020 161
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
2) No FDG-PET at baseline and a positive FDG-PET at follow-up: I f the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT,  this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the d ate of the initial a bnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on C T that is not progressing on the 
basis of the anatomic images, this is not PD.
5.3 Response Assessment
5.3.1 Evaluation of Best Overall Response
The best overall response is the best response recorded from th e start of the study treatment until 
disease progression or th e last response recorded, taking into account any requirement for 
confirmation and censoring rules regarding subsequent therapy. The patient‚Äôs best  overall response
assignment will depend on the findings of both target and non-target disease and will also take into 
consideration the appearance of new lesions. Furthermore, depen ding on the nature of the study 
and the protocol requirements, it may also require confirmatory  measurement.
5.3.2 Time Point Response
At each protocol specified time point, a response assessment oc curs. Table 5.3.2 -1 provides a 
summary of the overall re sponse status calculation at each time point for patients who have 
measurable disease at baseline. When patients have non-measurab le (therefore non-target) disease 
only, Table 5.3.2-2 is to be used. 
Table 5.3.2-1: Time Point Response: Patients With Target ( ¬±Non-Target) Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Revised Protocol No.: 03
Date: 13-Mar-2020 162
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 5.3.2-2: Time Point Response: Patients with Non-target Dis ease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = ineva luable
aNon-CR/non-PD is preferred over SD for non-target disease since  SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this categor y when no lesions can be measured is not advised.
5.3.3 Best Overall Response 
Best response determinati on of complete or par tial res ponse requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
‚â•4 weeks (28 days) later. In this circumstance, the best overall response can be interpreted as in 
Table 5.3.3-1. When SD is believed to be best response, it must  meet the protoc ol specified 
minimum time from the d ate of first treatment or randomization d ate.
For example, if the first scheduled follow-up imaging visit is Week 6 ( ¬±7 days) for a particular 
protocol, a Best Response of SD can only be made after the subje ct is on-study for a minimum of 
6 weeks (42 days) minus 7 days, for an absolute minimum time on -study of 35 days from the 
reference start date (reference date is considered Day 1 on stu dy).  If the subject is not on-study 
for at least this am ount of t ime, any tumor assessment indicating stable disease before this  time 
period will have a Best Response of NE unless PD is identified.
Special note on response assessment: When nodal disease is included in the sum of target lesions 
and the nodes decrease t o ‚Äònormal‚Äô s ize (< 10 mm), they may st ill have a measurement reported 
on scans. This measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‚Äòzero‚Äô on the case report form (CRF).
Table 5.3.3-1: Best Overall Response (Confirmation of CR and PR Required)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD duration met, otherwise, 
PD
CR PDSD provided minimum criteria for SD duration met, otherwise, PD
Revised Protocol No.: 03
Date: 13-Mar-2020 163
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 5.3.3-1: Best Overall Response (Confirmation of CR and PR Required)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR NESD provided minimum criteria for SD duration met, otherwise, 
NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
PR NESD provided minimum criteria for SD duration met, otherwise, NE
NE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable
aIf a CR is truly met at first time point, then any disease seen  at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was me t. However, sometimes ‚ÄòCR‚Äô may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR sh ould be changed to PR and the best response is PR.
5.3.4 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tum or measurements 
must be confirmed by consecutive or subsequent repeat assessmen ts that should be perform ed no 
less than 28 days after the criteria for response are first met.  Subsequent documentation of a CR 
may provide confirmation of a pre viously identified CR even wit h an intervening NE or PR 
(eg, CR NE CR or CR PR CR). Subsequent documentation of a  PR may provide confirmation of 
a previously identified PR even with an intervening NE or SD (e g, PR NE PR or PR SD PR). 
However, only one (1) intervening time point will be allowed between PR/CRs for confirmation.
Verification of Progression : Progressi on of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the 
initial scan. If repeat scans do not confirm PD, then the subje ct is considered to not have 
progressive disease.
REFERENCES
1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST 
guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
Revised Protocol No.: 03
Date: 13-Mar-2020 164
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 9 COUNTRY-SPECIFIC AMENDMENTS
Argentina, Czech Republic, Germany, Italy, Spain, and Any Other  Countries Where 
Exclusion of HIV Positive Participants Is Locally Mandated
Country-specific language
Section 2 Schedule of Activities, Table 2-1 : 
Screening Assessments - Laboratory TestsAdd ‚ÄúHIV‚Äù to the list of laboratory tests
Section 6.2  Exclusion
Criteria, Exclusion criterion 1) e)‚ÄúKnown human immunodeficiency virus (HIV) positive with 
an AIDS defining opportunistic infection within the last year, 
or a current CD4 count <350 cells/uL.‚Äù to be replaced with
‚ÄúPositive test for HIV‚Äù.
Revised Protocol No.: 03
Date: 13-Mar-2020 165
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 10 CONCOMITANT MEDICATIONS
In general, the use of any concomitant medication deemed n ecessary for the care of the patient is 
permitted in this study, excep t as specifically prohibited belo w. Combination administration of 
study drugs could result in drug-drug interactions (DDI) that c ould potentially lead to reduced 
activity or enhanced toxicity of the conco mitant medication and/or CDK4/ 6 inhibitors.
The following lists are based on the Oncology Clinical Pharmaco logy Drug-Drug Interaction and 
Co-Medication Considerations (v06 release date:  2016), which wa s compiled from the Indiana 
University School of Medicine‚Äôs ‚ÄúClinically Relevant‚Äù Table 
(medicine.iupui.edu/clinpharm/ddis/main-table/) and supplemente d with the FDA Draft 
Guidance for Industry, Drug Interaction Studies ‚Äì Study Design, D ata Analysis, and Implications 
for Dosing and Labeling (February 2012; fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation /guidances/ucm292362.pdf), 
and the University of Washington‚Äôs Drug Interaction Database (d ruginteractioninfo.org/). 
For current lists of medications that may cause QT prolongation and/or Torsades de Pointes (TdP), 
refer to the CredibleMeds
¬Æwebsite (qtdrugs.org/).
The lists provided in the tables below are not comprehensive and a re only meant to be used as a 
guide. Please contact the medical monit or with any questions.
Table 1: List of Prohibited Medications During Study Drug Treatment
Category Drug Name
Strong CYP3A4/5 Inhibitors VIEKIRA PAK2, indinavir/ritonavir, tipranavir/ritonavir, ritonavir, cobicistat 
(GS-9350), indinavir, ketoconazole, troleandomycin, telaprevir,  
danoprevir/ritonavir, elvitegravir/ritonavir, saquinavir/ritona vir, 
lopinavir/ritonavir, itraconazole, voriconazole, mibefradil, clarithromycin, 
posaconazole, telithromycin, grapefruit juice, conivaptan, nefaz odone, nelfinavir, 
saquinavir, idelalisib, boceprevir, darunavir/ritonavir
Strong CYP3A4/5 InducersAvasimibe,a,bcarbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin , 
rifabutin, rifampin (rifampicin)bSt. John's wort (hypericum perforatum)b
CYP3A Substrates with Narrow Therapeutic Index 
(NTI)cAlfentanil, apixaban (doses > 2.5 mg only), aprepitant, astemizo le, cisapride, 
cyclosporine, diergotamine (dihydroergotamine), ergotamine, fen tanyl, lovastatin, 
nicardipine, nisoldipine, pimozide, quinidine, rivaroxaban, sim vastatin, sirolimus, 
tacrolimus, terfenadine, thioridazine, lomitapide
Medications with a Known 
Risk for QT ProlongationdAmiodarone, anagrelide, arsenic trioxide, astemizole, azithromy cin, bepridil, 
chloroquine, chlorpromazine, cilostazol, ciprofloxacin, cisapri de, citalopram, 
clarithromycin, cocaine, disopyramide, dofetilide, domperidone,  donepezil, 
dronedarone, droperidol, erythromycin, escitalopram, flecainide , fluconazole, 
grepafloxacin, halofantrine, haloperidol, ibutilide, levofloxac in, levomethadyl,
mesoridazine, methadone, moxifloxacin, ondansetron (i.v. only),  oxaliplatin, 
papaverine HCl, pentamidine, pimozide, probucol, procainamide, p ropofol, 
quinidine, sevoflurane, sotalol, sparfloxacin, sulpiride, terfe nadine, thioridazine, 
vandetanib, venlafaxine
Herbal 
Preparations/medicationsHerbal preparations/medications known as string inducers or inh ibitors of 
CYP3A/5 are prohibited throughout the study. These herbal medications include, 
but are not limited to: St. John‚Äôs wort, Kava, ephedra (ma huan g), gingko biloba, 
Revised Protocol No.: 03
Date: 13-Mar-2020 166
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 1: List of Prohibited Medications During Study Drug Treatment
Category Drug Name
dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. 
Participants should stop using these herbal medications 7 days prior to first dose of study drug.
Other Investigational and Antineoplastic TherapiesOther investigational therapies must not be used while the part icipant is on the 
study. Antineoplastic therapy (chemotherapy, biologic or radiation therapy, and surgery) other than the study treatments must not be given to p articipants while 
the participant is on the study medic ation. If such agents are require d for a 
participant, then the participant must discontinue study drug.
aHerbal product.
bPg inducer.
cDrugs with exposure-response that indicates that increases in their exposure levels by the concomitant use of potent 
inhibitors may lead to serious safety concerns (eg, Torsades de  Pointes).
dSource: qtdrugs.org (as of 12-Dec-2016).
As far as possible, avoid co-administration of QT prolonging dr ugs or any other drugs with the 
potential to increase the risk of drug-related QT prolongation (eg, via a potential DDI that increases 
the exposure of ribociclib or the exposure of the QT prolonging  drug). A definitive list of drugs 
with a known risk, possible risk, or conditional risk of QT pro longation and/or TdP is available 
online at qtdrugs.org.
Revised Protocol No.: 03
Date: 13-Mar-2020 167
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2: List of Medications to be Used with Caution During Stud y Drug 
Treatment
Category Drug Name
Moderate CYP3A4/5 Inhibitors Amprenavir, atazanavir, casopitant, cimetidine, darunavir, diltiazem, 
fosamprenavir netupitant, tofisopam, verapamil, crizotinib, faldaprevir, imatinib, nilotinib
Moderate CYP3A4/5 Inducers Bosentan, efavirenz, etravirine, genistein, lersivirine, modafi nil, nafcillin, 
talviraline, semagacestat, lopinavir 
Sensitive CYP3A4/5 Substratesa Alpha-dihydroergocryptine, alis oporivir, almorexant, aplaviroc,  apixaban 
(doses < 2.5 mg only), atazanavir, atorvastatin, avanafil, bosu tinib, 
brecanavir, brotizolam, budesonide, buspirone, capravirine, casopitant, danoprevir,darifenacin, darunavir, dasatinib, ebastine, eletriptan, elvitegravir, eplerenone, everolimus,  felodipine, fluticasone, ibrutinib, ivacaftor, lumefantrine, lurasidone, maraviroc, midazolam, midostaurin, naloxegol, neratinib, perospirone, quetiapine, ridaforolimus, sildenafil, simeprevir, ticagrelor, tilidine, tipranavir, tolvaptan, triazola m, ulipristal, 
vardenafil, vicriviroc, voclosporin
Strong BSEP Inhibitors Alectinib, Atazanavir, bromocriptine, Bosentan, clofaziminie, cerivastatin, fusidate, glibenclamide, glyburide, nefazadone, paritaprevir, pioglitazone, reserpine, rosiglitazone, sulindac, troglitazone (TGZ-sulfate),  valinomycin
Medications That Carry a Possible 
Risk for QT ProlongationbAlfuzosin, apomorphine, aripiprazole, artenimol+piperaquine, at azanavir, 
atomoxetine, asenapine, bedaquiline, bortezomib, buprenorphine,  
capecitabine, ceritinib, clomipramine, crizotinib, clozapine, c yamemazine 
(cyamepromazine), dabrafenib, dasatinib, degarilix, delamanid, 
desipramine, dexmedetomidine, dolasetron, eribulin, ezogabine,famotidine, felbamate, fingolimod, foscarnet, gatifloxacin, gemifloxacin, granisertron, hydrocodone-ER, iloperidone, imipramine (meliprami ne),
isradipine, lapatinib, lenvatinib, leuprolide, lithium, mifepri stone,
mirabegron, mirtazapine, moexipril, norfloxacin, nortriptyline,  ofloxacin, 
olanzapine, osimertinib, ondansetron (PO only at 4 mg or 8 mg), o xytocin, 
paliperidone, panabinostat, pasireotide, pazopanib, pipamperone, promethazine, quetiapine, ranolazine, rilpivirine, risperidone,  
roxithromycin, sertindole, sorafenib, sunitinib, telavancin, tetrabenazine, tizanidine, tolterodine, toremifene, trimipramine, vardenafil, vemurafenib, 
vorinostat, ziprasidone
MATE1 and OCT2 substratesc Acyclovir, amantadine, amiloride, apricitabine , carboplatin, cisplatin, 
cephalexin, cephradine, cimetidine, dofetilde, famotidine, fexofenadine, furamidine, ganciclovir, glycopyrronium, Ipratropium, lamivudine, linagliptin, memantine, metformin (also a substrate for OCT1, M ATE1, 
and MATE2K), oxyplatin, pindolol, plisicainide, pramsorafenib, ranitidine, topotecan, tropisetron, trospium, umeclidinium, varencicline and zidovudine
BCRP substrates Daunorubicin, doxorubicin, ethinyl estradiol methotrexate, mitoxantrone, pitavastatin rosuvastatin, sulfasalazine, sofosbuvir, tenofovir  
Revised Protocol No.: 03
Date: 13-Mar-2020 168
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Table 2: List of Medications to be Used with Caution During Stud y Drug 
Treatment
Category Drug Name
CYP2C9 substrates
with NTI (for participants
receiving tamoxifen)Phenytoin, warfarin
aSensitive substrates: Drugs whose plasma AUC values have been s hown to increase 5-fold or higher when co-
administered with a potent inhibitor.
bSource: qtdrugs.org (as of 12-Dec-2016).
cSource: FDA Draft Guidance for I ndustry, Drug Inter action Studies ‚Äì St udy Desi gn, D ata Analysis, and 
implications for Dosing and Labeling (February 2012) and Yonezawa and Inui (2011) Importance of the multidrug 
and toxin extrusion MATE/SLC 47A family to phar macokinetics, pha rmacodynamics/toxicodynamics and 
pharmacogenomics. Br J Pharmacology 164:1817-25; www.druginteractioninfo.org (May-2016).
Table 3: List of Cytochrome P450 Substrates with Narrow Therapeu tic 
Range Cytochrome P450
Cytochrome P450 Substrates with Narrow 
Therapeutic Range Cytochrome P450Substrate
CYP1A2 Theophylline
Tizanidine
CYP2C8 Paclitaxel
CYP2C9 Warfarin Phenytoin
CYP2D6 Thioridazine Pimozide
CYP3AAlfentanil Astemizole Cisapride Cyclosporine 
Dihydroergotamine Ergotamine Fentanyl
Pimozide Quinidine Sirolimus Tacrolimus Terfenidine
Revised Protocol No.: 03
Date: 13-Mar-2020 169
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 11 NYHA FUNCTIONAL CLASSIFICATION
Heart failure is usually classified according to the severity o f the patient‚Äôs symptoms. The table 
below describes the most commonly used classification system, t he New York Heart Association
(NYHA) functional classificatio n. It places p atients in 1 of 4 categories based on how much they 
are limited during physical activity.
Class Patient Symptoms
INo limitation of physical activity. Ordinary phys ical activity does 
not cause undue fatigue, palpitati on, or dyspnea (shortness of 
breath).
IISlight limitation of physical activity. Comfortable at rest. Or dinary 
physical activity results in fatigue, palpi tation, or dyspnea 
(shortness of breath).
IIIMarked limitation of physical activity. Comfortable at rest. Le ss 
than ordinary activity causes fatigue, palpi tation, or dyspnea.
IVUnable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is 
undertaken, discomfort increases.
Class Objective Assessment
ANo objective evidence of cardiovascular disease. No symptoms 
and no limitation in ordinary physical activity.
BObjective evidence of minimal cardiovascular disease. Mild 
symptoms and slight limitation duri ng ordinary activity. 
Comfortable at rest.
CObjective evidence of moderately s evere cardiovascular disease.  
Marked limitation in activity due to symptoms, even during 
less-than-ordinary activity. Comfortable only at rest.
DObjective evidence of severe cardiovascular disease. Severe 
limitations. Experiences symptoms even while at rest.
Revised Protocol No.: 03
Date: 13-Mar-2020 170
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
APPENDIX 12 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY
Overall rationale for Revised Protocol 02, 24-July-2019
The primary reasons for these changes  
ensure that the protocol is consistent with internal 
BMS policies and operating procedures. Additional amendments, i ncluding to sections of the 
Synopsis, have been made to align the protocol with respect to these changes.
Summary of key changes for Revised Protocol 02
Section Number & 
TitleDescription of Change Brief Rationale
2: Schedule of ActivitiesModified Table 2-2 (screening procedural outline) 
to update inclusion criterion number in the notes for ‚Äòdocumentation of postmenopausal status.‚ÄôTo align with updates made in Section 6.1, described below.
4: Objectives and Endpoints
5.1.2.1: Safety Run-in 
PhaseThe following modifications were made:
‚Ä¢Updated definition of DLT.
‚Ä¢Added DLT criteria.These changes were made to 
refine wording to facilitate 
Investigator interpretation.
5.1: Overall Study DesignRevised window to perform definitive breast cancer 
surgery to 4 weeks after last dose of neoadjuvant 
treatment.
Modified Figure 5.1-1 to update key inclusion 
criteria to include men in addition to 
postmenopausal women.Allow flexibility to plan the 
breast surgery and reflect 
updated study design in which men are now also eligible.
5.4: Early Study 
Termination CriteriaAdded early study termination criteria.These changes were made to 
refine wording to facilitate 
Investigator interpretation.
6.1: Inclusion CriteriaThe following modifications were made:
‚Ä¢Moved eligibility criteria for women to sub-
criteria for criterion 3) b)
‚Ä¢Added additional sub-criteria related to 
eligibility of men to criterion 3)These changes were made to refine wording to facilitate 
Investigator understanding 
and include men in the study.
6.2: Exclusion Criteria
7.7.1: Prohibited and/or 
Restricted Treatments for 
Nivolumab
7.7.3: Other Restrictions 
and Precautions
7.7.4: Permitted TherapyThe following modifications were made:
‚Ä¢Changed criteria 1) d) and 1) i) to exclude 
steroids above physiological replacement dose.
‚Ä¢Changed from ‚Äòimmunosuppressive‚Äô to 
‚Äòsupraphysiological‚Äô when describing other restrictions and precautions.
‚Ä¢Deleted the prednisone permitted dose.
‚Ä¢Changed ‚Äò> 10 mg daily prednisone 
equivalent‚Äô to ‚Äòat above physiological replacement dose‚Äô when describing permitted therapy.These changes were made to 
refine wording to facilitate 
Investigator understanding.
7.4.1: Dose Modifications 
for Abemaciclib
7.4.2: Dose Modifications 
for PalbociclibThe following modifications were made:
‚Ä¢Aligned the section with the US prescribing 
information language for each medication.These changes were made to 
refine wording to facilitate 
Investigator understanding.
Revised Protocol No.: 03
Date: 13-Mar-2020 171
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Summary of key changes for Revised Protocol 02
Section Number & 
TitleDescription of Change Brief Rationale
7.4.3: Dose Modification 
for Anastrozole
9.2.5: Pregnancy
Appendix 4: Women of 
Childbearing Potential 
Definitions and Methods of 
ContraceptionAdded language describing male contraception 
expectations.Aligned methods of 
contraception with the update 
to the study design to now 
include men.
Appendix 6: Nivolumab 
Management AlgorithmsUpdated management algorithms and added 
myocarditis.These changes were made to reflect updates made to the IB.
Appendix 9: Country-
specific AmendmentsRemoved France from list of countries.France does not mandate HIV testing.
AllThe following global updates were made:
‚Ä¢Added males.
‚Ä¢Minor formatting and typographical 
corrections.These changes were made to:
‚Ä¢Clarify that men are 
eligible.
‚Ä¢Incorporate corrections 
for clarity and 
consistency within the document. These changes were minor, and therefore have not been summarized.
Overall rationale for revised protocol 01, 12-June-2019
The primary reasons for these changes are to clarify and decrea se the frequency of assessments 
and sample collections, clarify participant eligibility and stratification, and reduce the 
dose-limiting toxicity (DLT) peri od. These changes were mad e to reduce participant burden and 
increase overall feasibility of the study. Additional amendment s, including to sections of the 
Synopsis, have been made to align the protocol with respect to these changes.
Revised Protocol No.: 03
Date: 13-Mar-2020 172
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Summary of key changes for Revised Protocol 01
Section Number & 
TitleDescription of Change Brief Rationale
2: Schedule of Activities ‚Ä¢The following modifications were 
made:
‚Ä¢Table 2-1: 
‚àíAdded row describing Original Diagnosis IHC Tumor Slides Submission.
‚àíUpdated number of unstained slides for tumor tissue sections from 25 to 22 and lowered minimum number of slides for participant eligibility from 20 to 
15.
‚àíAdded respiratory rate to safety 
assessments.
‚àíUpdated ‚ÄúTumor Assessment by PE‚Äù to ‚ÄúClinical Breast Examination.‚Äù
‚àíAdded ‚Äúaxilla‚Äù to breast ultrasound (preferred) or mammogram.
‚àíAdded Axillary Lymph Nodes Fine Needle Biopsy or Core 
Biopsy row.
‚Ä¢Table 2-2:
‚àíDecreased the frequency of ocular 
exams and electrocardiograms.
‚àíUpdated ‚ÄúTumor Assessment by PE‚Äù to ‚ÄúClinical Breast 
Examination.‚Äù
‚àíAdded ‚Äúaxilla‚Äù to breast 
ultrasound (preferred) or mammogram and aligned timing of this assessment with on-
treatment biopsy (now on Cycle 2 
Day 22).
‚Ä¢Table 2-3:
‚àíUpdated ocular assessments to be 
as clinically indicated.These changes were made to clarify
assessment expectations and/or decrease the number of assessments to reduce participant burden.
4: Objectives and Endpoints ‚Ä¢Removed text describing timeframe of 
Safety Run-in Phase.‚Ä¢Streamlined text to improve readability.
4: Objectives and Endpoints;
9.1.2.1: RCB Determination‚Ä¢Removed local assessment of residual cancer burden (RCB) 0-1 rate as a 
secondary endpoint.‚Ä¢Updated to improve study 
feasibility.
Revised Protocol No.: 03
Date: 13-Mar-2020 173
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Summary of key changes for Revised Protocol 01
Section Number & 
TitleDescription of Change Brief Rationale
4: Objectives and Endpoints; 
5.1.2.1: Saf ety Run-in Phase; 
10.3.2: Safety AnalysesShortened the DLT period from 8 weeks to 
4 weeks and redefined DLT-evaluable participants as those who receive 1 dose.Aligned with clinical experience regarding safety feasibility of the study drugs.
5.1: Overall Design; 
5.1.2.2: Randomized Phase; 
7.2: Method of Treatment 
AssignmentSpecified axillary node status for 
stratification factor as ‚Äúcytologically 
positive vs radiologically or cytologically negative.‚ÄùClarified expectations for node 
status stratification factor.
5.1.1: Screening Period Added details related to documentation and tumor samples for central review.Clarified expectations for central review.
5.1.1: Screening Period; 
6.1: Inclusi on Criteria; 
 Modified number of unstained slides for tumor tissue sections from 25 to 22 and 
lowered minimum number of slides for participant eligibility from 20 to 15.Updated to improve study 
feasibility.
5.1: Overall Design;
5.2: Number of Participants; 
10.1: Sample Size 
Determination;
 Provided range of anticipated number of 
study participants for the Safety Run-in Phase within text and Study Design Schematic in Figure 5.1-1.Clarified expectations for number of participants.
5.1.2.1: Safety Run-in Phase Modified criteria for gastrointestinal and 
dermatologic DLTs.Updated for participant safety.
6.1: Inclusion Criteria The following modifications were made:
‚Ä¢Updated sub-criteria for criterion 2) b) to 
remove staging requirement but specify 
primary tumor size per radiological 
assessment.
‚Ä¢Incorporated details in previous criterion 
2) e) related to measurable disease into 
sub-criteria for criterion 2) b) iii).These changes were made to:
‚Ä¢Clarify expectations for 
participant inclusion criteria 
and improve study feasibility.
‚Ä¢Remove repetitive information 
per changes to 2) b) sub-criteria.
7.4.1: Dose Modifications for 
AbemaciclibAdded ‚ÄúThird dose reduction‚Äù row to Table 7.4.1-2.Clarified dose levels for abemaciclib.
9.1.1: Blinded Independent 
Pathology ReviewChanged ‚Äúmandatory‚Äù sample collections to 
‚Äúshould be performed‚Äù and removed 
statement on site training.Aligned expectations for sample 
collections with update described 
above to remove local RCB 
assessment as a secondary endpoint.
9.1.2.1: RCB Determination Slightly modified variables included in the 
RCB calculations.Updated for clarity and consistency with RCB calculator referenced in 
this section.
Revised Protocol No.: 03
Date: 13-Mar-2020 174
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Summary of key changes for Revised Protocol 01
Section Number & 
TitleDescription of Change Brief Rationale
9.1.3: Clinical Response 
AssessmentsThe following modifications were made:
‚Ä¢Replaced ‚Äútargeted PE‚Äù with ‚Äúclinical 
breast examination by palpati on of 
breast and axilla.‚Äù
‚Ä¢Added ‚Äúaxilla‚Äù to ultrasound (preferred) or mammogram.
‚Ä¢Added ‚Äúincluding pathologic examination of suspicious lesions.‚Äù
‚Ä¢Added statement: ‚ÄúAt the Sponsor‚Äôs discretion, scans may be collected for review.‚ÄùThese changes were made to:
‚Ä¢Align description of clinical 
response assessments with 
changes made to the Schedule of Activities described above.
‚Ä¢
‚Ä¢
‚Ä¢Clarify expectations for clinical 
response assessments.
Revised Protocol No.: 03
Date: 13-Mar-2020 175
Approved 5.0 v
Approved
1.0
v
Clinical Protocol CA2097A8
BMS-936558 nivolumab
Summary of key changes for Revised Protocol 01
Section Number & 
TitleDescription of Change Brief Rationale
10.3.1: Efficacy Analyses Updated Table 10.3.1-1  for consistency 
with changes to Table 4-1.Aligned efficacy analyses with 
updates to objectives and endpoints 
described above.
Appendix 8: Staging Criteria Prior Appendix 8 containing American 
Joint Committee on Cancer (AJCC) criteria 
was removed.AJCC criteria no longer relevant per 
updates made to Section 6.1.
All The following global updates were made:
‚Ä¢Replaced ‚ÄúStage II-III‚Äù with ‚Äú ‚â•2 cm‚Äù in 
titles, text, and in Figure 5.1-1.
‚Ä¢Minor formatting and typographical 
corrections.These changes were made to:
‚Ä¢Clarify breast cancer type 
throughout protocol.
‚Ä¢Incorporate corrections for clarity 
and consistency within the 
document. These changes were minor, and therefore have not been summarized.
Revised Protocol No.: 03
Date: 13-Mar-2020 176
Approved 5.0 v
Approved
1.0
v